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ABSTRACT
An exciting therapeutic goal would be to use agents in clinical practice which could 
increase the size of a patient’s functioning hepatic tissue in times of liver disease such 
as in the recovery phase from liver transplantation. An increase in the size and function 
of the liver at times such as this would ensure a more rapid recovery and less associated 
liver related morbidity and mortality.
As a group, the primary hepatomitogens might be employed to this end. Tri­
iodothyronine (T3) is a non carcinogenic agent and a very plausible candidate to be used 
in this setting.
T3 is one o f a number of drugs which can bring about proliferation of hepatocytes in the 
adult liver without any preceding cell loss i.e. a process of direct hyperplasia as opposed 
to the compensatory regeneration one sees following hepatectomy.
The work undertaken in this thesis aims to form a better understanding of the 
mechanism of action of the hepatomitogen tri-iodothyronine, T3.
Thus far the mitogenic response is reliably modelled in vivo in the rodent but not in 
hepatocyte culture. This research attempts to demonstrate directly for the first time a 
mitogenic effect in human liver and starts with exploring T 3 effects in perfused liver and 
then in vivo in the rodent model where gene array studies are performed to identify 
novel mediators o f the hepatic T 3 proliferative response.
Potential mediators have their serial expression profiles studied over time after T3 
stimulation by Real Time PCR.
Finally, the role of mTOR (important in mediating cell growth and proliferative 
signalling pathways) is identified in mediating the hepatic mitogenic T 3 response.
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Chapter 1 - General Introduction
1.1 Synopsis
The thyroid hormone tri-iodothyronine (T3) has been previously studied as a primary 
hepatic mitogen (Forbes et al. 2000; Short et al. 1972; Malik et al. 2003). It is an 
attractive candidate as a non-carcinogenic therapeutic agent which may be used in the 
future to enhance the functioning mass of a patient’s liver not only at the time of liver 
surgery, either following a resection or liver transplantation, but also during an acute 
chemical or viral liver related illness. A more rapid recovery of functional hepatic mass 
would lead to speedier patient recovery and quicker resolution of the diseased state.
The proliferative hepatic effect has been well established in vivo in the rodent model 
where one sees a peak in hepatocyte DNA synthesis 24 hours after a sub-cutaneous dose 
of T3 has been administered to the animal (Francavilla et al. 1994). However no such 
mitogenic mode of action has been shown in vitro in either rodent or human liver 
samples. The in vitro conditions likely do not reflect the more complex and highly 
regulated physiological state that exists in vivo.
The work undertaken in this PhD thesis therefore attempts to more accurately elucidate 
the T3 mitogenic mechanism of action and also to demonstrate a direct mitogenic effect 
o f T3 on perfused human liver pieces and human hepatocytes in cell culture conditions 
where no such T 3 effect has thus far been successfully demonstrated. A prime goal was 
to search for an early marker of the mitogenic T 3 effect which could then be used in 
organ perfusion and hepatocyte cell culture experiments to confirm a mitogenic T 3 
effect in human liver.
The first chapter is a general introduction.
The second chapter outlines the general methods that were utilised in carrying out this 
research project. More specific methodology relating to individual results chapters are 
outlined separately within each chapter.
The third chapter describes organ perfusion experiments and how it may be possible to 
model the effects of liver growth factors in an ex-vivo in vitro organ perfusion system 
and to attempt to demonstrate a mitogenic effect of T3 on human liver samples.
The fourth chapter investigates the in vivo rodent hepatic response to T 3 by measuring 
changes in cyclin D l, an important regulator of the cell cycle. An early molecular 
marker of the T3 mitogenic effect is searched for to enable T3 effects to be measured in
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the organ perfusion experiments of Chapter 3. The oncogene Bcl-3 is also probed as a 
potential candidate critically mediating the T3 mitogenic response by examining the 
hepatic proliferative response to T3 in Bcl-3 knockout mice.
The fifth chapter uses RNA expression microarray technology to define which genes 
are up or down regulated in T3 treated euthyroid rat liver after 1 hour and then after 3 
hours, a scenario not previously investigated in the published literature. This is once 
again in an effort to identify potential novel early candidates as mediators of the 
mitogenic T3 effect.
The sixth chapter describes using Real Time PCR technology to examine the hepatic 
expression profile of candidate T3 responsive genes, identified in Chapter Five, that may 
mediate the mitogenic response in rodent liver.
The seventh chapter investigates the role of the mammalian Target of Rapamycin 
(mTOR) in mediating the mitogenic hepatic T3 effect. Other workers have shown it lies 
at the heart of signal transduction pathways which are T3 responsive and therefore its 
role is further scrutinised.
Chapter eight outlines a general set of conclusions from this body of work as well as 
future directions of work.
1.2 Liver’s Role
Many vital functions for the body are provided for by the liver and these include 
synthesis of many of the plasma proteins, incorporation of toxic ammonia into the non­
toxic urea, regulation of plasma glucose levels, lipid mobilisation and export, synthesis 
and export of the bile to the intestine, metabolism of a host of drugs and toxins too. Loss 
o f life results within a few hours of liver removal.
Severe liver damage can result after exposure to a range of toxins such as the 
xenobiotics acetaminophen and carbon tetrachloride. Liver damage can also occur after 
exposure to other injurious agents for example viruses and alcohol which can cause 
massive and acute hepatic damage or over a longer period of time they may cause 
chronic liver injury leading to eventual fibrosis and then cirrhosis culminating in a 
diseased and failing liver with a myriad of systemic complications.
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1.3 Thyroid hormone production, transport and metabolism
The thyroid hormones have important effects on growth, development and metabolism. 
During foetal development and early childhood some of these effects are particularly 
important and this is reflected in the human clinical syndromes such as cretinism where 
one sees delayed growth for example (Gruters and Krude 2007). In adults the effects of 
thyroid hormones are seen in changes in oxygen consumption, lipid, protein and 
carbohydrate metabolism.
The thyroid gland produces two hormones, T4 (L-thyroxine) and T 3 (L- 
triiodothyronine). Iodine is an important constituent making up 65% of the weight of T4 
and 58% of the weight of T3. T3 has a ten times greater affinity and efficacy than 
thyroxine for the nuclear receptor. Only a very small fraction of the circulating hormone 
is free (unbound) and biologically active, as that which is bound to carrier proteins is 
inactive (Brent 1994).
Intracellular hormone is in equilibrium with free thyroid hormone in serum. Total 
hormone concentration in serum is kept at a level proportional to the concentration of 
carrier proteins, and appropriate to maintain a constant free hormone level. It is a minute 
fraction of the total extra-thyroidal hormone < 0.5% which is available to tissues. The 
major serum thyroid hormone binding proteins are thyroxine binding globulin (TBG), 
transthyretin and thyroxine binding pre-albumin and albumin (Kohrle et a l  1987). 
Thyroid hormone metabolism is regulated through three groups of enzymes termed the 
de-iodinases (Kohrle 2000). About 80% T3 is produced outside the thyroid gland by 
peripheral conversion of T4 to T3. The main organs involved in this are liver, muscle 
and kidneys. T3 is therefore the bioactive moiety of thyroid hormone and so T4 is 
viewed as a pro-hormone that becomes activated by conversion to T 3 (DiStefano, III et 
a l  1982).
Seleno-deiodinases are responsible for inactivation of T4 to r T3, conversion of rT3 and 
T3 to T2 and activation of T4 to T 3 (Figure 1).
20
Pathways of Thyroid Hormone Metabolism
ether bond cleavage 
(CUT)
oxidative deamination 
(TA4)
sulfation , 
(T4S) HO C H ij-C H  -C O O H
/  \
deiodination
(T3)
deiodination
(rT3)
Figure 1. The conversion o f  thyroxine T4 to a variety o f  products by the seleno- 
deiodinase enzyme system.
About one third of T4 is converted by ORD (outer ring deiodination) to T3 and about 
one third to rTY The remainder of the T4 is metabolised by different pathways using 
glucuronidation and sulfation. The metabolite 3,3’- T2 is produced by IRD (inner ring 
deiodination) of T 3 and ORD of rT3. Therefore IRD is considered to be a deactivating 
pathway while ORD is an activating pathway. All three de-iodinases have been cloned 
and characterised in various species.
Hepatic D1 is largely responsible for the major part of peripheral T 3 production. In 
clinical practice this is the enzyme inhibited by the anti-thyroid drug propylthiouracil, 
PTU (Sanders et al. 1997).
Type 2 de-iodinase is found in skeletal muscle, pituitary and the CNS and produces 
about 30 mmol extra-thyroidal T3. In critical tissues such as the brain, D2 enzyme is 
required to ensure local conversion of T 4 to T3 so that intracellular T3 levels can be 
regulated independently from variations in plasma T3 levels (Leonard et al. 2000). 
Inactivation o f T 3 and T4 can occur with the type 1 and 2 deiodinases but it is type 3 
which is the main inactivator, exhibiting mainly inner ring de-iodination. It catalyses the 
conversion of T4 to r T3 and T3 to T2, both inactive metabolites, in liver, skin and CNS 
(Bianco et al. 2002).
The first effects of thyroid hormone on metabolic rate were described over 100 years 
ago by Magnus-Levey in 1895 and since then there have been many proposed models 
described for its mechanism of action.
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The best characterised mode of action of thyroid hormone tri-iodothyronine (T3) is on 
its nuclear receptor which acts as a ligand gated transcription factor.
1.3.1 Specific Transporters
For the ‘classically’ described actions of thyroid hormone to occur on its nuclear 
receptor it has to cross the plasma membrane. It seems that it crosses the membrane by 
specific processes that may be energy dependent rather than just a simple process of 
diffusion which is frequently the mechanism quoted (Hennemann et a l  2001). Studies 
have shown in the isolated perfused rat liver that when hepatic ATP is decreased by 
fructose, uptake of thyroid hormone into the liver is decreased (de Jong et a l  1993). 
Saturable specific transport of thyroid hormones often found to be energy and sodium 
dependent has been found in normal human and rat liver cells, as well as in human and 
rat hepatoma cells.
A variety of specific iodothyronine transporters are now recognised. The Na- 
taurocholate cotransporting polypeptide (NTCP), and the Na-independent organic anion 
transporting polypeptide 1 (OATP1) are examples (Friesema et a l  2005a; Friesema et 
a l  2005b). The OATP represent a large family of homologous proteins many of which 
have been shown to transport different iodothyronines. OATP1B2 is expressed in rat 
liver for example and is involved in transport of T 3 (Cattori et a l  2000).
Another class of transporters are the amino acid transporters and since the 
iodothyronines are composed of 2 tyrosine residues this comes as no surprise. Two 
identified transporters are LAT1 and LAT2 (human system L amino acid transporters) 
and their involvement in T3 transport has been demonstrated extensively in studies 
using Xenopus oocytes which were injected with the cRNAs for human LAT1 and then
1 9 5the uptake of I labelled iodothyronines was examined (Friesema et a l  2001).
A T type amino acid transporter, a member of the monocarboxylate transporter family 
(MCT) identified as M CT8  has been shown to be an active and specific iodothyronine 
transporter (Friesema et a l  2003). In humans there is a clinical syndrome whereby 
mutations in this transporter lead to severe psychomotor retardation and elevated T 3 
levels. The gene is X linked. It seems it is important in neuronal T3 transport 
particularly during brain development (Friesema et a l  2006).
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1.3.2 6Classical’ actions of thyroid hormone
The major thyroid hormone receptor is the nuclear receptor for T3 (Brent 1994). It is 
part of the nuclear receptor superfamily which includes the glucocorticoid, androgen, 
oestrogen, progesterone, vitamin D, retinoid X, peroxisome proliferator receptor and 
retinoic acid receptor (RAR). T3 binds to its receptor with 10 to 15 times greater affinity 
than does T4 (Evans 1988).
There are two major receptor isoforms, TR a and TRp, located in humans on 
chromosomes 17 and 3 respectively (Lazar 1993). The thyroid receptors have a central 
DNA binding domain (DBD) and a carboxy terminal ligand -  binding domain (LBD). 
The DNA binding domains are comprised of two distinct zinc fingers that are separated 
by a 15-17 amino acid linker sequence. The P-box is a small stretch of amino acids at 
the base of the first finger and it dictates the DNA sequence specificity of the receptor 
(Nelson et a i  1993).
Multiple isoforms are generated by alternate splicing from each gene, and T R al and 
TRa2 as well as TR pi and TRp2 have all been cloned in humans (Williams 2000).
The T R al and TR pl isoforms bind thyroid hormone with near equal affinity and are 
ubiquitously expressed, however T R al predominates in the heart (50-70% TR) and 
TRPI in the liver (80% of TR).
Thyroid hormone receptors bind to TH response elements (TREs) in specific target 
genes and after binding TH, the receptor induces change in gene expression by either 
increasing or decreasing transcriptional activity (Figure 2).
The consensus sequence recognised by nuclear receptors frequently contains a hexamer 
AGGTCA known as the half site and two half site sequences are required for functional 
and efficient binding (Umesono et a l  1991). Although TR can bind to certain TREs as a 
homodimer, it binds to most TREs as a heterodimer with the retinoid X receptor or 
RXR. These RXR proteins represent its most important heterodimeric partners. They 
enhance TR binding to the DNA and reduce the rate of receptor dissociation from DNA 
(Wahlstrom et a l  1992).
After binding to DNA, TR alters transcriptional activity by interacting with an array of 
transcriptional co-factors. In the absence of thyroid hormone, TR represses basal 
transcription, a phenomenon known as transcriptional silencing. Adding TH reverses 
basal suppression and increases transcriptional activation.
Co-repressors form a complex with other repressors that have histone deacetylase 
activity. Local histone deacetylation plays a critical role in the basal repression by 
unliganded TR/co-repressor complex by maintaining local chromatin structure in a state
23
that decreases basal transcription. When T 3 binds the TR undergoes a conformational 
change that dissociates CoRs and recruits a host of co-activators (Shibata et al. 1997). 
The SRC family and CBP proteins are thought to form part of this co-activator complex 
and these proteins have histone acetlytransferase activity (HAT) (Ribeiro et al. 1998). 
The enzymatic acetylisation of the nucleosome allows for an open chromatin 
configuration of the TRE on genomic DNA. This open structure facilitates the assembly 
of the basal transcription machinery and enhances the rate of mRNA transcription of 
thyroid responsive genes.
Figure 2 Role o f  co-repressors and co-activators in the control ofTj-regulated genes. 
In the absence o fT iy the RXR-TR heterodimer recruits co-repressors (CoR), which in 
turn, assemble additional components o f  a repressor complex that includes histone 
deacetylase (HDAC). Deacetylation o f  histones induce transcriptional repression. In the 
presence o f T), the co-repressor complex dissociates and co-activators (CoA) bind to 
TR. The co-activator complex can include steroid receptor co-activators (SRCs)/pl60, 
CREB-binding protein (CBP), p300/CBP associated factor (P/CAF), and proteins with 
histone acetyltransferase (HAT) activity. Vitamin D receptor interacting protein/TR 
associated protein (DRIP/TRAP) complex can also interact with liganded TR, and may 
cycle with SRC/p 160 complex. General transcription factors (GTFs) are also indicated. 
Acetylation o f  histones modifies chromatin structure to enhance transcriptional 
activation (www. thyroidmanager. org).
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1.3.3 TRal and TRpl Receptor specific agonists
Data from knockout mice suggest that T R al mediates the effect of thyroid hormone on 
heart rate and TRpl is important in mediating the cholesterol lowering and TSH- 
suppressant effects of T3 (Forrest et a l  1991).
The advent of thyromimetic agents which can act specifically on one receptor or the 
other will be useful in reducing any potential harmful cardiac side effects for example 
tachycardia. This may allow the induction of hyperthyroidism in specific tissues while 
reducing the effect in others. There has been developed a new class of halogen free 
thyroid hormone agonists which are highly selective for the TR pl receptor. The first 
molecule in this group is termed GC-1 (Taylor et a l  1997).
Columbano (Columbano et a l  2006) has looked at the effects of GC-1 on the rodent 
liver and pancreas. A continuous bromodeoxyuridine (BrdU) labelling index of 48% 
after 2 days treatment compared to only 9.8% in controls was observed. After 18 hours 
following a single dose of GC-1 there was a 15 fold increase in the number of positive 
BrdU hepatocyte nuclei.
The proliferative effect was also noted in the pancreas with significantly increased rates 
o f acinar cell proliferation seen. Consistent with other primary mitogens there is no 
increase in the immediate early genes c-fos and c-jun seen in compensatory liver 
regeneration, however as with previous reports there is an early induction of the cell 
cycle protein cyclin D1 mRNA (after only 2 hours). These molecular processes are 
discussed later. The results of this study strongly suggest that the proliferative hepatic 
effect of T3 is mediated by the TR pl receptor, the prevalent isoform in the liver.
1.3.4 ‘Non Genomic’ effects of thyroid hormone
The ‘classical’ mode of action of T3 with its nuclear receptor leading to gene 
transcription events will have a latency response time of hours to days (Bassett et a l  
2003). There are however a number of T3 effects which occur in a matter of seconds or 
minutes and are therefore incompatible with the classic mode of action of T3 (Losel and 
Wehling 2003; Wehling and Losel 2006; Wehling et a l  2006). These ‘non- genomic’ or 
‘non-classical’ steroid hormone effects encompass any action that does not directly 
affect nuclear gene transcription (Davis and Davis 1996; Zhang and Lazar 2000). These 
are typified by having a short latency, are unaffected by inhibitors of transcription and 
translation and persist in genetically modified mice that lack the classical nuclear 
receptors. Generally these non-genomic pathways are mediated by secondary messenger
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signalling pathways for example phospholipase C, diacylglycerol, and the MAPK 
pathway (Kavok et al. 2001; Alisi et al. 2004). The actions may be mediated by 
membrane associated isoforms of the thyroid hormone nuclear receptor or by novel 
receptors which as yet have not have been fully identified.
Non-genomic actions of thyroid hormone have been described at the plasma membrane, 
in the cytosol and in other cellular organelles. They have included the modulation of 
Na+, K+, Ca2+ and glucose transport, activation of PKC, PKA and ERK/MAPK and 
regulation of phospholipid metabolism by activation of PLC and PLD (Tang et al. 2004; 
D'Arezzo et al. 2004).
One of the earliest reports o f the non genomic action was to increase 2-deoxyglucose 
uptake in chick embryo heart cells (Segal et al. 1977) and later the same author 
demonstrated the same effect in various tissues of the rat (Segal 1989a; Segal 1989c; 
Segal 1989b).
In red blood cells T4 and T 3 have been shown to stimulate plasma membrane and 
sarcoplasmic reticulum Ca2+ -ATPase, increasing Ca2+ efflux from the cytosol 
(Rubinacci et al. 1992). The action on Ca2+ -ATPase is likely mediated by PKC, and this 
follows from activation of PLC which forms DAG from phosphatidylinositol. IP3 is 
produced by this reaction and can liberate Ca2+ from intracellular stores (Berridge 
1993b; Berridge 1993a). The MAPK signal cascade may be driven by T4, finally 
exerting multiple effects such as modulating the phosphorylation of STAT, p53 and 
even T R pi. This is an example of non-genomic modulation of a nuclear i.e. 
genomically acting receptor for the same hormone (Shih et a l  2001).
In the cardiovascular system T 3 enhances cardiac output and reduces systemic vascular 
resistance in adult males within 3 minutes (Schmidt et al. 2002).
T3 treatment also lowered the prevalence of atrial fibrillation in artery bypass graft 
patients, which may be explained by the rapid response of voltage gated K+ channels to 
thyroid hormone (Klemperer et al. 1996).
Cell culture studies suggest that thyroid hormones rapidly, and non-genomically, 
regulate the Ca2+ATPase enzyme, the Na+ channel (INa) via PKC, the K+ channel ( Ik ) 
via PI3-kinase, the Na+/H+ anti-porter via PKC and MAPK and the inward rectifying 
potassium channel (IKi) (Davis and Davis 2002). Wang showed T3 has a positive 
inotropic and arrythmagenic effect by increasing sarcoplasmic reticulum Ca2+, cell 
shortening, contractility and calcium mediated arrhythmic activity (Wang et al. 2003).
In vitro, independent of protein synthesis, T 3 induces IP3 and calcium signalling and 
augments the effects of IFNy via PKC and PKA (Lakatos and Stem 1991; Lin et al.
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1997). In addition, T4-linked to agarose, which does not cross the plasma membrane, 
has been shown to activate MAPK by a pertussis toxin sensitive mechanism suggesting 
the actions of a G protein-coupled thyroid hormone membrane receptor (Lin et al. 
1999). In vivo, T4 regulates thermogenesis and the lipolytic activities of catecholamines 
within 30 minutes (Lynch et al. 1985).
Circulating T3 levels are kept very stable so it may be hard to see how such hormones 
can bring mediate such rapid and physiologically critical actions. However there is cell 
type specific regulation of pre-receptor ligand metabolism by the deiodinase enzyme 
system. D2 has a very short half life and so it may help in rapid regulation of 
intracellular T3. As thyroid hormone enters cells through carrier mediated mechanisms 
then these too represent targets for regulating intracellular thyroid hormone 
concentrations.
There is emerging evidence that there may be effects on cell proliferation and 
differentiation by way of these pathways just described. The signals may converge with 
more classical genomic effects so the cell can respond in an appropriate coordinated 
fashion, integrating short term and long term needs (Bassett et al. 2003).
In further understanding the combination of both non-genomic and classical genomic 
actions it is proposed that there is a two-step model of steroid hormone action. The 
rapid non-genomic as well as the delayed genomic actions are comprised together with 
possible mechanisms of modulation of classic receptor-induced gene transcription by 
non-genomic signal transduction pathways (Figure 3).
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Figure 3 The integration o f  genomic and non-genomic signalling cascades. In this 
example steroids act as the ligand fo r  their receptors which sit either at the cell 
membrane, the cell cytosol and/or the cell nucleus where previously their direct nuclear 
effects have been classically described. Novel nongenomic second messenger mediated 
effects are depicted which are initiated at the cell membrane (Wehling and Losel 2006).
1.4 Thyroid hormone membrane receptors
1.4.1 Non classical thyroid hormone receptors
Only recently has the identity of one cell surface thyroid hormone receptor been 
established (Davis et al. 2005), namely on the integrin aV(33 (Bergh et al. 2005; Cody et 
al. 2007). This is linked by transduction cascades involving MAPK to cell membrane 
transport functions and to MAPK-mediated intra-nuclear events including transcription. 
Integrins are ubiquitous heterodimeric structural proteins of the cell membrane that can 
convey signals from the extra-cellular matrix (ECM) to the cell. The integrins are a 
superfamily of glycoproteins that consist of an a- and P-subunit that associate in defined 
combinations that yield more than two dozen different mammalian integrin subtypes.
In one study T* was found to promote angiogenesis in a chick chorioallantoic membrane 
model but when it was attached to agarose and therefore unable to enter the cell interior 
it still had the angiogenic effect (Davis et al. 2004). It is clear that T3 can be associated 
with membrane initiated events that culminate in the cell nucleus, for example
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activation of the phosphatidyl-inositol 3-kinase Akt/protein kinase B signal 
transduction cascade modulates the transcription of the calcineurin inhibitor ZAKI4A in 
skin fibroblasts (Cao et al. 2005). Whether such activation occurs via aVP3 or another 
integrin is not yet clear.
The affinity of this integrin receptor is substantially lower for T 3. However further 
recent work has shown that T 3 (in higher concentration than T4) could bring about 
proliferation of glioma cell lines C6 , F98 and GL261 as measured by thymidine 
incorporation and PCNA accumulation (Davis et al. 2006). This effect was inhibited by 
the T4 analogue, tetraiodothyroacetic acid, and by an < ^ 6 3  RGD recognition site peptide, 
both of which block T4 binding to integrin ^ 6 3  but are not agonists.
1.5 The cell cycle
Control of cell proliferation is essential and the cell cycle describes the way in which 
cells try to achieve this. It is important to note that the vast majority of hepatocytes 
remain in the resting phase or Go phase of the cell cycle and only will emerge from this 
into the active parts of the cycle following certain stimuli. However after 2/3rds 
hepatectomy 95% of normally quiescent hepatic cells rapidly re-enter the cell cycle in 
response to this well established stimulus to bring about compensatory regeneration.
A key step in progression through the cell cycle is that of passing through Gi having 
emerged from the resting state and then going past a restriction point allowing DNA 
synthesis to occur and then cell division.
Cyclin D1 and its associated cyclin dependent kinases are important in the early phase 
of the cell cycle. Activation through phosphorylation between cyclins and the cyclin 
dependent kinases (CDKs) leads to cell cycle progression. After a complex chain of 
events the ultimate substrate is the retinoblastoma protein, pRb which is the major target 
of the cyclin D1/CDK4 complex. Following its phosphorylation E2F transcription 
factors are free and can trans- activate genes that allow progression from Gi to S phase. 
This is discussed in more detail in chapter four.
1.6 Compensatory and Direct Liver Hyperplasia
Liver regeneration occurs when there is a major loss of hepatic tissue. The liver is noted 
to possess the remarkable ability to regenerate itself back to an appropriate weight and 
in so doing to return to a normally functioning hepatic mass appropriate to the size of 
the organism. This process of liver growth is termed compensatory hyperplasia but in
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addition to this process it is recognised that the liver can be made to grow following the 
application of a mitogenic stimulus without any preceding loss of hepatic mass and this 
is termed direct hyperplasia (Michalopoulos and DeFrances 2005; Michalopoulos and 
DeFrances 1997).
In the first situation (compensatory hyperplasia), for example following the well known 
stimulus of partial hepatectomy, cells move from the resting phase of the cycle Go to Gi 
part of the active cell cycle.
Very briefly the molecular events involve hepatocyte priming by cytokines TNF-a and 
IL- 6  and then activation of the important downstream transcription factors including 
STAT-3 and NF-kB before activation of the immediate early genes c-fos, c-jun and c- 
myc (Fausto and Riehle 2005). Delayed gene activation leads to activation o f the cell 
cycle cyclins which allow progression through the cell cycle after passing the Gi 
restriction point, having emerged from the resting state Go (Columbano and Shinozuka 
1996).
In the direct hyperplasia response (which occurs without liver cell loss), proliferation 
comes about without the activation of these transcription factors and early response 
genes and cyclin D1 activation occurs earlier (within at least 8  hours compared to 16 
hours after partial hepatectomy in rodents). A host of ‘mitogens’ can bring about the 
direct hyperplasia response including of course T3 (Fausto 2000; Fausto et al. 1995).
1.6.1 Compensatory hyperplasia
The surgical model for partial hepatectomy (PH) leading to compensatory regeneration 
of the liver was described by Higgins and Anderson in the rat and mouse (Higgins and 
Anderson 1931). A two thirds PH removes 70% of the liver mass and the residual 30% 
grows to restore the organ back to its original mass. The growth does not however 
restore the shape of the liver, and it is now composed of two lobes instead of five. A 
similar pattern of restoration of hepatic mass is seen in humans in the setting of partial 
hepatectomy. Following hepatectomy a measurable peak in DNA synthesis is seen in 
hepatocytes at 24h in the rat and 40h in the mouse and this can even vary between 
strains. The onset of DNA synthesis is well synchronised beginning around the portal 
vein and proceeding to the central vein. DNA synthesis in the non parenchymal cells 
(npcs) peaks at around 36 to 48 hours (Figure 4).
The differences in timing of DNA replication in rats and mice is due to a longer Gi 
phase in mice. Studies using thymidine incorporation have shown that more than 90%
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of the hepatocytes participate in the regenerative process and so it is not solely due to a 
subset population. The proliferation begins in hepatocytes around the portal triads and 
progresses to the central veins by 48h in the rat. However proliferation of the other cell 
populations proceeds at a different rate, for exam ple endothelial cells start proliferating 
after three days and peak at day five (Grisham 1962).
Figure 4 Time kinetics o f  DNA synthesis in different liver cell types during liver 
regeneration after partial hepatectomy. The four major types o f  liver cells undergo 
DNA synthesis at different times. Hepatocyte DNA synthesis peaks at 24 hours, whereas 
the other cell types proliferate later. Regenerating hepatocytes produce growth factors 
that can function as mitogens fo r  these cells and it has been suggested that hepatocytes 
stimulate proliferation o f  the other cells by a paracrine mechanism (Michalopoulos and 
DeFrances 1997).
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Figure 5 A timeline fo r  the molecular processes involved in compensatory hepatic 
growth. Immediate early genes are expressed within four hours follow ed by delayed 
gene expression up to eight hours later. This parallels progression o f the cell cycle from  
the resting Go phase into the active Gi phase leading eventually to DNA synthesis in S 
phase.
1.6.1.1 Molecular events during compensatory hyperplasia
A number of genes are either newly expressed or increase their expression after partial 
hepatectomy (Taub 1996b; Taub 1996a) (Figure 5). The immediate early phase response 
occurs very rapidly and lasts for about 4 hours. As many as 100 genes participate in this 
phase (Taub 2004). The events upstream of this are still unclear but certain facts have 
been determined. Urokinase activity is up-regulated within minutes and the hepatocyte 
membrane is rapidly depolarised and this persists for more than 3 hours. EGF and HGF 
receptors are activated by tyrosine phosphorylation within 30 to 60 minutes.
An important group of transcription factors are activated after partial hepatectomy. 
These include NF-kB, AP-1 and STAT3. Their activation does not require de novo 
protein synthesis. After PH, NF-kB is activated within 30 minutes at the latest and this 
activation is transient and seen to disappear by 4 hours. Activation occurs through 
removal of the inhibitor IkB from the NF-kB heterodimer.
STAT3 activation is slower and is detectable in the liver 1 to 2 hours after hepatectomy. 
STAT3 is activated mainly by IL- 6  cytokines (Fausto et al. 2006; Michalopoulos and 
DeFrances 2005; Cressman et al. 1995; Cressman et al. 1995).
The second phase of gene expression is the delayed gene response. A variety of cell 
cycle genes become activated including p53, p21, cyclins and cyclin dependent kinases. 
The induction of cyclin D1 is the most reliable marker of cell cycle progression.
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Tumour necrosis factor (TNF) is a potent liver NF-icB inducer and it is hypothesised 
that the sequence of events after partial hepatectomy is TNF—►TNFR-l—* NF-kB —HL- 
6 —►STATS. The TNF-a primes liver cells to be transformed from a quiescent state to an 
activated Gi state. Following on there is an increase in IL- 6  levels occurring between 2 
to 6  hours. This eventually leads to STAT3 activation and the immediate early gene 
response. IL - 6  is produced by non parenchymal cells such as the Kupffer cell and it 
ligands with its receptor on the hepatocyte membrane. IL - 6  bound to gp80 activates its 
associated gpl30 molecule and then there is induction of homo-dimerisation of two 
gp l30  molecules which leads to receptor activation.
It is important to note that hepatic regeneration proceeds eventually in IL6  -/- and 
TNFR1 -/- mice so other growth factors must compensate in the absence of IL6  and 
TNF triggered signalling cascades.
Two distinct pathways are seen to operate: a cytokine dependent pathway and a growth 
factor dependent pathway.
1.6.1.2 Cytokine pathways
TNF-a binds to its Kupffer cell receptor which results in IL- 6  up-regulation. IL - 6  binds 
to its receptor on hepatocytes and activates the Janus kinase pathway and this stimulates 
the STAT3 pathway. STAT3 (which is now active after it has dimerised) translocates to 
the nucleus where it activates about 36% of the immediate early genes. The activated 
JAK also stimulates the MAPK pathway.
Lipopolysaccharide (LPS) interacts with its receptor on the Kupffer cells and this may 
trigger the signalling after PH.
So, during liver regeneration, IL - 6  activates two main pathways through the gp l30-IL - 
6 R complex —  the STAT3 and MAPK signalling pathways. As the STAT3-null 
phenotype is ‘embryonic-lethal’, liver-specific STAT3 knockouts (where Alb Alb+ 
STAT3fl/fl stands for albumin-driven promoter, and fl stands for floxed, or deleted, 
allele) were used to test the contribution of STAT3 to the growth response that is 
mediated by IL-6 . Hepatocyte DNA synthesis in Alb+ STAT3fl/fl livers was impaired 
after partial hepatectomy, and abnormalities in immediate-early-gene activation largely 
correlated with, but were not identical to, those seen in IL-6 '/_ livers. Normal activation 
o f the MAPK (pERK) pathway in Alb+ S T A T S ^  livers supports the idea that not all of 
the effects o f IL - 6  on hepatocyte proliferation are mediated by STAT3 (Li et al. 2002). 
Furthermore, this study provided the first in vivo evidence that STAT3 promotes cell-
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cycle progression and cell proliferation under physiological growth conditions, which 
implies that the separation between growth-factor- and cytokine-regulated pathways is 
not absolute.
1.6.1.3 Growth Factor pathways
On the basis of in vivo studies and in vitro studies in isolated hepatocytes, Transforming 
Growth factor (TGF-a) and Hepatocyte Growth Factor (HGF) are considered to be two 
of the most important growth factors. HGF is synthesised by stellate cells and acts in a 
paracrine manner for hepatocytes (Michalopoulos and Appasamy 1993). HGF and its 
receptor c-Met are important in many tissues and hence knockout of their genes results 
in a lethal phenotype. The mitogenic effect is mediated in part at least by TGF-a. 
However, as a large number of ligands and receptors belong to the TGF and EGF 
family, the inability to block all of these ligands and receptors simultaneously has made 
it difficult to prove that the potent hepatocyte mitogens TGF-a and EGF are crucial for 
regeneration.
1.6.2 Both pathways
HGF and TNF-a-IL - 6  signalling are necessary for liver regeneration. It is however not 
yet fully known how growth factors and cytokines interact to lead to a full regenerative 
response. For example both HGF and TNF-a can induce cell proliferation and cyclin D1 
activation (Schwabe et a l  2003; Talarmin et a l  1999).
The EL-6 -TN F-« and HGF pathways both up-regulate the activity of the various homo- 
and hetero-dimeric A PI transcription factors. API activity is required for the activation 
o f a number of proteins that are involved in the growth response
1.7 Direct hyperplasia
Proliferation of liver cells can also come about without preceding cell loss. A group of 
chemicals which is able to achieve this are known as primary hepatic mitogens (Table
1) and the process they invoke is termed direct hyperplasia (Columbano and Shinozuka 
1996). The signalling pathways leading to DNA replication differ from those following 
partial hepatectomy. After nafenopin for example there is no increased activation of 
NFKp, however this transcription factor is activated after partial hepatectomy 
(Menegazzi et a l  1997).
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The hepatocyte proliferation induced by these agents comes about in the absence of 
activation of the other transcription factors AP-1, and STAT-3 or changes in the 
immediate early genes c-jun, c-fos and c-myc which occur following partial 
hepatectomy.
Table 1 The primary hepatic mitogens
N uclear R eceptor Fam ily L igands O thers
Tri-iodothyronine (T3) Lead nitrate (LN)
Cyproterone acetate (CPA) Ethylene dibromide (EDB)
9-cis retinoic acid Tumour Necrosis Factor-a (TNF-a)
Peroxisome proliferators e.g. 
nafenopin and Wy14643 and BR931
4-Acetylaminofluorane
1,4-bis [2-(3,5-dichlo ropyridyloxy) ] 
benzene (TCPOBOP)
a -Hexachlorocyclohexane
Oestrogens Interleukin-6 (IL-6)
Phenobarbital
There is variety between these agents with regards to their mitogenic potency and the 
time taken to bring about DNA synthesis and cell replication (Ledda-Columbano et a l  
1993; Ledda-Columbano et a l  1994). Importantly after the mitogenic stimulus is 
withdrawn there is elimination o f the excess numbers of cells produced and this is most 
likely through the process of apoptosis.
A number of studies have shown that the pattern of immediate early gene expression 
seen after partial hepatectomy is not replicated after stimulation with either LN, EDB, 
CPA, nafenopin or W yl4643, where there was no increase in expression of for example 
c-fos (Coni et a l  1993; Chevalier et a l  1999). After induction of cell proliferation with 
CPA and nafenopin no changes were observed in either c-jun or c-myc (Menegazzi et 
a l  1997).
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Observations thus far indicate that different signalling pathways are involved in 
triggering hepatocyte proliferation depending on
1 ) whether the stimulus is direct or compensatory hyperplasia
2 ) the type of primary mitogen
The different known primary mitogens will now be discussed in more detail.
1.7.1 The Nuclear Receptor Superfamily-RAR, RXR, THR, PPR
N uclear recep tor superfam ily Ligand
Thyroid hormone receptor like:
RAR: RARa RARP RARy Retinoic acid
PPR: PPARa PPARp PPARy Peroxisome proliferators
Vitamin D receptor Vitamin D
Constitutive androstane receptor CAR TCPOBOP
THR TRct TRp Triiodothyronine
Retinoid X  receptor like:
Hepatocyte nuclear factor 4
RXR a  p y
Table 2 The Nuclear Receptor Superfamily
Nuclear hormone receptors comprise a large superfamily of ligand-modulated 
transcription factors, including the classical steroid and thyroid hormone receptors 
(TRs) as well as the retinoid hormone receptors (Table 2). These transcription factors 
classically activate target genes by binding specific DNA sequences located in the 
promoter of these genes. By comparing amino acid sequences of the first steroid 
hormone receptors cloned in the mid-1980s, a common structural and functional 
organization appeared. Four main domains are distinguished: the N-terminal A/B 
domain that varies in both sequence and length, comprising a ligand-independent 
transactivation function, called activation function 1 (AF-1); the highly conserved C 
domain forming an about 70 amino acid long DNA-binding domain (DBD); the D 
domain or so-called hinge domain, linking the DBD to the ligand-binding domain 
(LBD); and, the C-terminal E/F domain or LBD, containing a ligand-dependent 
transactivation function, termed AF-2.
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According to the proposed unified nomenclature of nuclear hormone receptors, PPARs 
form the group C in the subfamily 1 of the superfamily of nuclear hormone receptors, 
i.e. NR 1C. This large subfamily also comprises, for instance, the TRs (NR1A), the all- 
trans retinoic acid receptors, RARs, (NRIB), and the vitamin D3 receptor, VDR, 
(NR II) (Germain et a l  2006). There are three PPAR isotypes, namely 
PPARa (NR1C1), PPARP (NR1C2), and PPARy (NR1C3), which have been found so 
far in cyclostoma, teleosts, amphibians, rodents and humans.
Most nuclear receptors will bind to DNA as hetero-dimers with the RXR (Szanto et a l
2004). This is thought to enhance affinity and provide greater target gene specificity. 
Indeed, a hallmark of this receptor family is the DNA binding domain which is folded 
in two zinc fingers. The DNA response element of nuclear receptors comprises two 
short hexameric sequence motifs closely related to AGGTCA.
The Retinoic acid receptor (RAR), the retinoid X receptor (RXR), the thyroid hormone 
receptor and the peroxisome proliferator receptor all possess six domains, two of which 
are a ligand-binding region and a central region that constitutively binds to DNA. These 
receptors classically act as ligand activated transcription factors which have a direct 
effect on gene expression through their DNA response elements (Umesono et a l  1988; 
Columbano and Ledda-Columbano 2003), as described earlier in this chapter.
1,7.2 Peroxisome Proliferators (PPs)
Hypolipidaemic drugs:
clofibrate, clofibric acid, ciprofibrate, W Y -14,643, BR-931, methylclofenapate
cyproterone acetate, nafenopin
thiazolidinediones:
pioglitazone and rosiglitazone
Non-steroidal anti-inflammatory drugs:
Indomethacin, ibuprofen
The peroxisome proliferators are a diverse group of chemicals with a host of 
applications being used in medicine but also in industry and agriculture. In clinical 
medicine their uses are many, for example the hypolipidaemic fibrates and the insulin 
sensitising thiazolidinediones, pioglitazone and rosiglitazone (Escher and Wahli 2000). 
These drugs are so called because they induce peroxisome proliferation in the livers of 
rats and mice such that peroxisomal volume density is increased and certain
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peroxisomal enzyme activities are induced. However they exert another notable effect, 
that of cell mitosis (Cattley 2003), an effect first noted in the 1960s by Hess.
When BR931, for example, is administered to adult male Wistar rats a wave of DNA 
replication is seen to start after 12 hours and this peaked at 24 to 36 hours (Ohmura et 
al. 1996). Northern blot analysis shows that there is no induction of HGF, transforming 
growth factor-alpha, or tumour necrosis factor-alpha mRNAs. In addition no induction 
of the early growth response genes is seen and gel mobility shift assays reveal no 
enhanced NFicp binding to its DNA consensus sequence. The evidence points to the 
peroxisome proliferator binding directly to its nuclear receptor which then brings about 
DNA synthesis. This is a key difference in the unfolding molecular events when 
compared to the stimulus of PH.
The nuclear receptor binds to DNA as a heterodimer with the Retinoid X Receptor 
(RXR) which acts as the obligate partner for PPARs. The heterodimer binds to a 
specific response element the PPRE consisting of a direct repeat sequence separated by 
one oligonucleotide DR-1.
Three receptor isotypes have been identified: PPARa, PPARp and PPARy.
PPARa is predominantly expressed in the liver and is important in regulating fatty acid 
metabolism and the inflammatory response.
PPARp is expressed ubiquitously in various tissues and is thought to be important in 
embryo implantation.
PPARy is highly expressed in adipose tissue and is a potent regulator of adipocyte 
differentiation.
There is a good correlation between ability of a PP to bind to and/or activate PPARa 
and the potency of the PP as an inducer of hepatocarcinogenesis. Many, if not all, PP 
are ligands for PPARa, and it is hypothesised that this receptor is the major cellular 
target of hepatocarcinogenic PP in the liver.
Ligands have different affinities for the receptor sub-types. For example the fibrates 
such as Wy 14,643 and cloflbrate preferentially activate PPARa but at higher 
concentrations significant activation of PPARy does occur. The thiazolidinediones on 
the other hand show a much higher affinity for PPARy (Lehmann et al. 1995).
PPARa ligands Wy 14,643 and cloflbrate, are known to produce liver tumours in mice 
and rats. Wy 14,643 also induces DNA replication, as assessed by bromodeoxyuridine 
incorporation in vivo in mice and in primary rat hepatocyte cultures. The specific target 
genes mediating these effects remain unidentified (Peters et al. 2005). Clearly the
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increased rates of cell proliferation are contributory to the development of hepatic 
tumours in these rodent models (Corton et a l  2000).
In 1990 the PPAR was cloned from mouse liver (Issemann and Green 1990) and 
eventually a PPARa null mouse was created which did not respond to PP treatment 
(Lee et al. 1995). The knockout animal provided conclusive evidence for involvement 
o f the PPARa receptor. Feeding mice with Wy 14,643 or cloflbrate leads to hepatic 
peroxisome proliferation and hepatocellular neoplasms in the wild-type mice, whereas 
their knockout counterparts are unaffected. Thus, the PPARa knockout mouse presents 
a useful animal model to determine the role of this receptor in rodent hepatomegaly and 
hepatocarcinogenesis.
These observations identify PPARa as a mediator of pleiotropic responses to 
peroxisome proliferators, which may be partly achieved by H2O2 generated through 
activation of target genes in peroxisomal p-oxidation. PPARa may mediate pleiotropic 
effects of peroxisome proliferators also by interfering with the cell-cycle. Indeed, a 
dominant negative PPA Ra protein prevents the suppression of hepatocyte apoptosis by 
the peroxisome proliferator nafenopin, suggesting that PPARa can abrogate the 
commitment of hepatocytes to apoptosis (James et a l  1998). However, the respective 
contribution of peroxisome proliferation and enhanced cell proliferation to 
hepatocarcinogenesis remains to be evaluated. Furthermore, a link between species- 
specific hepatic PPARa expression and hepatocarcinogenesis may exist. For instance, 
hepatic PPARa expression is reported to be lower in human vs. rodents, and no liver 
tumours are reported in the former upon treatment with peroxisome proliferators. The 
molecular basis of this strong species difference remains elusive (Corton et a l  2000).
In rats treated with PPs the increase in S phase cells has been frequently observed to 
preferentially occur in the periportal region (Barrass et a l  1993). This is observed with 
WY-14,643, clofibric acid, nafenopin and methylclofenapate. There is an observed 
increase in mitosis 1 to 2 days after treatment with the drug. The greatest increase in S 
phase (measured usually by tritiated thymidine incorporation or BrdU incorporation) is 
seen in the first week in rats fed WY-14,643 in their diet for a year, and there is a 
corresponding increase in liver weight (Marsman et a l  1988). After 1 day 8 .8 % of 
hepatocyte nuclei were flash labelled with tritiated thymidine after WY-14,643 and 
5.6% after treatment with DEHP, compared to a control of 2.0%.
PPs may exert their effect on proliferation by affecting the expression of cyclins and 
cyclin dependent kinases. Roberts showed that cyclin E, cyclin D l, CDK4 and CDK2
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accumulate upon stimulation with the PP nafenopin (Roberts et a l  2002). It has also 
been shown that PPs have an effect on apoptosis and suppress it (Roberts et a l  1995). 
The basal frequency of apoptosis is low in the rat liver, about 0.03% but after treatment 
with nafenopin this falls to 0.002%. Again this effect varies between the PPs and even 
between species whereby CI-924 decreases apoptosis in rat but not mouse liver. This is 
most likely one of the reasons why one sees the development of pre-neoplatsic foci 
which can lead to malignant liver tumours. The regression of hyperplasia after 
withdrawal of the PP comes about through apoptosis, and a rise of almost 6  fold in 
apoptosis is seen in rat liver after withdrawal of nafenopin.
There is a notable species differences with these drugs. For example in marmosets 
nafenopin, DEHP or ciprofibrate fail to induce any increase in liver mass. Syrian 
hamsters are observed to gain liver weight but there is no increase in the number of S 
phase hepatocytes. Therefore, most of the studies to characterise these agents have been 
conducted in rats and mice.
1.7.2.1 PPARy and Liver Regeneration
More recently the role of the PPARy receptor isotype has been studied in the setting of 
PH. Liver regeneration has been shown to be impaired in a number of animal models of 
fatty liver disease (Yang et a l  2001). Recent work sought to investigate the role of 
PPARy in liver regeneration (Turmelle et a l  2006). The results show that 
thiazolidinediones impair liver regeneration with efficacies corresponding to their 
relative potencies of PPARy (i.e. rosiglitazone > pioglitazone > troglitazone) when 
levels of BrdU incorporation are measured 36 hours following partial hepatectomy in 
mice pre dosed with one of these agents. The data implicate PPARy as an important 
regulator in the hepatic regenerative response, a novel description reflecting the 
complexities that still exist in describing the molecular events in both direct and 
compensatory liver hyperplasia.
1.7.3 Retinoic Acid
Retinoids are natural and synthetic vitamin A derivatives which can have marked effects 
on cellular differentiation and proliferation.
Two classes of receptors mediate the effects of the retinoids, the retinoic acid receptor 
RAR (RARa, RARp and RARy) and the retinoid X receptor RXR (RXRa, RXRp and
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RXRy). Signal transduction comes about following heterodimerisation of these 
receptors after ligand binding. Very little data are available on the effect of trans- 
Retinoic Acid (tRA), a natural metabolite of vitamin A.
Ledda-Columbano has recently studied the effects of tRA on rodent liver in vivo 
(Ledda-Columbano et a l  2004b). Mice were fed a diet containing tRA for up to 4 
weeks. BrdU added in the drinking water prior to sacrifice enabled them to measure 
hepatocyte proliferation. At 150mg/kg a BrdU labelling index of 16.5% (against 1.7% 
of controls) was observed in the first week, when it was maximal. Most labelling was 
mid-zonal with the areas around zone III being relatively unaffected. DNA synthesis 
was noted to begin in the first 24 hours with even higher amounts of BrdU incorporation 
on days 4 and 5. There was no evidence of the mitogen having its effects due to liver 
damage i.e. compensatory regeneration as the liver enzymes were not raised and neither 
was the histological mitotic index. After 1 week liver weight and total DNA content was 
also raised.
After 2 days of treatment with tRA there was a strong induction of cyclin D1 over 
controls. Cyclin E levels were also increased. It seems this is consistent with the other 
mitogens which ligand with a nuclear receptor, and in these situations there is an 
increase in the GI cyclin, cyclin D1 early on after mitogenic stimulation, earlier than 
after the stimulus of partial hepatectomy. The evidence from this study again shows the 
difficulty when interpreting this data with regards to inter-species variations. For 
example, tRA given shortly before partial hepatectomy in the rat actually inhibits DNA 
synthesis in the regenerating liver (Ozeki and Tsukamoto 1999).
The effects of tRA are complex as previous work demonstrated a cytostatic effect of 
tRA in breast cancer (del Rincon et a l  2003) but it is thought that this may be as a result 
of a ‘re-differentiation effect’ on pre-neoplastic nodules. This is borne out with T3 as 
well whereby although it can act as a liver mitogen it also inhibits the development of 
hepatocellular carcinoma and accelerates regression of pre-neoplastic liver nodules 
(Ledda-Columbano et a l  2000a).
1.7.4 1,4-bis [2-(3,5-dichloropyridyloxy)] benzene (TCPOBOP)
The halogenated hydrocarbon 1,4-bis [2-(3,5-dichloropyridyloxy)] benzene 
(TCPOBOP) is a tumour promoting liver mitogen and a powerful inducer of cell 
proliferation and a complete carcinogen for mouse liver. It acts by activating the 
constitutive androstane receptor (CAR) which is another nuclear receptor transcription
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factor. Like some other nuclear receptors CAR forms a heterodimer with RXR and this 
is what binds to gene regulatory elements.
As with other mitogens that have a nuclear receptor, TCPOBOP does not require 
activation of the transcription factors NF-kB, STAT-3, immediate response genes and 
does not involve cytokines like TNF-a and IL- 6  (Columbano et a l  1997).
Mice treated with just one dose of TCPOBOP show levels of BrdU incorporation as 
high as after two thirds PH and there is a more rapid induction of the cyclins when 
compared to PH (Ledda-Columbano et a l  2000b). Signalling pathways differ once 
again whereby liver regeneration is severely impaired in TNF-RI and IL - 6  knockout 
mice but the proliferative response to TCPOBOP is normal in these animals.
Eighty per cent of hepatocytes enter S phase within 4 days of treatment and indeed there 
is an earlier onset o f DNA synthesis when compared to partial hepatectomy. After 
partial hepatectomy cyclin D1 levels are seen to rise after 30 hours whereas after 
TCPOBOP cyclin D1 mRNA is seen to rise after just 2 hours with the protein rising at 8  
hours. It seems that the mitogen TCPOBOP is having two effects i) a very rapid 
induction of cyclin D1 and ii) a shortening of the GI phase of the cell cycle, to about 12 
to 16 hours.
The cyclin D1 promoter contains an oestrogen responsive region and this may help 
explain how the gene may be regulated by other ligands which have nuclear receptors. 
This cyclin associates with CDK4 and CDK6  which act on pRb which is the cellular 
substrate for these enzymes. Columbano’s group looked at the response to TCPOBOP 
in mice deficient for the cyclin D 1 gene product (Ledda-Columbano et a l  2002). They 
showed that after 24 hours there was less BrdU incorporation compared to normal 
animals but by 36 then 72 hours there was no difference with the wild type. Lack of 
cyclin D1 delayed entry into S phase but the hepatocyte response was not ultimately 
inhibited. It may be hypothesised that other G I cyclins such as cyclin E can compensate 
and take over the role of cyclin D1 although this was not proved in the study just 
described.
This group also looked at the response to TCPOBOP in mice when compared with PH; 
the early molecular events were examined with the aid of microarray technology 
(Locker et a l  2003). 23 genes were regulated only by TCPOBOP, 57 only by PH and 
59 by both. Only 12 regulated genes were associated with the cell cycle directly and 
given the time between the stimulus and S phase of between 24-36 hours this makes 
some sense and suggests that cell cycle regulators are not direct targets o f CAR or for 
that matter STAT-3 and NF-kB. TCPOBOP selectively up regulated a set of
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detoxification enzymes and like partial hepatectomy elevated anti-apoptotic regulators 
and down regulated pro-apoptotic regulators.
1.7.5 Interleukin-6 (IL-6)
The multifunctional pro-inflammatory cytokine IL- 6  exhibits growth inhibitory, growth 
stimulatory and differentiation promoting activities depending on the cell type it is 
targeting (Taga and Kishimoto 1997).
The receptor for this cytokine is called gpl30. This complex causes dimerisation of 
gpl30  and subsequent activation of the Janus kinases which tyrosine phosphorylate 
gpl30. This results in the activation of STAT 3 and the MAP kinase pathway.
IL - 6  is essential for normal hepatic regeneration in response to partial hepatectomy or 
injury. Until recently no one had demonstrated a mitogenic role for IL - 6  in vivo. 
Zimmers has produced evidence which demonstrates the mitogenic action of IL - 6  
(Zimmers et a l  2003). A CHO cell line was developed which over-expressed human 
IL - 6  and then injected into athymic nude mice. CHO-IL - 6  treated mice became wasted 
during treatment and developed abdominal distension resulting in an enlarged liver seen 
at post mortem. There was increased liver DNA and protein in CHO-IL6  mice as well 
as increased expression of cyclin D1 and PCNA. Panlobular hepatocyte hyperplasia was 
seen histologically with many mitotic figures and increased numbers of cells 
undergoing DNA synthesis by way of BrdU incorporation. There was no evidence of 
liver injury.
Furthermore there was a dramatic increase in STAT-3 and following on from this an 
increase in its target genes c-myc and c-jun. No effect was seen on levels of HGF and 
EGF or TGF alpha and in fact these pathways appeared to be down regulated.
The long term high dose exposure to IL - 6  in this study is thought to have resulted in the 
increased hepatocyte proliferation which had not been demonstrated before as exposure 
was too short term and in too low a dose. The application of IL - 6  in a clinical 
environment to augment liver growth may however not be possible given the toxic side 
effects seen at high dose such as muscle wasting and splenomegaly. Just as with T 3 
though if the mechanism of action can be fully elucidated then we may be able to act on 
members of the IL - 6  signalling pathway to bring about specific therapeutic results.
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1.7.6 Tumour Necrosis Factor-a (TNF-a)
This cytokine has a well known wide range of biological activities including apoptosis, 
growth, differentiation and inflammation (Locksley et a l  2001). It has two ubiquitously 
expressed receptors TNFR1 and TNFR2. The transcription factor NF-kB is an essential 
component of the TNF proliferative pathway and TNF-induced changes in STAT-3, IL- 
6  and c-myc mRNA are dependent on NF-kB activation.
Iocca and Isom have shown that TNF-a can induce DNA synthesis in long term DMSO 
culture of rat hepatocytes (Iocca and Isom 2003). They observed maximal induction of 
DNA synthesis after 24 hours and progression through the cell cycle was confirmed by 
observing mitotic figures after 96 hours. NF-kB was activated by TNF-a within 1 hour. 
This is a good demonstration of TNF-a acting as a complete mitogen rather than just a 
priming factor.
1.7.7 Epidermal Growth Factor/Hepatocyte Growth 
Factor/Transforming Growth Factor-a
HGF, TGF-a and EGF have been shown to be potent hepatic mitogens in vitro and their 
role in direct hyperplasia has been referred to.
Hepatocyte growth factor (HGF) is the most potent of the hepatic mitogens. First
identified in 1984, it is a hetero-dimeric glycoprotein, also known as scatter factor,
composed of a 69-kDa a-chain and a 34-kDa p-chain (Nakamura et al. 1984). Serine
proteases are responsible for the conversion of a single chain precursor form into the
two-chain form and this is coupled to its activation. It is made by mesenchymal cells
throughout the body. Kupffer, endothelial and Ito cells produce it in the liver. HGF
binds with high affinity to its receptor, a transmembrane tyrosine kinase, encoded by the
c-Met proto-oncogene (Bottaro et al. 1991). The receptor is composed of an extra
cellular a-chain and a transmembrane p-chain. HGF activation results in a cascade of
signalling involving tyrosine kinases as well as phosphatidylinositol 3-kinase. Met is the
only known functional receptor for HGF and HGF is the only natural ligand for Met.
These growth factors have been shown to be complete mitogens for hepatocytes in
culture but their in vivo role is more difficult to characterise. In culture they act to
activate the immediate early genes which leads to DNA synthesis (Band et a l  1999).
When HGF and EGF are infused directly into the portal circulation in rats using mini
osmotic pumps their effects on DNA replication in the liver can be assessed by means
of BrdU incorporation into hepatocyte nuclei. When infused alone or even in
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combination no more than 10% of hepatocytes are labelled at 24 or 48 hours. When 
though the animals undergo only 30 % partial hepatectomy and are then given growth 
factors such as HGF one sees a restoration of a peak of DNA synthesis at 24 hours. This 
lead to the concept of priming of hepatocytes being necessary prior to these agents 
being able to exert their full effects on growth (Shiota et a l  1994; Fujiwara et a l  1993; 
Webber et al. 1994).
Further in vivo studies (Fujiwara et al. 1993; Patijn et a l  1998) suggest that quiescent 
hepatocytes may divide after more prolonged treatment but they do not respond to the 
administration of a discrete dose as occurs with some of the other primary mitogens that 
have been discussed here.
1.7.8 Lead Nitrate (LN)
Columbano’s group showed in 1983 that injections of intravenous lead nitrate into male 
Wistar rats resulted in hepatic enlargement and increased DNA content (Ledda- 
Columbano et a l  1983; Columbano et a l  1983; Columbano et a l  1984). Increased 
levels of DNA synthesis were seen as shown by increased amounts of labelled 
thymidine into hepatic DNA and more mitoses were seen histologically.
Increased labelling with BrdU is seen after an intravenous injection of lead nitrate both 
in the hepatocytes and in the non parenchymal cells after 12 hours (Shinozuka et a l  
1994; Shinozuka et a l  1996) with a peak at 36 hours. In these studies it was shown that 
both lead nitrate and TNF-a induced an early proliferative response of the non- 
parenchymal cells. Lead nitrate enhances the levels of hepatic TNF-a mRNA at a time 
preceding the onset of hepatocyte DNA synthesis. The peak of hepatocyte proliferation 
is approximately the same after LN and TNF-a. This is consistent with the observation 
that TNF-a mRNA is seen to rise within 1 hour after an injection of intravenous LN. 
Histologically it appears that the induced NPCs are indeed Kupffer cells.
1.7.9 Cadmium nitrate
The effect of a single intravenous injection of cadmium nitrate has been investigated in 
livers of male Wistar rats (Ledda-Columbano et a l  1984). A significant increase in liver 
weight, accompanied by an elevation of total hepatic DNA content was observed. DNA 
synthesis as measured by the incorporation of [3H]thymidine, was found to be 6  times 
greater than the control, at 24 h after treatment, and remained elevated over a period of
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72 h. This elevation in DNA synthesis was not a consequence of cell necrosis, since no 
increase of serum glutamate-pyruvate transaminase (SGPT) activity was observed.
1.7.10 Iron
The role of iron as a hepatic mitogenic stimulus has been investigated because in rodent 
models of iron overload hepatomegaly is frequently observed. Adult SD rats were 
administered iron dextran over a 22 week period (Brown et a l  2006). Iron loaded livers 
weighed twice as much and the total DNA content was greater in iron loaded livers. 
Immunohistochemical staining for PCNA (a marker of S phase) revealed a 3-fold 
increase in hepatocyte PCNA index in iron loaded livers. Furthermore Western blot 
analysis revealed significantly increased amounts of cyclin D 1 in iron overloaded livers. 
The study authors propose that iron most likely acts as a direct hepatic mitogen and the 
response is similar to that seen with lead nitrate.
1.7.11 Ethylene dibromide
Installation of ethylene dibromide (7.5 to 10 mg. per 100 gm. of body weight) into the 
stomach of nonfasted Wistar rats induces DNA synthesis and cell division in the liver 
(Nachtomi and Farber 1978; Ledda-Columbano et a l  1987). The peak of DNA 
synthesis, as measured by 3H-methyl thymidine incorporation, was attained at or shortly 
after 24 hours. The mitotic waves measured with the aid of colchicine occurred at 24 to 
30 hours and 48 to 54 hours after ethylene dibromide treatment. Approximately 16 per 
cent of liver cells entered mitosis.
1.7.12 3,5,3''-L-tri-iodothyronine (T3) as a primary hepatic mitogen
It was first reported in 1933 that feeding desiccated thyroid tissue to rats enhanced the 
regenerative hepatic response to partial hepatectomy. By 4 weeks after surgery the liver 
was 20% larger than in the control group. The control animals also showed an increase 
in liver weight having been given thyroid tissue but not having undergone surgery 
(Higgins 1933).
Later on in 1972, Short demonstrated the induction of DNA synthesis in the liver of 
adult rats after administration of T3 (Short et a l 1972) and again in 1980 (Short et a l  
1980). In their work an infusate was made called TAGH solution containing
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triiodothyronine, amino acids and glucagon* This solution when infused brought about 
DNA replication in the hepatocytes about half as well as that seen following 70% 
hepatectomy. Each ingredient of the TAGH solution contributed to the stimulation of 
DNA synthesis in the rat but the single most important constituent was T 3.
Francavilla further characterised the mitogenic effects of T 3 on rat liver (Francavilla et 
a l  1994). In doses which are many times supra-physiological (40x), there is a peak in 
hepatic DNA synthesis at 24hr (measured by 3H thymidine incorporation) and in the 
number of mitoses. There is a return to baseline by 96hr. The cells proliferating at 24 
hours after T3 are predominantly in the hepatic midzone and this compares with the 
stimulus of PH where the proliferating hepatocytes are predominantly in the periportal 
region of the liver.
Further work by Malik examined the effects of administering T3 at the time of PH and 
in so doing combing the two pathways of liver growth (compensatory and direct 
hyperplasia) (Malik et a l  2003). This study showed that by combining T3 with PH there 
were a greater number of hepatocytes undergoing DNA synthesis than after PH alone. 
There was a larger postoperative liver mass at day 4 with the co-administration of T 3 
and there were increases in both total DNA and total protein reflecting the increase in 
mass was cellular. The BrdU flash labelling index was far greater when T 3 was 
administered at the time of surgery when compared to partial hepatectomy alone (39.5% 
± 5.0% and 26.5% ± 2.8% respectively). In addition this study showed that the T3 
caused proliferation in the absence of any liver injury, with serum bilirubin and ALT 
levels remaining unchanged. Histological sections demonstrated no necro-inflammatory 
changes.
After T3 stimulation there is a peak in liver mass at 10 days and the decline in mass 
thereafter is through a process of hepatocyte apoptosis and in the absence of any 
histological necro-inflammatory changes in liver sections of experimental rodents, with 
a return to normal hepatic mass by 14 days (Malik et a l  2005). At 10 days after the T3 
dose there is an important observed increase in the metabolic capacity of the liver 
measured by galactose elimination which rises by between 10 and 15% (Malik et a l
2005).
If the T 3 was administered 10 days prior to 70% partial hepatectomy there was a larger 
remnant liver mass 24 hours after surgery. The liver enhanced in size and function was 
however shown to have a normal post resection regenerative capacity (Alisi et a l  2005; 
Bockhom et a l  2007).
47
The precise mechanism by which T3 mediates hepatocyte proliferation remains elusive. 
An important molecule to consider is cyclin D1 as the study of its kinetics has gone 
some way to explain the mechanism of action of T3. Its expression is increased early 
after T 3 administration.
Pibiri et al showed that cyclin D1 mRNA levels increase after 2 hours following a T3 
dose and reach a maximum at 4 hours. Increased cyclin D1 protein content also occurs 
after partial hepatectomy but it is only evident at 12 hours instead of 4 hours seen with 
T3. This activation of cyclin D1 by T3 is not the result o f induction of immediate early 
genes and activation of transcription factors. It is tempting therefore to conclude that 
the effects on cyclin D 1 may be as a result of a direct effect of thyroid receptor on the 
gene; this is supported by some evidence from using other ligands as mitogens for the 
nuclear receptor superfamily discussed earlier.
Interestingly, the mitogenic effects of T3 are not restricted solely to the liver. The 
pancreas is also a quiescent organ in the adult and it too has the potential for 
regeneration following resection. Ledda-Columbano has shown that T3 exerts a strong 
proliferative effect on pancreatic acinar cells in the mouse and rat and therefore 
concludes that T 3 is strongly involved in activating cell signal transduction pathways 
leading to cell cycle entry in different organs (Ledda-Columbano et al. 2005). 
Interestingly other primary mitogens with nuclear receptors notably TCPOBOP, tRA 
and ciprofibrate did not have the same effect on acinar cell proliferation.
In other work Ledda-Columbano has shown T3 can stimulate re-entry of adult rat 
cardiomyocytes (usually these cells lose their proliferative capacity after birth) into the 
cell cycle leading to DNA synthesis after an increase in the cell’s cyclin D1 content 
(Ledda-Columbano et al. 2006). Collectively these data point to the T3 proliferative 
effect being quite ubiquitous and therefore unique amongst the group of primary 
mitogens.
The liver is known to be a major target of thyroid hormone and up to 8 % of hepatic 
genes are regulated by thyroid hormone in vivo demonstrated by cDNA microarray 
technology which has been used to study gene expression in hypothyroid and 
hyperthyroid mice, six hours after T3 administration (Feng et al. 2000). 55 target genes, 
14 up-regulated and 41 down-regulated were identified. Many of these were involved in 
metabolic pathways such as hepatic Hpogenesis but changes in genes involved in cell 
cycle progression and apoptosis were also observed, including Bcl-3, a known 
oncogene. Bcl-3 is an IkB  related protein which can act as a co-activator for NF-kB
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homodimers. It is also co activator for AP-1 and RXR and so may act as a co-activator 
for the thyroid receptor itself. Its role is further evaluated in chapter four.
1.7.12.1 T3 A nti tum our properties
Intriguingly although T 3 has this well described effect on hepatocyte proliferation, it has 
been shown to possess anti tumour properties as well. Ledda-Columbano showed that 
rats treated with T 3 in their diet for 1 week had a reduction in the number of positive y- 
glutamyl transpeptidase (GSTP) lesions, where the GSTP acts as a phenotypic marker 
of a pre-neoplastic lesion (Ledda-Columbano et al. 2000a). Furthermore repeated 
treatment with T3 in rats with pre- neoplastic liver lesions led to a 50% reduction in the 
development of hepatocellular carcinoma (HCC) and a complete inhibition of lung 
metastasis. The loss of GSTP nodules occurred despite an increase in hepatocyte 
proliferation within nodules as well as in areas of normal liver. Remodelling (or 
regression) induced through a re-differentiation program appears to be the most likely 
explanation for the loss of hepatic nodules caused by T3. The other very important 
observation from this study is that cell proliferation per se may not necessarily represent 
a carcinogenic and/or promoting condition. On the other hand, the data suggest that 
certain proliferative stimuli may play an anti-carcinogenic effect, probably by causing a 
re-differentiation of pre-neoplastic cells.
1.8 Aim of thesis
Prior to its human use, elucidating the T 3 mitogenic mechanism of action is crucial. To 
this end, T3 has been widely studied in the animal rodent model where its mitogenic 
effects can be readily demonstrated (Malik et al. 2005) but so far it has not been 
possible to demonstrate a direct in vitro effect either in monolayer cell culture or in 
more sophisticated co-culture experiments using adult rodent or human hepatocytes. 
This may be as a result of several factors, for example the lack of a sophisticated 3-D 
microenvironment, which one sees in vivo, may account for its lack of effect but also it 
may be acting through intermediaries which are just not present in cell culture 
conditions. Since previous work in this laboratory has failed to show a mitogenic effect 
of T3 in either 3D culture or co-culture with other liver cell types, the primary aim of 
this research was to further elucidate the T3 mitogenic mechanism of action and to
demonstrate an effect in human liver in vitro.
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Chapter 2 General Methodology
2.1 Animal Protocols
Materials:
1 ml syringes and needles 
NUNC dishes (NUNC Denmark)
Dissection and surgical instruments 
Liquid N2 in a dewar
Formalin filled universal containers labelled
Cryogenic vials
Scalpel blade holder
Size 11 surgical blades
Foil squares
Method:
Male Sprague-Dawley rats (250g) were housed in a temperature- and light-controlled 
room (12-hour light/dark cycle) with free access to food and water. Animal care and all 
procedures were compatible with the Animal (Scientific Procedures) Act 1986, UK 
Home Office.
Animals were sacrificed at the appropriate time points by a schedule one procedure. 
Liver was harvested and sectioned for histology and pieces were snap frozen in liquid 
nitrogen and stored at -80°C for later analysis and RNA and protein isolation.
2.2 Histological Analysis
2.2.1 APES coated slides
Aminopropyl-trimethyl-silane (APES)/Silane coated slides
To improve tissue adherence for staining, microscope slides were APES/silane coated. 
Materials:
Microscope Slides (BDH).
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Acetone (Sigma-Aldrich Ltd.)
3 Aminopropyl-trimethyl-silane (APES), Sigma-Aldrich Ltd., #  A 1435. , Prepared as a 
2 % solution dissolved in acetoneat 4 ° C.
Method:
Slides were dipped in acetone for 1 minute, then in 2 % APES/acetone for 2 minutes, 
and rinsed thoroughly in running tap water, dried overnight before use and stored at 
room temperature.
2.2.2 Haematoxylin & Eosin staining
Materials:
Haematoxylin (Gill’s Haematoxylin, Merck Ltd.)
1 % Eosin (5 % aqueous, Merck Ltd.)
Xylene (BDH)
Aquamount (BDH)
Method’.
Formalin fixed sections were stained with haematoxylin and eosin after sequential 
dewaxing through graded alcohols 100% for 1 minute, 70% for 1 minute and in running 
tap water for 1 minute. Sections were mounted using aquamount.
2.2.3 Immunohistochemical staining
Materials:
Xylene (3 baths)
Acid alcohol 
1 0 0 % ethanol 
70% ethanol
Microwave with a rotating plate
dH20
lx  PBS:
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1L dH20 ,  8 g NaCl, 0.2g KCL, 1.44g Na2H P 04, 0.24g KH2P 0 4. Adjusted to pH 7.4 with 
a bench top pH meter
0.3% H202 in lx  phosphate buffered saline (PBS)
Citrate Saline Buffer (0.01 M citrate, NaCl 0.15M, pH 6.0)
DAKO pen for immunohistochemistry # S2002 
Rabbit serum Sigma-Aldrich # M0744 
Goat serum Sigma-Aldrich 
Avidin/Biotin blocking system (Vector Labs)
Streptavidin ABC Complex DAKO #K0492
Sigma Fast 3,3-Diaminobenzidine Tablet Sets (DAB Peroxidase Substrate) #D4293 
Sigma mouse IgG purified # I 8765 
Sigma sheep IgG 1-8265
Table 3 Primary and Secondary Antibodies fo r  immunohistochemistry used in this thesis
P rim ary  o r
secondary
an tibody
P ro d u c t code D ilution/incubation
tim e
Secondary  an tibody  d ilu tion / 
incubation  tim e
Mouse anti rat 
BrdU
DAKO
#M0744
1:100
120 minutes
1:200
90 minutes
Rabbit biotinylated anti mouse
Rat Ki-67 DAKO 1:100
90 minutes
1:100
biotinylated rabbit anti mouse
Cyclin D1 Lab Vision 
#RM-9104-SO
1:50
120 minutes
1:400
30 minutes
Goat biotinylated anti rabbit
Mouse
monoclonal anti 
human Ki-67
DAKO
#M7240
1:200
60 minutes
1:100 
30 minutes
Biotinylated rabbit anti-mouse
Rabbit
monoclonal anti p- 
mTOR
Cell Signalling 
Tech.
#2976
1:50
60 minutes
1:400
Goat biotinylated anti rabbit
Mouse
monoclonal anti 
phospho-AKT 
(Ser 473)
Cell Signalling
Technology
#40515
1:2000 
4 hours
1:400
Goat biotinylated anti mouse
Mouse Cell Signalling 1:1000 1:400
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monoclonal anti 
phospho-p70 S6 
kinase (Thr 389)
Technology 
# 9206S
4 hours Goat biotinylated anti mouse
Anti-BrdU Oxford 1:100 1:200
supernatant Biotech.
#00305
120 minutes 90 minutes
Rabbit anti rat DAKO 1:200
immunoglobulin 
HRP linked
#PO450 90 minutes
Rabbit PAP DAKO 1:300
(peroxidase anti­
peroxidase)
#Z0113 30 minutes
Biotinylated rabbit 
anti mouse
DAKO
#E0464
1:100
Method:
This general method applies to the technique used in this thesis. Where there are 
specific changes for a particular species or antibody these will be described separately 
either here or in individual results chapters.
Formalin fixed tissues were embedded in paraffin and 4pm thick sections were cut. 
Slides were left to dry overnight at room temperature for at least 12 hours.
Sections were deparaffinised in three baths of xylene and then placed in graded ethanol 
solutions (100%-70%), 1 minute each prior to re-hydration in running tap water for 1 
minute.
Non specific peroxidase activity was blocked by incubation in a 0.3% solution of 
hydrogen peroxide for twenty minutes. A wax pen was used to draw around the tissue 
section prior to immersion in citrate saline buffer pH 6.0 (0.01M citrate) and heated in a 
microwave on high power 800W for twenty minutes to expose antigen. Slides were then 
washed in cold distilled water and slides were incubated for ten minutes in either goat 
serum diluted 1:20 or rabbit serum 1:20, to block endogenous immunoglobulins. The 
blocking serum used was from the same species as the secondary antibody was raised in 
and so may vary according to which secondary antibody was used.
The serum was gently tapped off and a biotin blocking stage was introduced. Avidin 
solution was applied for 15 minutes, washed off and a biotin solution was applied for 15 
minutes.
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The primary antibody, appropriately diluted, was applied at an optimal concentration for 
incubation in a humid incubator.
The slides were again washed in xl PBS for ten minutes prior to addition of the ABC 
complex (streptavadin/biotinylated horseradish peroxidase mixture- DAKO UK) for one 
hour.
The slides were thoroughly washed in x l PBS prior to development with DAB solution 
(Sigma UK) for ten minutes. The sections were counterstained with haematoxylin, 
dehydrated and mounted ready for viewing under the microscope.
The antibodies used required optimising, varying their concentrations to obtain optimal 
staining results (Table 3).
2.2.3.1 N egative controls for im m unohistochem istry
Non-specific mouse or rabbit IgG controls were used as negative controls for primary 
antibodies. Both the species and specific IgG concentrations were taken into account.
2.2.4 Mouse BrdU
Materials:
Rat anti-BrdU supernatant (OBT)
DAKO rabbit anti rat immunoglobulin HRP linked 
DAKO Peroxidase anti peroxidase (PAP) rabbit polyclonal
Method:
Same as the general method, however after incubation in the secondary HRP-linked 
antibody at 1:200 dilution for 2 hours, the slides are washed and PAP was applied for 30 
minutes at 1:200 dilution. There was no need for a biotin blocking step in this protocol 
as the detection system did not rely on a biotinylated secondary antibody for detection. 
The subsequent steps are the same and detection was with the chromogen DAB applied 
for 1 0  minutes.
This method was used in mouse liver tissue to detect BrdU as the antibody product used 
had an established protocol in the laboratory and was known to work on mouse liver 
where other antibodies had proven to be less reliable.
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2.3 Isolation of RNA
Materials:
Qiagen RNEasy Mini Kit (cat. # 74104) consisting of:
RNeasy spin columns
Collection tubes 1.5ml and 2.0ml
Buffer RLT (guanidine thiocyanate - containing buffer)
Buffer RW1 (wash buffer)
Buffer RPE (wash buffer)
RNase- free water to elute 
Rotor Star homogeniser
Method:
The RNeasy procedure uses a silica-gel-based membrane within a column to bind RNA. 
Firstly, samples of appropriate size are lysed and homogenised in a highly denaturing 
guanidine isothiocyanate containing buffer, which inactivates RNases to ensure 
isolation of intact RNA. When applied to the membrane in the column, total RNA binds 
and contaminants are washed away. The high quality RNA is eluted in water at the very 
end. RNA molecules longer than 200 nucleotides are isolated and this provides 
enrichment for mRNA since most other RNAs less than 200 nucleotides are excluded. 
The maximum binding capacity of the column is lOOpg RNA and it provides an average 
yield of 40pg of RNA from lOmg of rodent liver tissue.
Samples were removed from -80°C and placed on ice. A piece of liver measuring 
approximately 3mm3 was removed placed in 600pi of buffer RLT and homogenised 
using a rotor star homogeniser for 40 seconds. Disruption and homogenisation of tissue 
is an absolute requirement for total RNA isolation.
Tissue lysate was centrifuged for 3 minutes at maximum speed. The supernatant was 
transferred to a new micro centrifuge tube by pipetting. 70% ethanol (600pl) was added 
to the lysate and mixed by pipetting. The lysate (700pl) was added to an RNeasy mini 
column and centrifuged for 15 seconds. The flow through was discarded. Buffer RW1 
(700pl) was added to the column and centrifuged for 15 seconds. The flow through was 
discarded. Buffer RPE (500pl) was added to the column and centrifuged for 15 seconds. 
A second volume of buffer RPE was added and the process repeated with the flow 
through discarded again after centrifuging for 2 minutes. The column was placed in a
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new collecting tube and eluted with 50pl of RNase-free water. The samples were placed 
on ice ready for immediate quantitation and aliquoting.
For micro-array work, total RNA was isolated using Promega (Southampton, UK) RNA 
reagents following the manufacturers protocol.
2.3.1 Determination of RNA yield
Materials:
RNA samples 
Glass cuvettes
UVIKON-930 Spectrophotometer 
Method:
The yield of RNA was determined spec trophotome trie ally at 260nm, where 1 
absorbance unit (A26o) equals 40^ig of single stranded RNA/ml. The purity was assessed 
by the relative absorbances at 260nm and 280nm (A26o/A28o)- The ratio between the 
readings at 260nm and 280nm provides an estimate of purity of the nucleic acid, with 
the ratio varying between 1.8 and 2.0 for pure samples.
The spectrophotometer was first set to zero optical density (O.D) value, against a blank 
cuvette of dH 20, at both 260nm and 280nm. RNA samples were then placed into the 
cuvette and the O.D value measured at 260nm and 280 nm. The concentration of RNA 
was calculated using the formula:
A?*n x 40 x dilution factor = conc. pg/pl 
1000
A ratio above 1.8 was obtained for all samples analysed.
A260 readings <0.1 and >1.0 lead to considerably lower reproducibility. Readings above 
3 are incorrect and this can lead to an underestimation of the amount of RNA. Therefore 
for reliable spectrophotometric quantification A26o readings should lie between 0.1 and 
1.0 and this was the case with all samples that were measured.
Immediately following quantitation, the RNA was aliquoted into volumes equivalent to 
0.5pg RNA per aliquot. This was done so the same amount of RNA would be used for 
each sample in the subsequent cDNA synthesis reaction, so reaction efficiencies would
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be more uniform across all samples and the problem of overloading the cDNA reaction
would be avoided. Samples were stored at -80°C.
2.3.2 RNA Gel Electrophoresis
Materials:
Agarose
Formaldehyde (Sigma) 
lOx MOPS solution:
200mM MOPS (3-[N-Morpholino] propanesulfonic acid) pH 7.0 
80mM sodium acetate
lOmM EDTA pH 8.0 Ethylenediaminetetraacetic acid 
Diethylpyrocarbonate (DEPC) water 
Formamide 1%
Ethidium bromide 1 %
Method:
Total RNA was analysed by electrophoresis of RNA samples on a denaturing 
formaldehyde RNA gel stained with ethidium bromide.
The following agarose gel preparation was used (1.5%):
0.9 g agarose
10.8ml 37% formaldehyde
12ml 5x MOPS (1:2 dilution with DEPC water of lOx MOPS)
37.2ml DEPC water
To each aliquot of RNA (0.5pg in variable volume of water) was added:
5x MOPS 4pl
3.5pl
lOpl
formaldehyde
formamide
ethidium bromide 2 0 0 pg/ml 1 pi 
DEPC water to make up to: 25pi
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The RNA samples were heated to 65°C for 5 minutes and placed on ice just prior to the 
addition of loading buffer 2.5pi. The gel was pre-run for 10 minutes at 5 Volts per cm 
length and samples were loaded onto the gel and electrophoresis was performed at 60 
Volts, 140mA for approximately 2 hours, RNA was examined under UV light to check 
the integrity of the RNA. Intact RNA has a sharp 28S and 18S ribosomal RNA bands 
with a 2:1 ratio (28S:18S).
2.4 cDNA synthesis
Materials:
Fermentas Revert Aid™ first strand cDNA synthesis kit (#K1622) containing:
RevertAid M-MuLV reverse transcriptase (200u/pl)
RiboLock Ribonulcease Inhibitor (20u/pl)
5x reaction buffer: 250mM Tris-HCl, 250mM KC1, 20mM M gCl2, 50mM DTT
10 mM dNTP mix
Random hexamer primer
DEPC treated water (DiEthylPyroCarbonate)
Heating block 
0.2ml PCR tubes
Method:
To 0.5pg RNA (previously quantitated and aliquoted) was added lp l random hexamer 
primer was added and the volume made up to 12pl with DEPC treated water. This was 
incubated for 5 minutes at 70°C and immediately placed on ice. Once on ice the 
following components were added:
5x reaction buffer 4pl
RiboLock Ribonuclease Inhibitor lp l
lOmM dNTP mix 2pl
This mixture was incubated at 25°C for 5 minutes.
The enzyme RevertAid M-MuLV reverse transcriptase was added, volume 1 pi.
The final volume o f 20pl was incubated at 25°C for 10 minutes then at 42 °C for 60 
minutes. The reaction was stopped by heating to 70°C for 10 minutes.
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This reaction was performed for all samples. The cDNA was stored at - 20°C.
2.5 A Note on Quantitative Real Time PCR
2.5.1 Principles of real-time PCR
Real-time PCR is traditional PCR with incorporation of a fluorescent reporter. 
Introduction of a fluorescent reporter simplifies the process of producing reproducible 
quantitation of mRNAs, however, the reaction remains complex as all physical and 
chemical components of the reaction are interdependent. During PCR, nucleic acids of a 
target sequence (within a cDNA template) are amplified. Primers anneal to a specific 
target sequence and synthesise the targeted DNA. The amplicon is then denatured into 
single strands allowing the primers to anneal again and repeat DNA synthesis. 
Repetition of this process results in amplified target DNA. The rate o f amplification, 
providing DNA polymerase, dNTPs and primers are in excess, follows a sigmoid 
relationship. Incorporation of a fluorescent reporter with suitable detection apparatus 
permits data acquisition during the exponential growth phase, hence the term ‘real­
time’. The fluorescent reporter signal is measured at every cycle and is proportional to 
the amount o f amplicon generated. The parameter of quantitation is the threshold cycle 
(Ct) and is defined as the cycle at which a significant increase in fluorescence is 
detected during the exponential phase of amplicon amplification which correlates to the 
initial amount of target template (Gibson et a l  1996; Higuchi et a l  1993).
Various fluorescent reporters are available to monitor DNA amplification; these include 
DNA-binding agents (SYBR Green I) (Bustin 2000), hydrolysis probes (exemplified by 
the TaqMan chemistry) (Gibson et a l  1996), hybridization probes (Bernard and 
Wittwer 2000) and hairpin probes (e.g. Molecular Beacons, Scorpions, Sunrise primers 
and LUX primers.
This thesis uses SYBR Green I (SG) a fluorogenic minor groove binding dye that 
exhibits little fluorescence when in solution but emits a strong fluorescent signal on 
binding to double-stranded DNA (Morrison et a l  1998). SG is extensively used in real­
time PCR as its photophysical properties are temperature stable and selective for 
double-stranded DNA, allowing for quantification with high sensitivity and once 
optimized, results in an easy, robust and reliable assay displaying a wide dynamic linear 
range. However, SG has disadvantages associated with its ability to bind double 
stranded DNA as it may bind non-specific sequences including non-specific
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amplifications and primer-dimer complexes. Hence, SG-based real-time PCR requires 
extensive optimisation and melt curve analysis to verify SG fluorescence is a direct 
measure of specific product amplification.
2.5.2 Methods of Quantitation
The advantage of using real-time PCR is the ability to quantify the targeted nucleic 
acids. Quantitation can be either absolute or relative and these methods have recently 
been reviewed (Wong and Medrano 2005).
2.5.2.1 A bsolute Q uantitation
Absolute quantitation determines the total amount of target (expressed as copy number 
or concentration) using external standards (Bustin 2000). The amplification efficiency 
of the target and the standards must be equivalent for absolute quantification. The 
external standards contain sequences equivalent to the target and identical primer 
binding sites whose absolute concentration is known. There are several criteria for 
absolute standards (Bustin 2000). Quantitation is achieved by establishing a standard 
curve (external standard CT value against log of amount of standard) using a dilution 
series of the standards from which unknown amounts of initial target (copy number) can 
be calculated. This copy number must be normalised, typically to the number of cells or 
total RNA used. The accuracy of absolute quantitation is dependent on the accuracy of 
the standards.
2.5.2.2 Relative Quantitation
Relative quantitation calculates the ratio between the amount of target and a normaliser. 
No absolute number is detected. Relative quantitation is the most commonly applied 
method for gene expression analysis as it accounts for differences in the amount of total 
RNA that arise between samples that may occur due to variations in efficiency, errors in 
sample quantitation and loading amounts. As expression of the normaliser should not 
change in different samples the ratio of the amplicon varies according to the expression 
level of the target gene. Thus, normalised values can be used to compare differential 
gene expression in different samples. There are two accepted methods for relative 
quantitation of gene expression, firstly the comparative Ct method (delta delta CT) and
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secondly the two standard curve method. The comparative C j  method requires the 
amplification efficiency of the target and normaliser to be identical. Invariably 
amplification efficiencies are different so relative quantitation using the two standard 
curve method, one for the target and the other for the endogenous normaliser is 
preferred. Real time PCR is a developing technology and additional mathematical 
models for relative quantitation have been described (Pfaffl 2001).
2.5.2.2 .1  Delta Delta CT Relative Quantitation
Comparative Ct method (delta delta Ct) does not require the running of standard curves. 
The amount of template present in an unknown is first normalised by relative 
comparison to an endogenous control (normaliser). The normalised value is further 
normalised relative to a calibrator (either a wild-type, untreated control or time zero 
sample). Reaction efficiencies must be the same and, for results to be valid, quantitation 
guidelines have been derived.
2.5.2 .2 . 2  Two Standard Curve Relative Quantitation
The two standard curve method analyses a sample for the gene of interest and 
endogenous control (normaliser) in two separate reactions. This method allows for 
quantification where the amplification efficiencies for the gene of interest and the 
endogenous control are different. PCR amplifications which proceed at different 
efficiencies result in unparallel standard curves (slope differences >0 .1 ) therefore the 
differences in C t values of the target and normaliser will not be constant when the 
amounts of target and normaliser are varied. The relative expression of the target of 
interest to the normaliser in a sample is calculated as the ratio of the resulting amounts 
of target to the normaliser using their respective C t values to assign an arbitrary 
concentration from its corresponding standard curve (standard CT value against log of 
estimated amount of standard).
2.5.3 Quantitation
In this thesis expression levels of the gene of interest were determined by relative 
quantitation using the two standard curve method with 18S as the normaliser.
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Standard curves for the gene of interest and 18S were constructed using standards, the 
preparation of which involved several steps; In brief, traditional PCR using specific 
primers was performed to amplify the target. The amount of amplicon was estimated by 
on an agarose gel and markers whose intensity using UV quantitation represented 
product concentration. Serial dilution of the amplified product provided arbitrary 
standards which were run in an optimised real-time PCR to construct a standard curve.
2.5.3.1 Preparation o f standards
Standards were prepared using rodent liver cDNA. Traditional PCR using specific real­
time primers amplified the target of interest. The amplified product was electrophoresed 
in a 2 % agarose gel containing ethidium bromide, to ensure the amplicon was a single 
band of the correct size. The amplicon was excised and extracted from the gel and a 
known volume was electrophoresed on an agarose gel with Hyperladder IV to ensure 
amplicon integrity and estimation of amount present. Using Avogadro’s constant (6.023 
xlO23) the number of molecules present was estimated to enable preparation of 
standards.
2.5.4 Rotor-Gene 3000 Real Time PCR machine
This system can detect all available Real-Time chemistries including SYBR Green. It 
has four light sources, six detection filters ensure no spectral overlap, and flexibility to 
detect different probes. An LED source illuminates the tube from the side wall and a 
photomultiplier (PMT) detects the energy from the base of the chamber. For SYBR 
Green this was an excitation wavelength of 470nm and detection through the 585nm- 
high pass filter.
The 36 well rotor for 0.2ml tubes was initially used but later a 72 well rotor for 0.1ml 
strip tubes was used for higher sample through put. All settings and programmes were 
performed with Rotor-Gene software version 6.0.14.
2.6 Primer design
2.6.1 Primer design rules that were applied:
(i) Should be 15-30 bases in length.
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(ii) G + C content should ideally be 30-80%. The run of an identical nucleotide 
should be avoided (especially for G, where more than 4 is not allowed).
(iii) maximum amplicon size should not exceed 400bp (ideally 50-150 bases). 
Smaller amplicons give more consistent results as PCR is more efficient and more 
tolerant of reaction conditions.
(iv) To avoid false positive results due to amplification of contaminating genomic 
DNA in the cDNA preparation, it is preferable to have primers spanning intron-exon 
boundaries in the cDNA sequence. By doing this genomic DNA will not be amplified. 
Successful real-time PCR requires optimal primer pair design and appropriate primer 
concentration.
Using GeneBank (http://www.ncbi.nlm.nih.gov) the complete mRNA sequences for the 
genes of interest were obtained. Forward and reverse primers were designed to comply 
with the rules set out above with the additional requirement for Real-Time PCR that the 
size of the amplicon should be no more than 150bp in length. Using the computer 
software Vector NTI the proposed primers were assessed to ensure that an intron-exon 
boundary was spanned (to minimize genomic DNA amplification), no potential 
formation of primer-dimers or secondary structures were predicted, and similar 
annealing temperatures were appropriate for each primer pair. The primer pairs were 
screened against the Blast database to ensure specificity to the gene of interest.
Primer sequences were purchased from SigmaGenosys, the sequences for which are 
given in individual results chapters. An appropriate volume of DEPC-MilliQ water was 
added to the lyophilized primers to make 100pM stock concentrations from which 
lOpM working concentrations of primers were made. All primers were stored at -20°C 
at lOOpM concentration for long term storage.
2.6.2 Conventional PCR to check primers
2.6.2.1 Polymerase chain reaction
This is a basic technique central to most modem molecular biology. It is powerful and 
results in the rapid production of multiple copies of a target DNA sequence. A thermo­
stable DNA polymerase enzyme synthesises dsDNA in vitro under certain conditions. 
The other components are:
-Oligo-nucleotides complementary to the sequences flanking the gene to be amplified 
-dNTPs- deoxyNucleotideTriphosphates
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-salts and buffering to allow enzyme activation 
-accurate and rapid temperature control
Amplification specificity of each primer pair was confirmed by traditional PCR. 
Materials:
HotStar Taq Mix containing: Taq DNA polymerase (5 units/pL), 2x PCR buffer, 3mM 
MgCl2 and 400pM of each dNTP (Qiagen)
Forward and reverse oligonulceotide primers (Sigma-Genosys)
DNA template (rat liver cDNA)
DEPC H20
Method:
5pl of rat liver cDNA (prepared from 0.5pg RNA) was added to:
HoStar TaqMix 25 pi
Forward primer 0.5pi
Reverse primer 0.5pi
DEPC H20  19pl
An additional reaction mix was set up with no cDNA to act as a non template control. 
The PCR reaction was run on a PCR block:
Step
Number of 
Cycles
Hot Start 1 95°C 15 min
Denaturation
35
95°C 30 sec
Annealing 60°C 30 sec
Extension 72°C 30 sec
Extension End 1 72°C 1 0  min
2.6.3 DNA gel Electrophoresis
Materials:
Agarose (BDH chemicals)
Ethidium bromide (Sigma) stock: 1 Omg/ml
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50x TAE: for 1L in ddH 20242g Tris base, 57.1ml glacial acetic acid, 100ml 0.5M 
EDTA in ddH20, pH 8.0
lx  TAE: 1 in 50 dilution of 50xTAE stock in ddH20.
DNA ladder: Hyperladder IV to detect 1000-100 base pairs (Bioline #33029)
Method:
Agarose (0.75g) was dissolved in 50mls TAE buffer and heated to 90°C in a 
microwave.
After cooling to 50°C, lp l of ethidium bromide at lOmg/ml was added and poured into 
a Perspex mould with an appropriate comb already in place and the ends of the tank pre 
sealed with tape. It was left to set.
20pl of PCR product was added to 4pl loading buffer. The set gel was placed in a tank 
and this was filled with lx  TAE buffer.
24pl of sample was loaded into each well and electrophoresis was performed at 90V 
and 140mA for 1 hour. The gel was then visualised under ultraviolet light and an image 
was captured on computer using the software Lab works 4.6 and a digital camera.
2.6.4 Preparation of standards for Real Time PCR
Materials:
Hotstar Taq MasterMix (Qiagen):
Hotstar Taq DNA polymerase 5 units/p 1 
PCR buffer
dNTPs at concentration of 200pM each 
Forward and reverse oligonucleotide primers 
Template cDNA
Method:
5pl of cDNA synthesised from 0.5pg RNA in reaction volume of 20pL was used to 
amplify specific product so standards could be made for the subsequent real time PCR 
analysis.
The cDNA was added to:
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HotStar Taq Mix (Qiagen) 25\i\
Forward cyclin D1 primer (1 OuM) 0.5pl
Reverse cyclin D1 primer (lOuM) 0.5pi
Water 19pl
The reaction was performed in a thermal cycler and heated to 95°C to allow separation 
of double stranded DNA, then a cooling to 60°C to permit the primer to anneal then a 
rise in temperature to 72°C for extension to take place. The cycle was repeated 35 times 
as outlined in the table above.
The reaction products were run on a DNA agarose gel as previously described.
2.6.5 Amplicon Excision from DNA Agarose Gel 
Materials:
1.5mL microcentrifuge tube 
scalpel 
UV light box 
UV protection
Method:
Wearing UV protection, the agarose gel was placed on a UV light. Using a sterile 
scalpel the amplicon band was cut out removing as much gel as possible without 
interfering with the band and placed in a microcentrifuge tube. The microcentrifuge 
tube was pre-weighed prior to adding the excised band as the weight of the gel was 
required for extraction reagent volumes using the QIAquick Gel Extraction Kit.
2.6.5.1 A m plicon extraction from  agarose gel
Materials:
DNA gel extraction Kit (Qiagen, UK 28704):
Buffer QG: solubilisation and binding buffer (pH <7.5)
Buffer PE: ethanol containing wash buffer 
Buffer EB: lOmM Tris Cl (pH 8.5) elution buffer
66
QIAquick spin column 
2mL collection tube 
Isopropanol
1.5mL microcentrifuge tube (autoclaved)
Heat block set to 50°C 
Microcentrifuge
Method:
DNA adsorbs to the silica-membrane in the presence of high salt while contaminants 
pass through the column. Impurities are washed away and the pure DNA is eluted with 
Tris buffer or water.
This extracts DNA (70bp-10kb) from agarose gels in TAE using spin-column 
technology with the selective binding properties of a silica-gel membrane accompanied 
with buffers optimized for efficient recovery of DNA. Each spin column can bind up to 
lOpig DNA.
In a microcentrifuge tube the agarose gel was solubilised by the addition of 3 volumes 
of Buffer QG per gel volume (lOOmg ~ tOO^L) and incubating at 50°C for 10 minutes 
and vortexed intermittently. Isopropanol (1 gel volume) was added to the solubilised 
gel, mixed by vortex then added to a QIAquick spin column inserted into a 2mL 
collection tube. The solubilised gel was passed through the column by centrifugation at 
14000 rpm for 1 minute at room temperature; the flow through was discarded. Buffer 
QG (500pL) was added to the column and centrifuged; the flow through was discarded. 
The column was washed with the addition of 750pL Buffer PE to the column and 
centrifuged. The flow through was discarded and centrifugation was repeated to remove 
residual ethanol present in the Buffer PE from the washed column. The column was 
transferred to a 1.5mL microcentrifuge tube and the DNA was eluted by the addition of 
30pL Buffer EB to the centre of the column for 1 minute prior to centrifugation. The 
eluted DNA was stored at -20°C.
2.7 DNA estimation
Materials:
2% agarose gel
DNA ladder hyperladder IV (Bioline)
TAE buffer
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UV light and digital camera/software
Method:
To estimate amplicon amount and ensure integrity following its extraction small 
volumes were analysed by electrophoresis and compared to Hyperladder IV.
5pL hyperladder IV was run on a 2% agarose gel alongside 1 pL of eluted amplicon and 
2pL of eluted amplicon, added to lpL  loading buffer and DEPC water to make a final 
volume of 6 pL. Electrophoresis was performed in lx  TAE buffer for 45 minutes and the 
separated products visualized under UV light.
2.7.1 Amount of specific product estimation using Avogadro’s number
The number of amplicon molecules was calculated using Avogadro’s number (6.022 
xlO23), the molecular weight of the amplicon and the estimated concentration of 
amplicon.
An example of such a calculation for cyclin D1 
Amplicon 104 bp
Molecular weight of the amplicon = 330 x (length of the amplicon x 2)
1 mole = 68,640g = 6.022 xlO23 
Ing = 8.77xl09
From the gel, 2pl = 20ng = 1.75 xlO 11 copies 
Standard = 8.75 x l0 1 0copies/pl
2.8 Developing a Real Time PCR protocol to quantify candidate gene 
expression in rat liver
2.8.1 Optimisation Steps
Prior to construction of the necessary standard curves and sample analysis several 
stages had to be optimised using the Rotor gene machine.
These were: SYBR concentration, primer concentration and magnesium concentration. 
Reaction mixtures were set up in individual tubes (HotStar Taq, primers, SYBR Green 
and DEPC water) and each parameter was then varied while the others remained 
constant to see which amounts gave the best results.
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In each 20pl reaction volume the optimal primer volume was found to be 2pl of lOpM 
primer stock (which gives a final concentration of 800nM), 1.5pl of 1:3000 SYBR 
Green equivalent to a final dilution of 1:50 000. It was found that no additional 
magnesium was required for optimal results.
2.8.2 Standard Curve
For construction of the standard curves, the serially diluted amplified specific product 
were added in duplicate a volume of lp l each to the reaction mixture already described 
and then run on the Real Time PCR machine. Duplicate samples established 
reproducibility and accuracy of the assay. The Biogene software constructed standard 
curves for 18S and cyclin D1 at the end of the reaction.
2.8.2.1 Samples
With acceptable standard curves, all samples were run for the target of interest 
followed by 18S to which the copy numbers per reaction were normalised. Accuracy of 
the assay was demonstrated by showing reproducibility across more than one Real Time 
PCR run. Two separate Real Time PCRs were consistently performed each time.
Reaction Mix for cyclin D 1 : Hotstar Mix 1 Opl
Forward primer 
Reverse primer
2 pl 
2 pl 
1.5 pi 
2.5pl 
2  pi 
2 0 pl
SYBR Green
h 2o
cDNA
TOTAL
Reaction Mix for 18S: HotStar Taq Mix
Forward primer 
Reverse primer
lOpl
0.5pl
0.5pl
1.5 pi
6.5pl
lp l
2 0 pl
SYBR Green
h 2o
cDNA
TOTAL
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Within each individual Real Time PCR run the appropriate Non Template Controls 
(NTCs) were included as well as the standards. The standards chosen would lie between 
the range of fluorescences of the experimental samples and were run in duplicate. At 
least three standards were included in each reaction. At the completion of each reaction 
the appropriate standard curve, either for amplicon of interest or 18S, was imported to 
allow the software to calculate the copy number of amplicon per reaction. This number 
was then normalised to the 18S copy number per reaction.
2.8.3 cDNA synthesis for the Kruppel Factors (Chapter 6)
Materials:
RNA sample 0.5pg
QuantiTect® Reverse Transcription Kit (Qiagen Cat.#205311) contains: 
genomicDNA wipeout buffer 7x 
Quantiscript Reverse Transcriptase 
Quantiscript RT Buffer 5x 
RT primer mix 
RNase-free water
Method:
The use of this kit speeds up throughput enabling more efficient handling of a greater 
number of samples. It was therefore used for the subsequent Real Time PCR analysis of 
a number of Kruppel Factors discussed in Chapter six.
The RNA sample (variable volume but constant quantity of 0.5pg) was incubated in 
genomicDNA wipeout buffer at 42°C for 2 minutes to remove all genomic DNA.
The Quantiscript RT, Quantiscript buffer and RT primer mix were added and the total 
volume of 20pl was incubated for 15 minutes at 42°C. Finally to inactivate the reverse 
transcriptase the reaction was heated to 95°C for 3 minutes The cDNA was stored until 
required at -20°C.
The Quantiscript Reverse Transcriptase has a high affinity for RNA and has been 
optimised by the manufacturer for efficient and sensitive cDNA synthesis from 10 pg to 
1 pg of RNA. This enables high cDNA yields.
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2.8.3.1 Real Time PCR for the Kruppel Factors
Materials:
QuantiTect™ SYBR® Green PCR Kit (Qiagen #204143) contains:
HotStar Taq® DNA Polymerase 
Quantitect SYBR Green PCR buffer 
dNTP mix 
SYBR Green
ROX (passive reference dye)
5 mM MgCl2 
RNase free water
Method:
The kit provides accurate Real Time quantification of DNA and cDNA targets in an 
easy to handle format. Optimisation steps previously performed for MgCl2 
concentration and SYBR Green concentration were now not required and therefore this 
method was employed for the remainder of the thesis for quantitation of Kruppel Factor 
mRNA expression. This method allowed greater sample throughput with better 
reproducibility across Real Time experimental runs.
A master mix was prepared with each component in the following volumes:
QuantiTect™ Master Mix 1 Opl
Forward Primer 2 pi
Reverse Primer 2 pi
Water 5 pi
19 pi of this was aliquoted into each PCR strip tube and finally the cDNA was added: 
cDNA 1 pi
TOTAL VOLUME 20 pi
Reactions were run in strip tubes in a 72 carousel to enable higher sample throughput.
In each Real Time PCR run, the appropriate standards in duplicate were included as 
well as two NTCs
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The PCR reaction used an initial activation step for 15 minutes at 95°C, then 45 cycles 
of 95°C for 30s, 60°C for 30s, 72°C for 30s, finally 72°C for 10 minutes.
2.9 Isolation of Primary Human Hepatocytes
Normal human liver samples were acquired with patient consent (Ethics ID38-2000 
Culture of human liver cells obtained at surgery) from specimens taken during liver 
resection for colorectal cancer performed at the North Hampshire Hospital. Only tissue 
considered ‘normal’ away from tumour margins were used. The weight of the tissue 
ranged from 29g to 69g. Samples were provided by Mr M. Rees, Department of 
Surgery, North Hampshire Hospital. These tissue samples have been designated the 
label BS.
This was carried out by other colleagues.
Materials:
Chelating Buffer (20mM HEPES, 0.5mM EGTA in PBS)
Perfusion Buffer (20mM HEPES in PBS)
Digestion Buffer (20mM Hepes, l,5g BSA (0.5% w/v), 50pg/ml ascorbic acid and 
4jig/ml insulin in 300ml HBSS. Just prior to digestion of the liver 150mg 
Collagenase Type IV (0.05% w/v) and 30mg DNase I (0.01 %w/v) added) 
Dispersal Buffer (50ml FCS (10%v/v) and 50mg (0.01% w/v) to 500ml Williams E 
medium)
Collagenase (Sigma)
Method:
Primary human hepatocytes were isolated from a freshly resected piece of liver by 
collagenase digestion through the remaining vasculature and differential centrifugation.
2.9.1 Viable cell count by trypan blue exclusion
The viable cell count was performed by trypan blue exclusion. An aliquot of the cells 
was diluted (1:10) into HBSS (8:10) with trypan blue (1:10) (0.2% Trypan blue in PBS) 
and kept at room temperature for 2min, The cells were then counted with a 
haemocytometer. The live cells will exclude the dye, whereas the dead cells have nuclei 
stained blue.
72
2.9.2 Preparation of collagen coated plates
Materials:
6 -well plates
Sterile HBSS, calcium and magnesium free (Gibco, Invitrogen)
Sterile Saline
Collagen type I prepared from rat tail tendons ( lg  tendons in 300mls 0.01M sterile 
acetic acid, stirred at 4°C for 2 days, centrifuged at 800xg for 2 hours and stored at 4°C) 
UV lamp
Method:
To a 6  well plate 2ml/well of collagen was added. After 5 minutes the collagen was 
flicked vigorously out of the wells and rinsed twice with 4mL HBSS. Sterile saline 
(1.5mL) was added to each well to sufficiently cover collagen. With the lid removed 
wells were irradiated under UV light. The plates were either used on the same day or 
stored at 4°C until use.
2.9.3 Culture of Primary Human Hepatocytes
Materials:
Williams E Medium (Gibco #22551, Invitrogen)
T3 deplete FCS (final concentration 10%) (Hyclone)
Penicillin/Streptomycin (final concentration 50U/ml) (Gibco)
Fungizone (final concentration 0.292g/L) (Gibco)
L-glutamine (final concentration 1.25pg/ml) (Gibco)
Insulin (final concentration 10'8M)
Method:
Williams E medium was made up with all the above supplements. Once isolated, 
hepatocytes were seeded in collagen coated plates at l x l 0 6cells/ml, with 2 ml per well of 
a six well plate.
Primary hepatocytes were plated at a density of 2 million cells per well on collagen 
coated tissue culture plates and maintained with William’s E medium supplemented 
with fetal calf serum (10%), penicillin (200U/ml), streptomycin (200U/ml). The culture
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plates were maintained in a humidified incubator with an atmosphere of 95% oxygen 
and 5% carbon dioxide overnight. The next day the wells were washed with HBSS to 
remove non-viable cells and the culture medium was then replaced with fresh medium 
prior to the start of the experiments.
2.9.4 T3 deplete Foetal Calf Serum (FCS)
Materials:
AG 1-X8 resin (Biorad, Richmond CA USA) 
dH20
50ml NUNC tubes 
Filters
Foetal calf serum (Hyclone)
Method:
FCS was incubated at room temperature with 50mg/ml AG 1-X8 resin (Biorad), which 
had been previously washed three times with distilled water. After 5 hours of incubation 
under stirring, the resin was removed by centrifugation at l,000g for 10 minutes. An 
additional quantity o f fresh resin was added at a concentration of 50mg/ml to the 
residual serum and the serum was incubated for a further 15-18 hours at room 
temperature. The resin was finally removed by two centrifugation steps at l,000g for 10 
minutes and 30,000g for 20 minutes at room temperature. The serum was then sterilised 
through a 0.2pm filter and stored at -20°C until required.
2.10 Bicinchoninic Acid (BCA) protein assay
Materials:
96 well plate
Bovine serum albumin stock 100mg/ml 
Reagents A and B:
Reagent A: 1 gm sodium bicinchoninate (BCA), 2 g sodium carbonate, 0.16 g sodium 
tartrate, 0.4 g NaOH, and 0.95 g sodium bicarbonate, brought to 100 ml with distilled 
water. Adjust the pH to 11.25 with 10 M NaOH.
Reagent B: 0.4 g cupric sulfate (5 x hydrated) in 10 ml distilled water.
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Reagent ratio A: B is 50 parts to 1 part
Method:
BSA standards were prepared 1, 0.5, 0.25 and 0.125pg/ml.
Protein samples were first diluted 1:10 in water as they were otherwise too 
concentrated.
10 gl of standard or sample was pipetted into a well before the BCA reagent volume 
(A+B ratio 50:1) 200 pi was added.
The plate was then placed in an incubator at 37°C for 30 minutes.
The absorbance was read at 570nm. A standard curve was generated each time and from 
this the protein concentration of the samples was determined from the equation of the 
line.
2.11 Western Blot Protocol
Materials:
NuPAGE Novex Tris-Acetate 3-8% gel (Invitrogen)
RIPA lysis buffer lx  (Autogen-Bioclear # SC24948)
Phenylmethylsulphonyl fluoride (PMSF)
Protease Inhibitor cocktail
Sodium Ortho vanadate
Sodium fluoride (50mM final concentration)
Rotor Star Homogeniser
NuPAGE 20X Tris-Acetate SDS Running Buffer (Invitrogen)
Deionised water
NuPAGE Antioxidant (Invitrogen)
Invitrogen gel tank 
Methanol (BdH)
IX PBS 
Tween
Loading buffer containing SDS 
Heating block
Full range 10,000 -  250,000 rainbow molecular weight rainbow marker (Amersham 
Biosciences)
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Polyvinylidene Difluoride (PVDF) membrane Hybond-P PVDF (Amersham)
Whatmann filter paper 
Gel tank 
Power supply
Ice cold Transfer buffer: 9g TrisBase
43.3g Glycine 
1.2g SDS 
600ml Methanol
Make this up to a total of 3L with dH 20
Ponceau red 
Coomassie reagent 
X ray film (Kodak)
ECL plus (Amersham) Solution A contains ECL plus substrate solution in Tris buffer 
and solution B is stock Acridan solution in Dioxane and ethanol 
Cling film wrap
Restore Western Blot Stripping Buffer (Pierce)
Marvel non fat dry milk
Method:
Lysis buffer was prepared by combining lOpl PMSF, lOpl sodium ortho vanadate 
solution and lOpl protease inhibitor cocktail to 1ml of IX  RIP A lysis buffer. To this 
lysis buffer 50 pi 1M NaF solution was added.
A piece of liver tissue was placed in a 5mL plastic bijou container and the pre-prepared 
lysis buffer was added in a volume of lmL. The sample was homogenised for 30 
seconds with a rotor star homogeniser while on ice.
The sample was placed on ice for 15 minutes and centrifuged at 1500x g for 10 minutes 
at 4°C. The supernatant containing the protein lysate was removed and aliquoted into 
100 pi aliquots in labelled 1.5ml centrifuge tubes and stored at -80°C until further use in 
quantitation and gel electrophoresis.
2.11.1 Protein electrophoresis
The appropriate volume of sample was added to an equal volume of SDS loading buffer 
and 1 pi bromophenol blue was added, total volume 2 0  pi.
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Each sample was heated to 100°C for 5 minutes on a heating block.
The pre-cast gel was mounted into the electrophoresis apparatus and running buffer was 
added. The molecular weight marker was loaded in the first lane.
The denatured samples were then added to individual lanes.
The electrophoresis apparatus was connected to the electrical supply and a constant 
voltage o f 150V was applied for 60 minutes.
After the samples had run, the gel was removed from the apparatus and im mediately 
prepared for transfer o f the polypeptides to the PVDF membrane by western blotting.
2.11.2 Western blotting
Four pieces of W hatmann 3mm paper were cut and soaked in ice cold transfer buffer for 
five minutes. The blotting tray was then set up as depicted in Figure 6.
Blotting pad
Filter paper
PVDF membrane
Figure 6 A schematic o f  the gel and blotting membrane used in the Western blot 
experiments described in this thesis.
The PVDF m em brane was cut to the size of the gel and then activated in cold methanol, 
washed in water and then soaked in ice cold transfer buffer ready for use and assembly 
of the blotting apparatus could then take place.
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A constant current of 350mA was applied across the assembly for 3 hours to facilitate 
the transfer of polypeptides from the gel onto the membrane.
2.11.2.1 Staining the membrane
After transfer the membrane was placed in Ponceau Red to demonstrate successful 
transfer of protein. The gel itself was placed in Coomassie reagent and then washed to 
demonstrate that no protein bands were visible in the gel i.e. successful transfer to the 
membrane had taken place.
2.11.2.2 Probing the membrane
The PVDF membrane was placed overnight on a rotating wheel in a sealed bag 
containing 5% Marvel milk in IX  PBS as a blocking solution at 4°C.
The following day the membrane was removed and placed in a new bag containing the 
appropriate primary antibody (Table 4) at a correct dilution in lx  PBS Tween in 5% 
Marvel. This was for 2 hours at room temperature on a shaking platform 
The membrane was then removed and washed in PBS Tween 3 times 15 minutes each 
wash on a rocking platform.
It was placed in a new bag containing the appropriate dilution of secondary antibody for 
90 minutes at room temperature.
Finally it was removed and washed 3 times again in IX PBS Tween before exposure to 
the detection reagent ECL plus.
ECL plus utilises a technology whereby the enzymatic degradation of an acridinium 
ester produces an intense light emission of longer duration. The reagents are removed 
and allowed to equilibrate to room temperature. Solutions A and B are mixed in a ratio 
40:1 and the final volume is 0.1ml/cm2. The membrane was placed protein side up on 
Saran wrap and the detection reagent was pipetted on and left in the dark for 5 minutes 
before exposure to X- ray film in the developing room.
2.11.2.3 Membrane Stripping
Materials:
Restore™ Western Blot Stripping Buffer (Pierce # 21059)
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XI PBS
ECL+ (Amersham)
Kodak film
IgG HRP linked antibody 
Method:
So that the PVDF membrane could be probed with a different primary antibody it was 
stripped using a commercially available stripping buffer.
The buffer was warmed to room temperature. The blot was placed in an adequate 
volume of buffer for 15 minutes at room temperature. The blot was washed in IX PBS. 
To test for complete removal of HRP label, the blot was incubated with new ECL+ and 
exposed to film. To test for complete removal of primary antibody the blot was 
incubated with the appropriate secondary HRP labelled antibody, followed by a wash 
and then incubation in fresh ECL+ and exposed to film.
As no signal was detected at either step of this procedure it was possible to go on and 
probe the same membrane with another primary antibody.
Table 4 Antibodies used in Western Blot in this thesis
Antibody Product Dilution Secondary
Rabbit anti p- 
mTOR (Ser 2448)
#2971 1:1000 
120 minutes
1:2000 
60 minutes
Rabbit
monoclonal anti 
mTOR
Cell Signalling
Tech
#2983
1:1000 
120 minutes
1:2000 
60 minutes
Anti rabbit IgG 
HRP linked 
secondary
Cell Signalling 
Tech #7074
1:2000
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Chapter 3 Liver Perfusion
3.1 Background
The mitogenic T3 effect is modelled successfully in rodents in vivo but as yet it cannot 
be used in man until evidence is produced that documents a mitogenic effect in human 
liver. An important goal therefore is to demonstrate a mitogenic effect of T3 on human 
liver tissue prior to its experimental use in vivo in man. As yet no mitogenic effect has 
been demonstrated in hepatocyte culture (either simple monolayer or more complex 3D 
and co-culture scenarios) in rodent or human hepatocytes. Using therefore an in vitro 
system to model mitogenic effects in the more architecturally sophisticated environment 
of either an ex-vivo in vitro whole rat liver perfusion or in perfusion of pieces o f human 
liver, provides an experimental solution which may offer exciting answers as to whether 
T3 exerts a mitogenic effect in human liver.
In this Chapter therefore liver perfusion experiments using rodent and human liver are 
described in more detail preceded by initial experiments undertaken to define the in vivo 
rodent T 3 proliferative response to better characterise the optimal mitogenic dose and its 
time course of effect.
3.1.1 Organ perfusion
There is a long history of organ perfusion particularly as a tool to study liver 
metabolism and the effects of drugs and toxins on the liver and how these agents may 
be metabolised by the liver (Brauer et a i  1951; Bessems et al. 2006; Cheung et a l  
1996) and a lot of work has been done to perfect the technique of the isolated perfused 
rat liver (IPRL) i.e. an ex-vivo perfusion. Numerous studies describe conditions which 
need to be optimised to enable an optimal perfusion experiment to be completed 
successfully. The IPRL most closely reflects the in vivo scenario, allowing the hepatic 
response to various xenobiotics to be measured. Oxygen consumption, bile production, 
liver enzyme levels, pH of perfusate, lactate levels and histological sections are amongst 
the parameters which have been measured in various publications to date (Cheung et a l  
1996). Studies thus far have optimally perfused rodent liver for periods of up to 6  hours 
and the gold standard to assess tissue viability has been the histological appearance on 
Haematoxylin and Eosin liver tissue sections.
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Researchers have for over fifty years used perfusate made up of a buffer with diluted 
erythrocytes (Brauer et a l  1951; Miller et al. 1951) or indeed buffer combined with 
hyperbaric oxygen (Schmucker et al. 1975). Early studies found that a haematocrit of 
2 0  % provides the optimal combination of blood flow and oxygen carrying capability 
whilst maintaining physiological perfusion pressures of about 10 mmHg (Riedel et a l 
1983).
Mischinger and Starzl (Mischinger et a l  1992) describe one technique of organ 
perfusion although many others have published on how this may be perfected. In their 
study it was found that the liver could be perfused optimally for up to 3 hours with 
oxygenated Krebs- Henseleit buffer (KHB) without the addition of red blood cells. 
Changes in hepatocellular enzymes, bile production, and liver histology were measured 
to determine the best perfusion parameters and it was found that bovine serum albumin 
(BSA) when added to the perfusate may actually be damaging to the perfused organ.
A separate study (Alexander et a l  1998) examined whether using perfusion buffer alone 
was sufficient in maintaining hepatic function over the time course of the perfusion, 
typically up to 6  hours. A comparison was made between 6  adult male Sprague Dawley 
(SD) rat liver perfusions with the addition of rat red blood cells and 6  adult SD male rat 
liver perfusions without the addition of any red cells. The conclusion from this study 
was that perfusion using buffer alone was insufficient to maintain optimum liver 
function.
Many perfusion systems have been cumbersome and required large priming volumes 
(Alexander et a l  1995), and consideration must also be given to the oxygenator which 
is a crucial part of any successful perfusion circuit, enabling delivery o f appropriate 
oxygen to the tissue which requires it for efficient metabolism and maintenance of as 
near normal physiological conditions as one can achieve (Alexander et a l  1984). 
Problems described in the past have included the formation of bubbles and foam due to 
direct contact of the perfusate with the gas phase. An oxygenator therefore needs to be 
atraumatic, easy to clean and require a small priming volume as a reflection of its 
oxygen delivery efficiency. The use of a gas permeable membrane allows the avoidance 
of direct contact of gas with the aqueous phase (Galletti 1971; Robb 1968), and this is 
one more way in which perfusion circuitry has been improved over the decades.
For this project a perfusion apparatus was designed with the intention of perfusing 
initially whole rodent liver but then also pieces of human liver, to enable the mitogenic 
effect of T3 to be modelled for the first time in human liver tissue.
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3.2 Aims
a) To determine the T3 hepatocyte proliferative dose response and time course of 
response in rat liver in vivo.
b) To develop an in vitro organ perfusion system to enable the delivery of growth 
factors and T3 to rodent and human liver to model their effects and assess proliferation 
by means of BrdU incorporation and expression of the cell cycle antigen Ki-67 using 
histological and immunohistochemical techniques.
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3.3 Materials and Method
3.3.1 In vivo Rodent T3 Dose Response and Time course
BrdU is a synthetic thymidine analogue and when administered to the animal at a dose 
of 50mg/kg solubilised in sterile normal saline at 12.5mg/ml, given intra-peritoneally 
(i/p), it is incorporated into the DNA of cells undergoing DNA synthesis. Its subsequent 
detection is achieved using an immunohistochemical technique. It is frequently used in 
the technique of ‘flash labelling’, being administered 1 hour prior to animal sacrifice.
T3 was obtained from Sigma (Poole, England) and dissolved in 1M NaOH at a 
concentration of 1 mg/ml. It was administered to rats (n=3) by subcutaneous injection at 
a variable dose in 1ml volume (diluted in 960pl normal saline and 40pl 1M NaOH), to 
determine the T3 hepatic proliferative effect according to dose (0-10 fxg/rat). A second 
experiment was performed whereby the optimum dose (5pg) was administered to 
animals (n=3) sacrificed at different time points (14, 18, 24, 26, 30 hours post stimulus) 
to determine the time of the peak in vivo proliferative hepatocyte response. Establishing 
the most effective in vivo T3 dose and time course of response enables the in vitro dose 
to be estimated.
3.3.2 Whole Rat Liver Perfusions
The perfusion technique was first designed using whole livers from adult male Sprague 
Dawley rats. Attempts were made to study whether T3 exerted a mitogenic effect at 24 
hours post dose by using BrdU incorporation similar to the in vivo scenario which is 
well established (Francavilla et al. 1994) and where one sees a peak hepatocyte 
proliferative response to T3 at 24 hours post dose (see Results). Given the ready supply 
of resected pieces of human livers in the laboratory, work promptly moved on to 
attempt perfusion in these to see if the T3 effect could be directly demonstrated in 
human liver. The human liver samples were obtained from a hospital in Basingstoke 
UK (designated BS) and are described in General Methods Chapter Two These livers 
were also the source of cells for the primary hepatocyte cell work described in Chapter 
Seven.
Materials:
Perfusate 500mls consisting of:
480mls W illiam’s E Medium (Gibco)
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25mM HEPES buffer (12.5mls of 1M to 500mls Williams E to make 25mM final 
concentration) (Sigma)
3.5 mis 1M NaOH to a full bottle, filter sterilised, pH 7.4 final 
5 mis penicillin/streptomycin
Insulin at a final concentration 10'7M (500pl of a 10'4M stock to 500ml of perfusion 
buffer)
5 or 20% by volume human red blood cells (when used and obtained from the Royal 
Free Hospital Blood Bank)
1 , 0 0 0  units heparin
The organ perfusion buffer was prepared under cell culture conditions and was filter 
sterilised prior to use. It was made fresh the day before a perfusion experiment was 
performed and stored overnight at 4°C. Antibiotics were added to ensure the perfusate 
remained sterile and heparin was added only in the presence of blood to act as an 
anticoagulant preventing activation of clotting cascades which could have compromised 
normal perfusion of the liver. HEPES acted as a buffer to maintain pH within a normal 
physiological range.
Additional materials:
Silicone lid for glass organ beaker (autoclaved)
Watson-Marlow peristaltic pump set at 3 rpm equivalent to a flow rate of lOmls/minute
95% O2/  5% CO2 was at piped into the oxygenator at 500cc/min (BOC gases)
Autoclaved 500ml glass beaker as the organ bath
Water bath at 37°C
Jelly pads- microwave heated
Mechanical electronic stirrer (Heidolph)
Altec plastic tubing Altesil high strength silicone tubing bore 2.5mm wall 0.5mm (#01- 
93-1457)
GE Silicone #03-71-5201 
Three way taps (Baxter Healthcare)
22g blue human paediatric cannula (Medisave)
Syringe driver (Baxter Healthcare)
Silicone autoclaved bubble trap tube (Altec)
Hepatocyte Growth Factor (HGF) lOng/pl and Epidermal Growth Factor (EGF) 
lOpg/ml (Sigma)
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T3 (Sigma)
BrdU (Sigma)
Hypnorm® containing fentanyl citrate 0.315mg/ml and fluanisone lOmg/ml 
(VetaPharma UK)
Method:
A diagram of the perfusion apparatus is outlined in Figure 7.
The oxygenator was constructed from a length of hollow polydimethylsiloxane (PDS) 
tubing. The tubing was wrapped around 2 glass pipettes and held in place with silicone 
gel. The assembly was then inserted into a glass bottle of volume 1L and in the lid four 
holes were made using an electric drill. Through these the perfusate tubing could pass, 
while through another hole oxygen could be introduced from a cylinder at 500cc/min. 
Oxygen could then be delivered into the beaker and diffuse across the perfusate tubing 
and into the circulating perfusate.
The perfusion circuit was set up before animal sacrifice and organ harvest. A volume of 
500mls perfusate was brought to 37°C in the incubator and this was used to prime the 
system in preparation to receive the organ or piece of liver.
The oxygenator bottle was immersed in a warmed water bath and the perfusion beaker 
sat on a metal support in the water bath so its sides were adequately bathed in water 
kept at a constant physiological temperature of 37°C. Perfusate was stirred at a constant 
rate using an electronic stirrer to ensure proper mixing and therefore even distribution of 
added drugs such as mitogens and BrdU but also red blood cells which would otherwise 
sediment out over time.
3.3.3 Perfusate
A volume of 500ml was needed to prime the circuit. Early experiments used packed 
human red blood cells which were added to the perfusion buffer in an attempt to 
improve its oxygen carrying and delivery capabilities. The red cells were collected from 
the Royal Free Hospital Blood Bank and were taken from stocks that were to be 
discarded for a number of reasons, for example reaching the end of their shelf life.
The ABO blood group and Rhesus antibody status was recorded for all samples and for 
the human perfusion work an exact match to the perfused liver sample was always 
sought.
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WATER
Initial experiments were conducted with 20% red cells by volume and then a 
concentration of 5% was used before perfusate was eventually utilised with the addition 
of no red blood cells.
The consequences and reasons for doing this will be discussed in the results and 
discussion sections.
3 wav tap
PERISTALTIC
Bubble
drap
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BATH
liver
Oxygenator 95% 0 2/ 5%CO:
Figure 7 Schematic diagram showing the perfusion circuit. For simplicity and clarity 
the electronic stirrer is not shown. The entire system was maintained in a water bath 
held at a constant temperature o f  37 °C. The circuit tubing is composed o f  Silastic 
silicone tubing. Strategically placed 3 way taps and a bubble trap allowed the removal 
or containment o f  potentially harmful air bubbles.
3.3.4 Animal Protocols
Male Sprague-Dawley rats (250g) were housed in a temperature- and light-controlled 
room (12-hour light/dark cycle) with free access to food and water. Animal care and all 
procedures were compatible with the Animal (Scientific Procedures) Act 1986, UK 
Home Office.
The animal had its weight recorded and was anaesthetised with a dose of 1 ml/kg
Hypnormw given IM into a thigh muscle. The drug took about 10 minutes to take effect.
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The perfusion apparatus was already set up and primed with warm perfusate as shown 
in Figure 7. The anaesthetised animal was laid onto the surgical bench placed on top of 
a warmed jelly bag and a midline laparotomy incision was made to expose the liver 
fully. The limbs were fixed to the bench using surgical tape.
Heparin was injected through the femoral vein to fully anti-coagulate the animal. Two 
3/0 silk ligatures were placed under the portal vein. The organ was mobilised by cutting 
the falciform and gastrohepatic ligaments and portal vein cannulation was carried out 
with a polyethylene 22g blue paediatric cannula filled with heparinised W illiam’s E 
medium ( 2  units/ml) attached to a syringe driver to ensure constant and even perfusion 
of the organ before it was connected to the perfusion circuit.
The organ was then perfused with 20mls of perfusate until it turned a uniform beige 
colour. It was then excised and transported on a Petri dish to the perfusion apparatus 
where it was placed in the glass beaker bathed in perfusate and then connected to the 
perfusion circuit. The peristaltic pump was set at 3 revolutions per minute (rpm) which 
corresponded to a flow rate of lOmls/min of perfusate.
Strategically placed 3-way taps enabled sampling of perfusate and also injection of 
mitogenic agents and BrdU in solution. In addition these permitted the removal of air 
bubbles which on occasion did arise, despite the bubble trap, and could have been 
harmful to the perfused liver.
A silicone cover was cut to loosely fit over the organ containing glass beaker. This was 
autoclavable and therefore sterile and acted to limit evaporation from the system and 
also to limit access from air-borne microbes. Times were carefully recorded and once 
the organ was in position and the perfusion circuit was functioning mitogen or vehicle 
could be introduced to the perfused liver up stream by means of a 3 way tap. Any 
solution injected was done so carefully to avoid the introduction of air into the circuit. 
Perfused liver either received a mitogenic dose of T3 (see Chapter 3 Results), vehicle 
only or the potent hepatomitogens HGF and EGF.
Twenty three hours after the start of a perfusion BrdU solubilised in normal saline was 
introduced to the perfusion circuit (final concentration 40pM  i.e analogous to the in vivo 
dose of 50mg/kg) to allow cells actively synthesising DNA to be identified at later 
immunohistochemical analysis.
At the end of each experiment the circuit was switched off and the liver was removed 
onto a Petri dish. The organ was flushed with fresh formalin and then sectioned and 
placed in 10% formalin for 24 hours to fix the tissues. Sections were cut from obviously
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healthy looking areas of liver and areas which appeared to be poorly perfused so 
comparisons could be made histologically.
3.3.5 Human Liver Perfusions
Materials:
Human liver designated a BS number 
University of Wisconsin (USW) solution 
Ice
Cold bag
2 2 g paediatric cannula 
Tissue glue (3M)
Cell culture hood
Perfusion buffer already made up and stored at 4°C but made ready by pre-warming to 
37°C.
Human liver samples were acquired with patient consent (Ethics ID38-2000 Culture of 
human liver cells obtained at surgery) from specimens taken during liver resection for 
colorectal cancer performed at the North Hampshire Hospital as described in Chapter 
Two General Methods.
On the day of surgery the liver sample was transported by car to the Centre for 
Hepatology as soon after surgery as was feasible. It was transported bathed in USW 
solution and on ice in a cold bag prior to transfer to the cell culture hood. A small piece 
of pre-perfusion liver tissue was resected on arrival and placed in formalin for later 
histological analysis.
After successful cannulation of a visible vessel lumen in the liver segment using a 22g 
human paediatric blue cannula which was secured in place using tissue glue, the liver 
was flushed with perfusate and transferred to the perfusion beaker and connected to the 
pump apparatus and perfused for a period which varied between 90 minutes and 48 
hours following delivery of T3 or vehicle only.
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3.3.6 T3 dose for organ perfusion
The optimum in vivo T3 dose was found to be 5pg/250mg rat (see Results) to bring 
about hepatocyte proliferation with the peak in vivo response at 24 hours post dose. The 
assumption made for the perfusion experiments was that 5pg is distributed in the whole 
blood of the adult rat i.e. 15 mis total circulating blood volume. So for the volume of 
perfusate the amount needed equates to 166pg T3 given in 1ml total diluent.
The T3 was solubilised at lmg/mL in 1M NaOH and the diluent used was 0.9% normal 
saline.
3.3.7 HGF/EGF
These potent hepatic mitogens were added to the perfusion circuit in one experiment on 
human liver, BS10, one hour after the perfusion was started in an attempt to 
demonstrate a hepatic mitogenic response if a response to less potent mitogens such as 
T3 was not demonstrated. The amount administered was lp g  HGF (lOOpl o f lOpg HGF 
in 1ml water stock) and lOpg EGF (lOpg in 1 ml water).
3.3.8 Bromodeoxyuridine (BrdU)
BrdU was added to give a final concentration of 40pM based on a dose given to the 
rodent in vivo of 50mg/kg. For 500 ml of perfusate therefore, 270 mg BrdU was 
solubilised in 5 mis sterile 0.9% sodium chloride solution.
3.3.9 Haematoxylin & Eosin (H&E), BrdU and Ki-67
The quality of the perfusion experiments was assessed by examining tissue sections 
with Haematoxylin & Eosin, immunohistochemical techniques used to enable detection 
of the cell cycle marker Ki-67 and to look for the incorporation of BrdU into nuclei of 
cells undergoing DNA synthesis (see General Methods Chapter 2).
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3.4 Results
3.4.1 T3 dose response and time course
The peak proliferative response as assessed by Bromodeoxyuridine (BrdU) 
incorporation occurs at 24 hours post T3 when administered at a dose of 5pg per whole 
animal (Figure 8  and Figure 9). This compares with a peak in response noted by Pibiri 
et al (Pibiri et al. 2001) at 18 hours when using a larger T 3 dose o f 20pg/I00g body 
weight.
The dose of T3 per animal gave the maximal proliferative response was 5pg (Figure 10). 
The hepatocyte proliferative response is predominantly seen to occur in the midzone 
region of the hepatic lobule consistent with previous published reports (Malik et al.
2003).
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Figure 8  Histological section o f rat liver showing the hepatic proliferative response 
after mitogenic T< as measured by BrdU incorporation (a) after 5pg T3 and (b) after 
vehicle only at 24 hours post dose. Cell nuclei within which DNA synthesis is occurring 
have incorporated BrdU and are stained brown in these tissue sections, xlO objective.
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Figure 9 Time course o f  hepatocyte DNA synthesis in response to T3 over time in adult 
male Sprague Dawley rats as measured by BrdU incorporation. Data points represent 
mean and range, n = 3 per time point. A total o f 2,000 hepatocyte nuclei were scored 
fo r  number o f  BrdU positive nuclei.
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Figure 10 Dose response curve o f  hepatocyte DNA synthesis after T3 as assessed by 
BrdU incorporation in adult male SD rats. A t least 2,000 hepatocyte nuclei were 
scored. Data points represent mean and range, n = 3.
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3.4.2 Organ Perfusions undertaken
The overall number of perfusions conducted are summarised in the Table 5. Nine 
separate rat perfusions were performed in addition to twelve human perfusions.
Table 5 A summary o f  the rodent and human liver perfusion experiments undertaken. 
The animal perfusions are designated ‘rat’ and the human liver perfusions as ‘BS
LIV ER PERFU SIO N  
T IM E  (hrs)
t 3 B rdU R ed Blood Cells
(RBCs) %
Rat 1 24 + + 20%
Rat 2 24 - + 20%
Rat 3 24 - + 5%
Rat 4 24 - + 5%
Rat 5 24 + + 5%
Rat 6 24 + + -
Rat 7 24 - + -
Rat 8 24 + + 5%
Rat 9 24 + + 5%
BS4 27 + + 20%
BS5 24 + + 20%
BS6 24 + + 5%
BS7 24 - + 5%
BS8 6 + - -
BS9 10 + - -
BS10 24 HGF/EGF + -
BS13 48 + + 5%
BS17 48 + + 5%
BS 33 6 + - -
BS 35 6 - - -
BS 39 x2 90 minutes +/- - -
The quality of the perfusions was variable but consistently improved upon and the 
perfusion parameters which affected the outcome are discussed further in the remainder 
of this results section.
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3.4.3 Quiescent Rat Liver
A representative H and E section of quiescent unstimulated adult male Sprague Dawley 
rat liver is shown to demonstrate the normal hepatic architecture to enable comparisons 
to be made in the against sections o f perfused liver (Figure 11).
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Figure 11 H and E section o f  unstimulated adult rat liver x20 objective, reflecting the 
normal hepatic lobular architecture. The vessel seen in the centre o f  the fie ld  is a 
hepatic vein and a few  red blood cells can be seen to occupying its lumen.
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3.4.4 Rat liver perfusion with 20% Red Blood Cells
Rat liver perfusion 2 was perfused with perfusate containing 20% RBCs and this 
resulted in areas o f hepatic parenchyma becoming engorged with blood leading to 
significant architectural distortion (Figure 12). However in the same perfusion a 
relatively well preserved area o f liver can be seen in a different part o f the organ (Figure 
13) with much less parenchymal red cell engorgement.
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Figure 12 Rat liver histology after 24h perfusion x40 objective H & E  section. Perfusate 
containing 20% red blood cells was used and a perfusion time o f  24 hours. Note the 
architectural disruption and parenchymal engorgement with red blood cells
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Figure 13 Rat liver histology x40 objective H & E tissue section. Perfused with 20% 
RBCs over 24 hours. This tissue section shows an area o f  liver which is better preserved 
histologically and in which there is no parenchymal engorgement with red cells.
The hepatocytes in the better perfused area look healthy with intact nuclei and intact cell 
membranes with no signs o f vacuolation. In one tissue section there is evidence of a 
mitotic figure (Figure 14) which suggests that the perfusion conditions were favourable 
enough to allow this critical process to take place.
Figure 14 Rat liver histology x40 objective. Perfused with 20% red blood cells over 24 
hours. This tissue section contains a single hepatocyte undergoing mitosis (indicated by 
the arrow).
3.4.5 Rat liver perfusion with 5%  Red Blood Cells
Despite a lower concentration o f red blood cells there were still significant areas which 
appeared engorged with blood in these perfusion experiments (Figure 15).
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Figure 15 Rat liver histology x20 objective. Perfused with 5% red blood cells over 24 
hours H  and E section. In this tissue section parenchymal disruption is still apparent 
despite a lower concentration o f  red blood cells used in the perfusate.
The addition o f red blood cells at concentrations of 5% and 20%  led to a picture of 
engorgem ent o f the hepatic parenchym a and a distorted hepatic architecture and in some 
areas there was evidence o f tissue necrosis and apoptosis. This did not always follow 
the same pattern. For exam ple it may have been the periphery o f the perfused liver 
which was affected or a m ore central area or both. These differences depended on which 
vessel had been cannulated (either portal or hepatic vein) in the hum an livers and in the 
whole rat perfusion it indicated that the entire organ was not being equally and 
adequately perfused at all times despite secure placem ent o f the perfusion cannula in the 
portal vein. Identifying w hether a portal or hepatic vein had been cannulated proved 
very difficult when exam ining the human liver specim ens but cannulation o f a portal 
vessel was the experimental aim every time.
3.4.6 Rat liver perfusion with addition of no Red Blood Cells
In subsequent organ perfusion experiments conducted without the addition o f red blood 
cells to the perfusate, the parenchymal engorgem ent with red cells and disruption seen 
previously was lost and some very well perfused areas o f liver can be seen on the H and 
E sections (Figure 16).
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In subsequent perfusion experiments the red blood cells were omitted given the 
frequency with which engorgem ent of the parenchym a was noted and appeared to lead 
to histologically poor areas o f liver tissue. The oxygen saturation o f the perfusate when 
measured was satisfactorily maintained (> 90%) despite the om ission of red cells and as 
mentioned in the introduction the published experiences have been very variable but 
certainly other workers recom mend the omission o f red cells for short (up to 6 hours) 
perfusions. Indeed, m aintaining a perfusion histologically intact for less than six hours 
was found to be the most plausible theoretically and experim entally in this thesis.
Figure 16 Rat liver histology x40 objective. Organ perfusion with the addition o f  no red 
blood cells to the perfusate, H  & E section. There is no parenchymal engorgement and 
this area o f liver is well perfused. Perfusate flu id  can be seen filling the lumen o f  two 
vessels at the top o f the tissue section.
3.4.7 BS Human Liver Perfusions
An example of a successful BS human liver perfusion can be seen in Figure 17, with a 
well perfused area of liver clearly visible under higher magnification.
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Figure 17 Histological section o f human liver perfusion BS8  x40 objective H & E  
section reflecting a well perfused area o f hepatic parenchyma adjacent to a vein. The 
liver was perfused fo r  6  hours with no red blood cells added to the perfusate.
3.4.8 Perfusate analysis
On one occasion serial m easurements of perfusate fluid were undertaken to assess the 
change in various param eters such as oxygen saturation and pH using a blood gas 
analysis machine located within the Royal Free Hospital (Figure 18). Oxygen saturation 
was adequately m aintained but by 18 hours lactate levels had risen sharply and by 24 
hours the perfusate pH was almost 7.1, a clearly unacceptable value for normal 
physiological processes to occur, however it does lie close to rat portal blood pH which 
is 7.2 (Cheung et al. 1996). This analysis further supported the conclusion that 
perfusions over shorter time periods of only a few hours (0-6 hours) would be more 
successful.
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Figure 18 Serial analysis o f  perfusion parameters during a 24 hour rat liver perfusion 
experiment. pH  is seen to fa ll and lactate rise after six hours o f  perfusion. (Normal rat 
portal blood pH  in vivo is 7.2). Units: pCC>2 and pC>2 kilopascal (kPa); glucose, HCO3, 
lactate, and K+ mmol/l. O2 saturation expressed as % / 1 0 .
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3.4.9 Immunohistochemistry
In an attempt to model the effects of growth agents on the liver it was possible to 
identify cells which were undertaking DNA synthesis as evidenced by the incorporation 
of BrdU into their nuclei (Figure 19). However no increase in the number of BrdU 
positive hepatocytes was seen at 24 hours following the addition of T3 into the liver 
perfusion circuit. Indeed in a perfusion without the addition of a mitogen there were 
very few hepatocytes that stained positive for BrdU but the fact that this agent was 
actually incorporated into cell nuclei reflected that the perfusion milieu was 
physiologically normal enough to allow DNA synthesis to take place. BrdU was only 
added when the perfusion was run over 24 hours or more as it is at this time point in the 
in vivo model that one sees a peak of incorporation in hepatocytes.
Figure 19 Rat liver tissue section after immunohistochemical analysis showing an 
example o f  BrdU incorporation (indicated by the arrows) in the cells o f  a perfused rat 
liver x  2 0  objective.
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3.4.9.1 Human BS Liver perfusions
It was possible to demonstrate BrdU incorporation in human hepatocyte nuclei after a 
perfusion experiment (Figure 20). The number of positive cells was small however and 
certainly their numbers were not increased following the administration of T3 into the 
perfusion circuit.
Figure 20 Human liver section from  BS6  x  40 objective stained fo r  BrdU. At least 3 
cells are seen to stain positive fo r  BrdU. A single hepatocyte positive fo r  BrdU is 
indicated by the arrow.
3.4.9.2 Ki-67
Ki-67 is a cell cycle protein expressed in all active parts of the cycle but is absent while 
the cell remains in Go (majority of quiescent hepatocytes in vivo). Commercial 
antibodies exist that are directed against human and rat Ki-67. Human liver tissue was 
stained for Ki-67 to see if the number of positive cells was greater after mitogenic 
stimulation. In humans, if T3 is ever to be administered in vivo the hepatic proliferative 
response cannot be measured using BrdU incorporation as this agent may be a potential 
carcinogen in humans (Gaglio et al. 2002; Gerlach et al. 1997; Huang et al. 2004). It 
was therefore worthwhile examining human liver sections for this protein as staining for 
Ki-67 would be useful in the future to assess T3 treated human liver in vivo, for example 
in biopsy specimens. Unfortunately the numbers of cells positive for Ki-67 were very 
few and no greater following mitogen administration (Figure 21).
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Figure 21 Human liver tissue section from  BS6  stained fo r  Ki-67, x40 objective. A non 
parenchymal cell indicated within the black circle stains strongly positive fo r  human 
Ki-67 on this human liver section perfused fo r  24 hours. All the hepatocyte nuclei in this 
tissue section stain negative fo r  Ki-67.
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3.5 Discussion
The successful perfusion experiments achieved here were of short duration (up to 6  
hours or less) and therefore this does not enable the more traditional means of 
identifying cells synthesising DNA, using BrdU incorporation, to be used to ascertain 
whether T3 is exerting a proliferative effect on the hepatocytes. Other early markers of 
the T3 mitogenic effect have to be sought. The attempts at organ perfusion described in 
this Chapter were carefully designed but despite the shortcomings in this early work, if 
the technique was further perfected it could become a very valuable tool in assessing the 
hepatic response to mitogenic stimuli, including T3, as long as a marker of such an 
effect can be found.
There are technical considerations which when addressed might lead to more successful 
and more prolonged tissue perfusion times but even if this was achieved it remains as 
yet unclear as to whether the mitogenic agents would exert their desired effects as they 
are known to do in vivo. The in vitro perfusion is an attempt at replicating the more 
subtle and complicated milieu seen in the living organism. T3 in particular may be 
acting through intermediate steps which require the interactions o f all the animal’s 
major organ systems. In addition even if it does act directly on hepatocytes its mode of 
action may be exquisitively sensitive to anything other than completely normal 
physiological conditions and these are difficult to replicate and maintain in the 
perfusion apparatus described here.
When human liver pieces were perfused it was frequently very difficult to identify the 
exact nature of the vessel cannulated. Ideally this would have been a portal vein as 
direction of perfusate flow would have been physiologically normal. However 
practically speaking the ‘best’ vessel had to be cannulated and if this was a hepatic vein 
the direction of perfusate flow would have been unphysiological and this could have led 
to an adverse outcome in any one perfusion experiment. A further obvious but 
nonetheless important experimental improvement is to manufacture duplicate apparatus 
that allows one to run two perfusions in parallel, thus enabling one to act as a control. 
Clearly exactly matching all the potential experimental variables is impossible but at 
least two perfusions undertaken at the same time adjacent to one another on the same 
day permits more reliable comparisons to be made than those conclusions one may draw 
by comparing separate perfusions on different days.
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3.5.1 Additional improvements
Bile volume production has been reported to be the most sensitive indicator of hepatic 
function (Gores et al. 1986) and a reduction in bile volume production by 4 hours has 
been reported, likely representing a decline in hepatic function. Cannulating the bile 
duct in the rat liver perfusions undertaken here and measuring bile production would be 
a further important improvement to the experimental design. In future the portal 
pressure may also be accurately measured by using a pressure transducer during a 
perfusion experiment to more accurately control the rate and constancy of fluid flow 
and hence perfusion pressure. Furthermore regular and more frequent measurements of 
perfusate biochemical parameters may lead to a better understanding of which other 
experimental variables can be more accurately controlled in future.
Turning to the actual composition of the perfusate, it may be worthwhile to consider the 
use of perfluorocarbon emulsions as a perfusion medium (Kamada et a l  1980). 
Perfluorochemicals are chemically inert synthetic molecules that consist primarily of 
carbon and fluorine atoms, and are clear, colourless liquids. They have the ability to 
physically dissolve significant quantities of many gases including oxygen and carbon 
dioxide. Perfluorochemicals are hydrophobic, and are therefore not miscible with water 
and thus have to be emulsified for intravenous use. With sophisticated technology, it is 
possible to generate a stable perfluorocarbon emulsion with exceptionally small 
particles (median diameter < 0 . 2  pm) and the future use of these agents may allow more 
efficient tissue perfusion and oxygen delivery with less parenchymal disruption.
3.5.2 Future work
There is clearly enormous scope for perfecting and improving upon the technique of 
liver perfusion described in this Chapter. In parallel with this it would be very 
worthwhile trying to pursue another means of in vitro modelling of the T3 mitogenic 
effect, and this could be achieved through the use of the tissue slice (Martin et al. 2002). 
Liver slices would provide the more sophisticated hepatic architectural tissue platform 
required to study the effects of mitogens and several unique characteristics are attributed 
to precision-cut liver slices. By contrast with other in vitro models, the preparation of 
tissue slices does not require the use of proteolytic enzymes that disturb cell-cell 
interactions and may be damaging for cells (Lerche-Langrand and Toutain 2000). 
Additionally, with many in vitro systems, the conditions of organ preparation or 
isolation vary from species to species. In contrast, a similar and convenient procedure is
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used to prepare and incubate tissue slices of several organs from different species, 
including humans, making this model particularly suitable to perform inter-organ and 
inter-species studies. The maintenance of cell heterogeneity and cell-cell interactions 
within the original tissue matrix contained in a slice of tissue better reflects the high 
level of biological organization of the organ. The first attempts to maintain intact liver 
slices in vitro were made as early as 1923 (Warburg O. 1923) but the liver slice has 
been used to study the hepatic response to toxins more recently and it has been used as a 
model to study liver fibrosis in the animal and human (van de et a l  2006a; van de et a l  
2006b; van de et a l  2007b; van de et a l  2007a).
There are now available commercial units such as the Krumdieck tissue slicer, which 
enable fully automated tissue slicing with pieces of uniform thickness in a reliable and 
reproducible manner. For the purposes of modelling the mitogenic effects of T 3 the use 
of this technology would seem a logical next step. A sensitive and early marker (within 
6  hours) of the mitogenic T3 effect which can then be used in vitro and in vivo to 
measure mitogenic T3 effect needs to be found. Such a marker can then be employed to 
measure the mitogenic response in perfused liver as well as in precision cut liver slice 
experiments.
In summary, the perfusion experiments described in this chapter have shown how 
difficult it is to obtain a reliable system in which mitogenic effects can be modelled on 
rodent and human liver. Under these current experimental conditions, short perfusions 
of up to 6  hours are the most successful but this does not allow the more conventional 
methods of measuring a proliferative response using BrdU and Ki-67. Therefore in the 
next chapter this research thesis turns to identify early mediators of the T3 proliferative 
response in the in vivo rodent model which could then be used in the in vitro scenario of 
organ perfusion and precision cut liver slices.
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Chapter 4 Investigating Cyclin D1 and 
Bcl-3 as Mediators of the T3 Mitogenic 
Response
4.1 Background
As outlined in the previous chapter the liver tissue which underwent perfusion could 
only be maintained in a satisfactory histological state for up to 6  hours and therefore 
traditional means of measuring DNA synthesis, in response to growth factors, such as 
by way of BrdU incorporation, was not possible. The search therefore for a ‘marker’ of 
the early mitogenic effects of T3 becomes important.
Others have shown the cell cycle associated protein cyclin D1 is up regulated in vivo 
after T3 within 4 hours at the mRNA level in the rodent model (Pibiri et a l  2001). 
Cyclin D1 protein content was increased at 4 hours after T3, further elevated at 12 hours 
and maintained for 24 hours in their study. It was decided therefore to investigate cyclin 
D1 as a potential early marker of the hepatic T3 response in vivo before using it to 
measure the in vitro response. The first part of this Chapter sets about characterising the 
in vivo rodent response of hepatic cyclin D1 to T3 in this laboratory.
In the second part of the Chapter a further set of in vivo experiments are reported and 
investigate the hypothesised role of a novel candidate mediator, Bcl-3, of the mitogenic 
T3 response using a Bcl-3 knock out murine model. The starting point for this analysis 
was the murine cDNA microarray data published by Feng et al, analysing hepatic genes 
expressed 6  hours after treating hypothyroid mice with a single high dose of T3 (Feng et 
a l  2000). The data revealed that expression of 10 genes involved in cell proliferation 
was altered, including up-regulation of three genes -  B61, Bcl-3 and kinesin-like 
protein. Bcl-3 is an IkB-related protein that can act as a co-activator for NFkB 
homodimers and for the liver-enriched transcription factor AP-1 which is relevant to 
hepatocyte proliferation and may therefore be a plausible candidate as an early mediator 
of hepatocyte proliferation.
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The analysis is in two parts:
a) ‘cyclin D 1 as an early mediator of the mitogenic T3 effect’
b) ‘Bcl-3 as a mediator of the mitogenic T3 effect’
4.1.1 Cell Cycle
The eukaryotic cell cycle is divided into four stages: G l, S, G2 and M (Figure 22).
The Gl and G2 phases represent the ‘gaps’ in the cell cycle that occur between the 
Mitotic phase and the DNA Synthesis phase (Schafer 1998).
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Figure 22 Diagram o f  the eukaryotic cell cycle indicating the different stages. In 
quiescent liver most hepatocytes are in the Go or resting phase. To undergo DNA 
synthesis they have to emerge from  Go and enter the active G/ phase prior to DNA 
synthesis in S phase.
In Gl the cell is preparing for DNA synthesis and in G2 it is preparing for mitosis. Go 
describes cells that are not within the active phases of the cell cycle but which have the 
potential for division. During Gl phase the cell integrates mitogenic and growth 
inhibitory signals and becomes committed to either proceeding with or exiting the cell
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cycle (Johnson and Walker 1999). In the quiescent state the vast majority of hepatocytes 
exist in Go but have the ability to enter the cell cycle readily, given the correct 
conditions and stimuli (Sherr and Roberts 2004).
The serine/threonine protein kinases called cyclin dependent kinases (CDKs) complex 
with proteins called cyclins and this association catalyses progression of the cell cycle. 
Each CDK has a cyclin partner and binding to a cyclin is necessary for CDK activation. 
CDK inactivation prevents mitosis and the phosphorylation state of the CDK determines 
whether cycle progression can occur or not. Phosphorylation at certain residues can 
either stimulate or inhibit activity of the CDKs and other protein kinases can bring this 
about, for example the kinases w eel and m ikl.
The cyclins are so called because they undergo cyclic expression. Part of the cyclic 
expression of cyclins is due to regulated degradation as they contain specific protein 
sequences that target them for ubiquitination at very specific times (Lu et a l  1992). 
Cyclin binding to CDKs is necessary for CDK activation and nuclear localisation and a 
cell enters the next phase of the cycle only once the cyclin from the previous phase has 
been degraded and the cyclin for the next phase has been synthesised.
In mammals there are more than 16 known cyclins (A, B l, B2, C, D l, D2, D3, E, F, G l, 
G2, H, I, K, T1 and T2) and more than 10 known CDKs. All cyclins contain a common 
region of homology called the cyclin box and it is here that CDKs bind and can then be 
activated. However other additional functions have been identified for cyclins and 
CDKs and these include DNA repair, apoptosis and regulation of transcription (Johnson 
and Walker 1999). For example, cyclin H/CDK7 is a component of the basal 
transcription machinery as is cyclin C/CDK8.
The CDKs phosphorylate a variety of substances allowing the cell cycle to progress. For 
example in G2 and M phases, nuclear laminins and microtubules act as substrates. 
Retinoblastoma protein in G l (pRb) is another very important CDK substrate and it is 
described next.
41.1.1 D -type cyclins and pRb
The human cyclin D l gene was initially cloned as a break point rearrangement in 
parathyroid adenoma. The murine homologue was identified as a colony-stimulating 
factor-1 responsive gene in macrophages (Fu et al. 2004). The cyclin D l gene is over 
expressed in 30-50% of primary human breast cancers and a number of other human 
neoplasms show cyclin D l up-regulation including squamous carcinoma of the head
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and neck as well as several leukaemias and cyclin D l has become well known for its 
prominent role in driving tumourogenesis. However the biological function of cyclin D l 
when investigated in transgenic species is surprisingly redundant. In cyclin D l deficient 
mice one sees retinal apoptosis, altered fat metabolism, hepatic steatosis and defects in 
macrophage migration.
D type cyclins associate with and activate the kinases CDK4 and CDK6 (Boylan and 
Gruppuso 2005; Rickheim et al. 2002) and the retinoblastoma protein (pRb) is the 
primary substrate for D-type cyclin kinases. Many oncogenic signals induce cyclin D l 
expression and do this through distinct DNA sequences in the cyclin D l promoter; these 
include: Ras, Src, ErbB2, and STATs.
pRb is very important as a gatekeeper of the G l phase and its cell cycle inhibiting 
function is inactivated by cyclin D l acting as the regulatory subunit of the holoenzymes 
that phosphoiylate it (Nelsen et al. 2001). There is a point in G l beyond which cells no 
longer respond to the withdrawal of growth factors and so it is termed the restriction 
point. So, if the growth factors are withdrawn prior to this the cell can revert to Go but 
after the restriction point the cell will go on into the DNA synthesis phase of the cycle. 
pRb is an important controlling factor of this restriction point (Loyer et al. 1996; 
Albrecht and Hansen 1999). Once the cyclin-CDK complex phosphorylates pRb, the 
transcription factor E2F is released and is free to transactivate genes necessary for cell 
cycle progression. Hypophosphorylated pRb binds E2F and prevents it from acting as a 
transcription factor. E2F factors regulate the expression of many genes that encode 
proteins involved in cell cycle progression and DNA synthesis, including cyclins E and 
A, CDK1 and DNA polymerase alpha (
Figure 23). After activation of E2F, cyclin E is the next cyclin to be induced and after it 
associates with its kinase, CDK2, the cell can now make the crucial transition from G l 
into S phase (Moroy and Geisen 2004; Calbo et al. 2002).
Genes that are active in S phase are silenced by pRb by active repression of E2F 
transcriptional activity and this is reduced by cyclin D l. pRb acts as a tumour 
suppressor and loss of function results in loss of the restriction point check and 
therefore loss of cell cycle control.
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Figure 23 Functions o f  cyclin D l. Cyclin D l form s a complex with its kinase partner 
CDK4 and. this activation step leads to phosphorylation o f  retinoblastoma protein Rb. 
The transcription factor E2F is released and can transactivate genes necessary for cell 
cycle progression (Fu et al. 2004).
There are many negative regulators o f the cell cycle and they occur at different stages:
In the G l and S phase the m ost extensively investigated ceil cycle inhibitors are the p 16 
and p21 families. These proteins form stable com plexes with the CD Ks before they are 
bound to cyclins, and excess expression of cyclin will not dissociate them from the 
CDK. p l6  inactivates CDK4 and CDK6 in G l and thereby prevents phosphorylation 
and inactivation o f pRb. The p21 family is o f primary im portance in G l regulation 
where family members can bind cyclins thereby preventing the CDK from 
phosphorylating pRb and inducing its dissociation from E2F (A lbrecht et al. 1999; 
Albrecht et al. 1995). Unlike p l6 , cell cycle inhibition by p21 can be prevented by 
increasing cellular concentrations o f cyclins.
Feng (Feng et al. 2000) used a quantitative fluorescent cD N A  microarray to identify 
genes regulated by thyroid hormone. Fluorescent labelled cDN A  was prepared from  the 
hepatic RNA of T 3-treated hypothyroid mice and hypothyroid mice within 6 hours of 
stimulation. Following array hybridisation relative changes in gene expression were 
analysed. 55 genes, 45 not previously known to be thyroid responsive genes, were 
found to be regulated by thyroid hormone. O f these 41 were negatively regulated and 14 
were positively regulated.
4.1.1.2 Bcl-3
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Bcl-3 was striking as one of th eT 3 regulated genes up-regulated in this array study and 
it is of interest given its involvement in control of cell proliferation. Bcl-3 belongs to a 
family of IkP proteins, originally identified as a candidate proto-oncogene over 
expressed in certain cases of B-cell chronic lymphocytic leukemia as a consequence of a 
t(14;19) chromosomal translocation and its involvement in the pathogenesis of solid 
tumors such as nasopharyngeal carcinoma is now well recognised (Brocke-Heidrich 
2006).
Through an ankyrin repeat domain, the activity of NFxp transcription factors can be 
regulated. In mammals there are five members of the NFicp family RelA (p65), RelB, c- 
Rel, p50 and p52. Bcl-3 can either activate or repress gene transcription by forming 
complexes with p50 and p52 homodimers. Thus, Bcl-3 over-expression is proposed to 
cause dysregulation of genes normally regulated by NFKp transcription factors 
implicated in cell proliferation, differentiation and apoptosis. Given the oncogenic 
potential of Bcl-3 and its likely effects on proliferative pathways, the hypothesis tested 
in this chapter is whether it acts as a critical mediator of the mitogenic hepatic effects of 
T3. To this end the acquisition of a Bcl-3 knockout mouse from the University of 
Tubingen in Germany made the testing of this hypothesis possible.
4.2 Hypotheses and Experiments
Hypothesis (a) Cyclin D l is an early mediator o f the hepatic T3 mitogenic effect
Experiments used to investigate this hypothesis:
i. Measure the mRNA expression of cyclin D l in liver in vivo in adult euthyroid 
Sprague-Dawley rats, following mitogenic stimulation with the hepatomitogen T 3 using 
quantitative Real Time PCR.
ii. Use an immunohistochemical technique with a novel rabbit monoclonal anti 
cyclin D l antibody to measure the in vivo protein expression of cyclin D l in T3 treated 
rat liver over time.
iii. Use the same technique to study the pattern of staining for cyclin D l in 
quiescent rat liver, partial hepatectomy rat liver and human liver specimens.
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Hypothesis (b) There is a reduced hepatocyte proliferative response to T3 in Bcl-3 knock 
out mice
Experiments used to investigate this hypothesis:
i. Administer T3 at a mitogenic dose to a group of Bcl-3 knock-out mice, to 
determine whether this protein is a critical mediator of the hepatic T3 mitogenic effect.
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4.3 Materials and Methods
4.3.1 Animal Protocols
Adult male Sprague Dawley rats weighing 200-250g were used. Animal care and all 
procedures were compatible with the Animals (Scientific Procedures) Act 1986 (see 
General Methods Chapter 2).
a) First time course experiment:
Rats (n=3) were injected with a single sub-cutaneous dose of 5pg T3 (5pl of lpg /p l T3 
dissolved in 1M NaOH added to 35pl 1M NaOH made up to 1ml with normal saline) 
and sacrificed at 1, 3, 14, 18, 22, 26 and 30 hours post dose.
A group of animals (n=3) were injected with vehicle only and sacrificed at 1 and 3 
hours to act as a control.
The liver was sectioned after sacrifice, snap frozen in liquid nitrogen and stored at 
-80°C until use. Sections were also placed in formalin and after 24 hours sent for routine 
histological processing prior to embedding in paraffin blocks in readiness to cut 4pm 
paraffin sections for immunohistochemistry.
Second time course experiment:
A male SD rat (n=l) was injected with a dose of 5pg T3 and sacrificed at 1 , 3, 6 , 9, 12, 
14 and 18 hours post dose. A second animal was injected with vehicle only and 
sacrificed at the same time points. Tissue was collected in the same manner as before.
b) Bcl-3 protocol
Bcl-3 knock out (KO) mice were obtained in collaboration with Professor Schmidt at 
the University of Tubingen, Germany. The animals were imported into the United 
Kingdom and all animal care procedures were adhered to according to the Animals 
(Scientific Procedures) Act 1986. After a period of a few days following their arrival the 
animals had adapted to their new environment and were deemed in a healthy state 
permitting the experiment to be undertaken.
C57 Black 6  mice of a similar age were used as wild type controls. These were bred 
within the animal house at the Royal Free hospital.
Bcl-3 KO mice (n=4) were administered a mitogenic dose of T3 (5pg) subcutaneously 
and sacrificed 24 hours later. One hour prior to sacrifice BrdU was administered
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intraperitoneally at a dose of 50mg/kg to identify those hepatocytes undergoing DNA 
synthesis (flash labelling).
Bcl-3 KO mice (n=2) were administered vehicle only and sacrificed 24 hours later with 
flash labelling with BrdU at 23 hours post dose.
C57 Black 6  mice (n=4) were administered a mitogenic dose of 5pg T3 and sacrificed
24 hours later with flash labelling with BrdU at 23 hours post dose.
C57 Black 6  mice (n=2) were administered vehicle only and sacrificed 24 hours later 
with flash labelling with BrdU at 23 hours post dose.
Following animal sacrifice, livers were harvested, sectioned and placed in formalin
prior to histological processing for further analysis (General Methods Chapter 2).
4.3.2 Isolation of RNA
Please refer to General Methods Chapter 2.
4.3.2.1 Determination of RNA yield
Please refer to General Methods in Chapter 2.
A ratio above 1.8 (A26o/A28o) was obtained for all samples analysed.
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4.3.2.2 RNA Gel E lectrophoresis
Please refer to General Methods in Chapter 2.
The RNA obtained was of good quality as shown on RNA gel electrophoresis (Figure 
24).
Figure 24 A 1.5% agarose gel showing intact RNA from liver samples 1 to 6 . This is a 
representative example o f  all the samples obtained. The RNA is intact as shown by the 
sharp 28S (top) and 18S (bottom) bands and the 2:1 ratio o f '28S:18S.
4.3.3 cDNA synthesis
Please refer to General Methods Chapter 2.
4.3.4 Primer design for cyclin Dl and 18S
Please refer to General Methods Chapter 2.
4.3.5 Primer design rules that were applied
Please refer to General Methods Chapter 2.
Using GeneBank (http://ww w.ncbi.nlm .nih.gov) the com plete mRNA sequences for 
cyclin D l and rat 18S were obtained. For both these targets forward and reverse primers 
were designed to com ply with the rules set out above with the additional requirement
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for real-time PCR that the size of the amplicon should be no more than 150bp in length. 
Using the computer software Vector NTI the proposed primers were assessed to ensure 
that an intron-exon boundary was spanned (to minimize genomic DNA amplification), 
no potential formation of primer-dimers or secondary structures was predicted, and 
similar annealing temperatures were appropriate for each primer pair. The primer pairs 
were screened against the Blast database to ensure specificity to the gene of interest, 
cyclin D l and 18S primer sequences were purchased from SigmaGenosys. An 
appropriate volume of DEPC-MilliQ water was added to the lyophilized primers to 
make lOOpM stock concentrations from which lOpM working concentrations of 
primers were made. All primers were stored at -20°C at lOOpM concentration for long 
term storage. Primer sequences are shown in Table 6 .
Table 6 Primer sequences fo r  cyclin D l and 18S.
Target Primer Sequence Temp
(°C)
Cyclin Dl
Cyclin Dl 
forward 5’- AGGAGTTGCTGCAAATGG -3’ 61.2
Cyclin Dl 
reverse 5’- CTGGC ATTTTGGAG AGG A AG-3 ’ 61.4
18S
18S forward
5 ’ -CTTAGAGGG AC AAGTGGCG-3 ’ 62.4
18S reverse
5’-GGACATCTAAGGGCATCACA-3’ 62.5
A set of primers was designed to amplify a sequence of DNA from the cyclin D l coding 
region.
Forward position 560-577 
Reverse position 645-664 
Predicted PCR product is 104 bases.
A set of primers was designed to amplify a sequence of DNA from the 18S coding 
region.
Forward position 1488-1466 
Reverse position 1517-1498 
Predicted PCR product is 69 bases.
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4.3.6 Conventional PCR to check primers (for cyclin D l and 18S)
Please refer to General Methods Chapter 2.
4.3.7 DNA gel Electrophoresis
Please refer to General Methods Chapter 2.
The cyclin D l PCR product was 104 base pairs when m easured against a lane 
containing 7pl o f Hyperladder IV (Figure 25).
The 18S PCR product was 69 base pairs when measured against a lane containing 7pl of 
Hyperladder IV (Figure 25).
a) cyclin D l b) 18S
Figure 25 2% agarose gel electrophoresis o f  the PCR products, (a) a single band o f  
104 nucleotides is seen in the samples (5 lanes) consistent with the size o f  the cyclin D l 
amplicon and (b) a single band o f 69 nucleotides is seen in the second gel samples (4 
lanes) consistent with the size o f  the 18S amplicon. The 200 base pair marker (first lane 
in each gel) is indicated by the arrows.
4.3.8 Preparation of standards
Please refer to General Methods Chapter 2.
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Method:
5pl of cDNA from a sample was used to make cyclin D l product so as standards could 
be made for the real time PCR analysis for both cyclin D l and 18S.
4.3.9 Amplicon Excision from DNA Agarose Gel
Please refer to General Methods Chapter 2.
4.3.9.1 Amplicon extraction from agarose gel
Please refer to General Methods Chapter 2.
4.3.9.2 Amount of specific product estimation using Avogadro’s number
Please refer to General Methods Chapter 2.
The number of amplicon molecules was calculated using Avogadro’s number (6.022 
xlO23), the molecular weight of the amplicon and the estimated concentration of 
amplicon.
For cyclin D l:
Product 104 bp
Molecular weight of the amplicon = 330 x (length of the amplicon x 2)
1 mole = 68,640g = 6.022 xlO23 
lng  = 8.77xl09
From the gel, 2pl = 20ng = 1.75 xlO 11 copies 
Standard = 8.75 x l0 1 0copies/[xl
4.3.9.3 Developing a real time PCR protocol to quantify the expression 
of cyclin D l mRNA in the liver
Please refer to General Methods Chapter 2.
4.3.9.3.1 Optimisation Steps
Please refer to General Methods Chapter 2.
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4.3.9 3.2 Standard Curve
Please refer to General Methods Chapter 2.
4.3.9.3 3 Samples
With acceptable standard curves, all samples could then be run for cyclin D l followed 
by 18S to which the copy numbers per reaction can be normalised. Accuracy of the 
assay was demonstrated by showing reproducibility across more than two separate real 
time runs.
Reaction Mix for cyclin D l : Hotstar Mix 1 Opl
Forward primer 2 pi
Reverse primer 2pi
SYBR Green 1.5pl
H20  2.5pl
cDNA 2 pi
TOTAL 20pl
Reaction Mix for 18S: Hotstar Mix lOpl
Forward primer 0.5pl
Reverse primer 0.5pi
SYBR Green 1.5pl
H20  6.5pi
cDNA lp l
TOTAL 20pl
Within each individual real time PCR run the appropriate non template controls (NTCs) 
were included as well as the standards. The standards chosen would lie between the 
range of fluorescences of the experimental samples and were run in duplicate. At least 
three standards were included in each reaction. At the completion of each reaction the 
appropriate standard curve, either for cyclin D l or 18S, was imported to allow the 
software to calculate the copy number of amplicon per reaction. This number was then 
normalised to the 18S copy number per reaction. Figure 26 shows an example of the 
raw data generated for cyclin D l standards and the standard curve can then be 
constructed (Figure 27).
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Fluorescence
Figure 26 Raw Real Time PCR data fo r  cyclin D l standards. The sigmoid curves 
reflecting target amplification during the Real Time PCR reaction can be seen fo r  each 
standard with the most concentrated standard with the lowest C j value appearing first. 
Each standard is in duplicate.
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Figure 27 Cyclin D l standard curve with C rvalues fo r  standards plotted ranging from  
1 0  2 to 1 0  10.
Figure 28 shows raw data for 18S standards and from these the 18S standard curve can 
be constructed (Figure 29).
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Fluorescence
Figure 28 Raw Real Time PCR data fo r  18S standards. The sigmoid curves reflecting 
target amplification during the Real Time PCR reaction can be seen fo r  each standard 
with the most concentrated standard with the lowest Ct value appearing first. Each 
standard is in duplicate.
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Figure 29 Rat 18S standard curve with C t values fo r  standards plotted ranging from  
1 0  3 to 1 0  9
122
4.3.10 Immunohistochemical analysis of cyclin D l in the liver
Please refer to General Methods Chapter 2.
Materials:
rabbit monoclonal anti - cyclin D l antibody SP4 (Labvision, UK) 
goat biotinylated anti rabbit antibody (DAKO)
sections of human breast carcinoma (Royal Free Hospital Histopathology Department) 
M ethod:
See General Methods Chapter 2
The primary antibody (LabVision monoclonal rabbit anti cyclin D l)  was applied to 
tissue sections at an optimal dilution of 1:50 for a 1 hour incubation in a humid 
incubator (Cheuk et al. 2004).
Sections of human breast carcinoma acted as a positive control and a section without the 
primary antibody but instead incubated with the appropriate concentration of rabbit IgG 
acted as a negative control. The sections were washed for ten minutes in x l PBS and 
incubated with the secondary antibody (DAKO goat biotinylated anti rabbit) for thirty 
minutes at an optimal dilution of 1:400.
The primary antibody used initially required optimising, varying its concentration to 
obtain optimal staining results at the dilutions defined above.
4.3.10.1 M easurem ent o f positive staining for cyclin  D l
Positive nuclear staining of hepatocytes was determined visually and then the number of 
positive cells was counted per 2,000 hepatocyte nuclei. All slides were blinded prior to 
counting to avoid bias.
4.3.10.2 H  & E staining
Please refer to General Methods Chapter 2.
4.3.10.3 Immunohistochemistry for BrdU in mice
Please refer to General Methods Chapter 2.
Monoclonal Rat anti-BrdU supernatant (OBT 0030S) acted as the primary antibody.
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4.4 Results
4.4.1 Quantifying the level of expression of cyclin D l in vivo in rat liver 
following mitogenic stimulation with T3 over time
Real Time PCR was used to quantify levels of cyclin Dl per unit 18S ribosomal RNA 
in all samples. There was an increase in the hepatic expression of cyclin D 1 at 14 hours 
after T3 was administered (Figure 30).
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Figure 30 Time course o f  expression o f  cyclin D l after Tj in male adult SD rats as 
measured by Real Time PCR and normalised to 18S copy number per reaction. Data is 
presented as the mean and range fo r  each time point (n -3). Vehicle only is indicated in 
red at 1 hour and at 3 hours.
At the early time point of 3 hours there was no significant increase in expression of 
cyclin D l after a mitogenic dose of T3 when compared to vehicle only treated animals.
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4.4.2 Quantifying the level of expression of cyclin D1 in vivo in rat liver 
following mitogenic stimulation with T3- a preliminary experiment 
looking at early time points
A further time course experiment was undertaken to examine more early time points 
between 0 and 14 hours post dose (Figure 31). This experiment included only one 
animal in each group (T3 or vehicle only) as a preliminary indication of change in cyclin 
D1 expression was sought prior to consideration of larger and more expensive animal 
experiments being undertaken between these time points.
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Figure 31 Cyclin D1 expression over time after a mitogenic dose o f  T3 in male adult SD 
rats measured by Real Time PCR and normalised to IRS copy number per reaction, n -  
1 at each time point and ‘normal’ represents an animal that received neither T? nor 
vehicle only.
There was no difference in expression of cyclin D1 between T 3 and vehicle only treated 
animals over the first ten hours. The expression in both groups rises over this time 
period. At 12 and 14 hours the expression was greater in the T3 treated animal compared 
to vehicle only but the vehicle only response is still greater than the response at time 0 .
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4.4.3 Quantifying the level of cyclin D1 protein expression in vivo in T3 
treated Rat Liver
An immunohistochemical technique was used to determine hepatic cyclin D1 protein 
expression in response to T 3 and the number of positive hepatocyte nuclei were counted 
per tissue section (Figure 32).
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Figure 32 Number o f  positive hepatocyte nuclei fa r  cyclin D1 over time after Tj in male 
SD rats. 2,000 hepatocyte nuclei were counted. Data points represent mean and range, 
n -3 .
There is an increase in the number of positively stained hepatocytes which is maximal 
at fourteen hours after stimulation with T3.
4.4.3.1 The immunohistochemical pattern for cyclin D1 observed in rat 
and human liver
Staining for cyclin D1 in human breast cancer tissue sections was used as a positive 
control (Figure 33). An example of a section of rat liver incubated without primary 
antibody is shown, and this acted as a negative control (Figure 34).
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Figure 33 Human breast carcinoma stained fo r  cyclin D1 x20 objective. The dark 
brown nuclear staining o f positive cancer cell nuclei can be seen. These tissue sections 
acted as a positive control fo r  cyclin D1 in the rodent immunohistochemical analysis.
Figure 34 Rat liver section x40 objective, stained without primary antibody acts as a 
negative control fo r  cyclin D l.
Further immunohistochemical examination o f rat and human liver sections revealed 
interesting patterns o f staining. Comparisons were made between quiescent rat liver, rat 
liver after partial hepatectomy at 24 hours and BS human liver placed in formalin on
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arrival in the laboratory. The sections of partial hepatectomy rat liver were donated by a 
colleague in the laboratory.
In quiescent rat liver there is marked staining of hepatocyte nuclei but with notable 
sparing around the central veins (Figure 35), and when a comparison is made with rat 
liver after partial hepatectomy at 24 hours the observed staining is more widespread and 
intense with many more non parenchymal cells staining positive (Figure 35), however 
the marked sparing around the central veins is still seen to occur.
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(a) rat liver quiescent x20 objective, x40 objective
(Note sparing around the central vein)
(b) rat liver after partial hepatectomy at 24 hours
x20 objective x40 objective
(Note sparing around the central vein)
Figure 35. Rat liver stained fo r  cyclin D l in (a) quiescent state and (b) after partial 
hepatectomy at 24 hours, where more NPCs are stained positive fo r  cyclin D l and the 
staining intensity appears to be increased generally across the tissue section.
In BS human liver, the staining for cyclin Dl is much less intense and not as widespread 
with only a few small groups of cells neighbouring one another staining positive 
(Figure 36).
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Figure 36. Human liver section (BS sample) x40 objective stained fo r  cyclin D l. A few  
hepatocytes stain positive but most are negative. Compare this to quiescent rat liver 
where there are many more hepatocytes stained and the staining is more intense.
4.4.4 The T3 Hepatic Proliferative Response in Bcl-3 Knock-out Mice
The result of administering a mitogenic T3 dose to Bcl-3 knock-out mice is detailed in 
Figure 37.
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Figure 37 BrdU positive hepatocyte nuclei per 5,000 hepatocyte nuclei in T3 treated 
wild type (WT) and Bcl-3 Knock out (KO) mice. V = vehicle only. Hep = hepatocyte.
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The p  value when comparing T3 treated wild type and 7j treated Bcl-3 knock-out mice 
does not reach statistical significance (p N/S).
The most striking result is that the hepatocyte proliferative response to T 3 in the Bcl-3 
knockout animals is no less than in the wild type mice suggesting that Bcl-3 is not a 
critical mediator of the T3 hepatocyte proliferative response seen in mice.
It is interesting to note that the overall hepatocyte proliferative response is less in mice 
at 24 hours (up to 0.1% hepatocytes positive for BrdU) post stimulus when compared to 
the rat model (approximately 5-7% BrdU positive hepatocyes at 24 hours after T3). This 
observation is consistent with the published literature where it is also noted that the cell 
cycle is of a longer duration in mice and the proliferative response to partial 
hepatectomy is also more latent (Fausto 2000).
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4.5 Discussion
Work by Pibiri (Pibiri et a l  2001) indicates the important role cyclin D l may have in 
mediating the effects of T3. The hepatic response to T 3 and partial hepatectomy (PH) 
was compared in their study. An increase in cyclin D l mRNA (using Northern blot 
analysis) occurred much more rapidly after T3 than after PH. The increase was evident 
as early as 2 hours after treatment and reached a maximum at 4 hours, however no 
change in cyclin D l mRNA was seen in rats which had undergone PH at this time. 
Western blot analysis showed that cyclin D l protein was increased at 4 hours after T3, 
elevated further at 12 hours and maintained for up to 24 hours. The increase in cyclin 
D l protein after hepatectomy was much delayed, being evident at only 12 hours. The 
changes described in cyclin D l at 4 hours were however not compared with a control 
group of animals at the same time point in the Western blot analysis in their study.
Pibiri then considered whether this T3 action may be common to the group of mitogens 
that act on nuclear receptors. Nafenopin, a peroxisome proliferator (a PPAR-alpha 
ligand member of the steroid/thyroid nuclear receptor superfamily) also caused a rapid 
increase in cyclin D l protein content evident 2  hours after treatment, thereby indicating 
this group of mitogens may act in a similar way. The activation of cyclin D l by T3 and 
nafenopin may, they hypothesise, be a direct action of thyroid hormone and nafenopin 
on the cyclin D l gene promoter. The hypothesis that cyclin D l is an absolutely 
necessary factor in mediating these mitogenic effects is disputed in follow up work 
(Ledda-Columbano et a l  2002). Loss of cyclin D l in knock out mice suggests it is not 
mandatory for development of most mouse tissues and during development other 
mechanisms compensate for its loss and this makes perfect evolutionary sense. 
Columbano used the powerful mitogen 1,4-bis [2-(3,5-dichloropyridyloxy)] benzene 
(TCPOBOP), a ligand of the constitutive androstane receptor, to see if lack of cyclin D l 
in knock out mice, had an effect on the hepatic proliferative response (Ledda- 
Columbano et al. 2003). Entry into S phase was delayed but there was no effect on 
proliferation. The study suggests that other cyclins such as cyclin E may take over the 
role of cyclin D l, but further work is yet to be done to confirm this hypothesis.
The research undertaken in this thesis demonstrated a rise in cyclin D l by 14 hours in 
rat liver at the mRNA level and at the protein level after a mitogenic dose of T3. The 
much earlier rise (maximal at 4 hours) evident in Pibiri’s work is not conclusively 
replicated here using the method of Real Time PCR analysis, as opposed to Northern 
blot analysis which was used in the Pibiri study. At the early time point of 3 hours there
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is no difference in cyclin D l expression between T 3 treated and vehicle only treated rat 
liver in this thesis.
However, when more of the early time points were examined, cyclin D l expression is 
seen to rise in T3 treated and vehicle only animals and this corresponds to the change in 
time of day when the animals were sacrificed. Indeed the trend in the extended time 
course experiment may reveal a change in cyclin D l expression due to diurnal variation 
in the rat liver transcriptome. This complicates the analysis as to whether what is being 
observed is due to the specific effects of T3 or due to a diurnal variation in expression
i.e. a circadian rhythm or a combination of these two. The initial time course experiment 
was carried out using a group of vehicle only treated animals at 1 hour. This time point 
of animal sacrifice corresponded with a time in the morning of 10:00 and the 14 hour 
time point corresponded with animal sacrifice at 2 2 : 0 0  when levels of cyclin D l are 
seen to rise again. Further possible evidence for a diurnal pattern of expression is the 
fall at the next time point of animal sacrifice of 18 hours which corresponds to 1 0 : 0 0  in 
the morning.
The question of a diurnal variation was partially addressed in the third time course 
experiment with a single animal at each time point paired with a control animal. 
Increased levels of cyclin D l expression corresponded with the evening at 22:00 and 
lower levels with the morning at 10:00. This experiment may support the existence of a 
diurnal variation in hepatic cyclin D l expression but clearly a further experiment needs 
to be undertaken which is powered with enough animals to answer this question 
definitively. Such an experiment was not done for the purposes of this research project 
given the considerable additional costs involved and it remains a future aim. The 
physiology of circadian rhythms is however briefly discussed next as it raises relevant 
issues regarding experimental design, important when examining the hepatic 
transcriptome under any experimental conditions.
4.5.1 Circadian rhythms
Circadian rhythms are endogenous rhythms of physiology and behaviour occurring in a 
majority of organisms (Desai et a l  2004). In mammals the central regulator of the cycle 
is the suprachiasmatic nucleus of the hypothalamus, affected by the light/dark cycle 
through the retinohypothalamic tract. At the molecular level, the clock functions as a 
result of interacting positive and negative transcriptional-translational feedback loops 
that govern the expression of specific clock control genes (Morgan et a l  2005). Some
133
peripheral tissues show tissue-specific rhythms regulated by many of the same clock 
control genes. Since some of these clock control genes encode transcription factors, the 
expression of a whole host of genes may be tied to the daily rhythm of the molecular 
clock (Akhtar et a l  2002).
Since tissue collection may occur throughout the day, understanding hepatic gene 
expression over time is critical (Boorman et a l  2005). Most work thus far has 
documented circadian effects on the mouse transcriptome and the rat has not been 
extensively studied.
Microarrays have been used to perform direct day/night 12h offset comparisons of rat 
hepatic transcripts and also compared transcripts of livers collected at different times of 
the day, notably comparing expression between 4 hours after lights on and 10 hours 
after lights on ( 6  hours apart) (Boorman et a l  2005). This study demonstrated the rat 
transcriptome exhibits significant circadian variation in expression and there was a 
marked difference in gene expression in livers collected 6  hours apart during the light 
period using quantitative reverse transcription PCR. Hepatic expression of many of the 
circadian genes rises during the day and the magnitude of variation of these was greater 
than those genes involved in metabolic pathways. There is no comment specifically on 
cyclin D l in this study but given a whole host of hepatic transcripts rise or fall over a 6  
hour period during the day, it is not inconceivable that cyclin D l may be subject to the 
same circadian variation in expression.
4.5.2 Patterns of cyclin D l staining in rat and human liver
Immunohistochemical analysis for cyclin D l of T3 treated rat liver over time was 
undertaken to see if at the protein level cyclin D l could be used as a marker of the 
effects of T3 in the in vitro conditions of the organ perfusion preparation of Chapter 
Three. At 14 hours post mitogenic stimulus a maximal response was observed as 
measured by hepatocyte staining for cyclin D l protein. This is too late a time for the 
purposes of an early marker of T3 effects in the liver perfusion experiments described in 
the previous chapter where changes within the first six hours are sought. Furthermore 
the marked basal staining in quiescent rat liver would make it difficult to detect small 
and subtle changes in cyclin D l protein expression. Beyond these limitations, the 
pattern and intensity of staining in rat and human BS liver samples raises further 
interesting questions given that a measurable hepatic response to T3 is ultimately sought 
in human liver.
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The differences in staining for cyclin D 1 between rat and human liver are borne out by 
some other but rather limited work in the literature. The expression of cyclin D l protein 
in regenerating human liver is of interest although little work exists in the literature on 
this. Some comparisons between species and also quiescent and regenerating human 
liver have been made (Albrecht et al. 1995). In this study there was no detectable cyclin 
D l in resting mouse liver, but significant basal protein expression in rat liver using 
Western blot analysis. There was some protein expression in resting human liver and 
certainly more than was seen in the quiescent mouse liver. Furthermore when samples 
of regenerating human liver were looked at, one year post transplant, there was a < 2  
fold increase in the expression of cyclin D l protein compared to normals. In the 8  to 21 
days after transplantation cyclin D l protein levels were 2  to 1 0  fold higher.
The results presented in this thesis demonstrated marked staining for cyclin D l in 
resting rat liver with much less in resected human liver samples and this observation 
supports the findings in the Albrecht study where Western blot analysis was used to 
measure cyclin D l protein expression.
4.5.2.1 Distribution of staining
4.5.2.1.1 Rat Liver
The distribution of staining for cyclin D 1 in quiescent rat liver, with notable sparing of 
cells around the central veins, poses several questions. In addition the staining following 
PH is markedly more intense and many more NPCs stain positive. This increase is 
consistent with the changes that will be taking place with regards to hepatocyte 
regeneration after hepatectomy. Partial hepatectomy provides the strongest stimulus to 
hepatic regeneration and the up-regulation of cyclin D l at 24 hours after surgery is 
expected and Pibiri confirmed that cyclin D l was increased by 12 hours and remained 
elevated at 24 hours following PH (Pibiri et a i  2001).
After partial hepatectomy, hepatocyte proliferation starts in the area of the lobules 
surrounding the portal triads and proceeds to the pericentral areas by 36 to 48 hours. 
The peak rat proliferative response is 24 hours in the hepatocytes but more latent in the 
mouse after PH. The other liver cell populations enter into DNA synthesis at 48 hours 
or even later, in the rat and enhanced expression of cyclin D l occurs before the onset of 
DNA synthesis. Increased cyclin D l expression in this situation is known to occur late 
in G1 (12 hours in rat liver). The increased staining demonstrated in this Chapter at 24
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hours after PH is consistent therefore with a persistent earlier rise in cyclin D l protein 
expression.
The pattern of staining in quiescent liver is intriguing and one possible yet controversial 
explanation for it is the ‘streaming liver hypothesis’.
After partial hepatectomy the majority of new hepatocytes are formed in the periportal 
region as shown by (3H) thymidine autoradiography (Grisham 1962). The ‘streaming 
liver hypothesis’ suggests that parenchymal cells located in the periportal region give 
rise to daughter cells that stream slowly toward the central vein (Zajicek et al. 1985). It 
proposes that new hepatocytes are constantly produced at the outer rim of the portal 
space and these cells move along the sinusoid toward the central vein where they are 
eventually eliminated. The hepatocytes mature as they get older and as a consequence 
they may display different enzymatic patterns and replicative potential.
The staining pattern for cyclin D l may provide some support for this hypothesis, in that 
there is less staining for cyclin D l within the hepatocytes located around the central 
veins. Since cyclin D l is associated with progression in the cell cycle and subsequent 
DNA synthesis and cell replication, its absence may support the idea that these cells are 
no longer dividing or able to do so. However on-going controversy surrounds cell 
renewal in the adult liver and more recent work refutes the streaming liver model. 
Magami et al used 3H-thymidine incorporation to study hepatic cell kinetics in the adult 
mouse (Magami et al. 2002). They found that hepatocytes are supplied by postnatal 
replication and that streaming of hepatocytes from periportal to pericentral regions did 
not occur.
A more plausible approach to understanding this differential gradient for cyclin D l 
staining would be to consider the known heterogeneity that exists amongst hepatocytes 
across the zones of the hepatic lobule and there is considerable published work 
describing this (Jungermann and Katz 1982; Jungermann et al. 1982; Jungermann and 
Katz 1989). The sophisticated techniques of microchemistry and microdissection and 
separation of periportal and perivenous hepatocytes were used in these studies. The 
periportal and perivenous hepatocytes have different metabolic capacities and each 
cell’s metabolism and physiology may change as one moves from the periportal zone to 
the pericentral zone, and some of these changes may be controlled by different signal 
inputs. During passage through the liver the concentrations of hormones will change 
according to how they are metabolised or synthesised. The ratio of humoral signals 
changes from the periportal to the perivenous zone and therefore the net effect in any 
one area across the hepatic lobule will change. Similarly neural inputs are not equally
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distributed across the hepatocytes. Many other factors should be taken into 
consideration such as individual receptor densities on hepatocytes which also may 
change across the zones. All in all these factors may combine to explain why there is a 
gradient of expression of cyclin D l across the lobule consistent with the different 
metabolic capacities of the hepatocytes as one moves from pericentral to perivenous 
areas.
4.5.2 .1 .2  Human Liver
In the quiescent human liver there is some staining for cyclin D 1 although it is variable 
and much less intense and very few cells stain positive. Cyclin D 1 protein may therefore 
be a useful marker of T3 effects in in vitro human liver perfusions but its rise is most 
likely too latent for the human liver perfusions described in Chapter Three where once 
again a much earlier marker of the proliferative response is needed given the inability at 
present to maintain the liver tissue in a reasonable histological condition beyond six 
hours.
4.5.3 Bcl-3
The hepatocyte proliferative response to T 3 is notably much less in mice than rats, with 
approximately 4 hepatocyte nuclei per 5000 positive for BrdU in the mouse and 350 per 
5000 (up to 7%) positive at 24 hours in the rat (see Chapter Three). This highlights the 
already known to exist species differences in the duration of the cell cycle 
(Michalopoulos 2007). The peak hepatocyte proliferative response after two thirds PH 
in the rat is 24 hours and in the mouse model it is 36 hours. The time course and 
magnitude of the proliferative response to T3 is not known in mice but others have 
described the response to a single dose of the more powerful hepatomitogen TCPOBOP 
(Ledda-Columbano et al. 2004a). In that study there were a significant number of 
hepatocytes positive for BrdU by 24 hours with a peak response at 30 hours. It was 
thought reasonable in this thesis to compare identical time points between rats and mice 
given that there is a measurable response in mice by 24 hours after T3, however the 
magnitude of this response is less than in rats. Given the small numbers of hepatocytes 
which are undergoing DNA synthesis at 24 hours in the mouse model, it would be an 
important future aim to undertake a full time course experiment in the future to ascertain 
the exact peak proliferative hepatocyte response in the mouse model after T3 
stimulation. For the purposes of this thesis this experiment has not yet been done as all
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other in vivo work was consolidated and reliably replicated in the rat model. Despite the 
notable differences in response between species, the data presented here clearly shows 
that the response to T3 in the Bcl-3 knock out mice was no less than that in the wild type 
age matched control animals.
In conclusion this chapter investigated cyclin D l and Bcl-3 as mediators of the T 3 
hepatocyte proliferative response. The peak of expression of cyclin D l mRNA and 
protein was found to be at 14 hours which is a later time point than others have 
demonstrated in the published literature. A further preliminary experiment highlighted 
the complexities in interpreting these data as the variation in expression may be affected 
by a diurnal variation in the hepatic transcriptome. Cyclin D l protein was expressed 
abundantly in hepatocytes in quiescent rat liver at the immunohistochemistry level. For 
these reasons it could not be used as an early marker of the T3 proliferative response in 
the organ perfusion experiments described in Chapter 3. In the second part of the 
analysis Bcl-3 was found not to be a critical mediator of the mitogenic T3 effect using a 
murine knock out model for the Bcl-3.
Given these results it is logical to apply a more generic approach and this is the strategy 
pursued in the next chapter where gene array studies are used for the first time to 
identify novel plausible mediators of the hepatic T 3 response in the rat.
Chapter 5 Affymetrix Whole Rat Genome 
Expression Array
5.1 Background
The hepatic rat expression profile after in vivo administration of T 3 is examined in this 
chapter to identify expression changes in potential novel candidate genes which may act 
as early markers of the T 3 mitogenic signal in the organ perfusion experiments outlined 
in Chapter 3. Cyclin D l was not used to this end as its rise at 14 hours after T3 
demonstrated in the previous chapter is too late a time point to prove useful in the organ 
perfusion experiments.
The use of an expression gene chip array is a powerful means by which one can 
interrogate rodent liver tissue that has been stimulated with T3 and this Chapter 
describes novel work examining the euthyroid rat hepatic expression profile within 
three hours of T3 stimulation using expression array gene chip technology.
5.1.1 Micro-arrays
The principles of microarray technology were conceived over 20 years ago based on 
developments made from Southern blotting, but it was not to be for at least another 
decade that high quality slides and precision robotics made them into more of a 
commercial success (Jaluria et al. 2007; Brown and Botstein 1999). In recent years 
there has been a huge surge in the amount of papers published in the scientific literature 
based on data generated from microarray experiments.
A DNA microarray is a collection of microscopic DNA spots attached to a solid surface. 
These so called 'chips’ are fabricated by high speed robotics on glass or nylon 
substances. The array therefore provides an orderly arrangement of samples against 
which the experimental sample of cDNA can be hybridised according to base pair rules. 
The attached oligonucleotides are hybridised with cDNA from 2 different experimental 
conditions for example normal vs. diseased state where the 2  different samples are 
labelled with 2 different fluorophores. After appropriate incubation and hybridisation 
the chip can be scanned so a comparison of expression across thousands of genes 
between the 2 experimental samples can be made in just one go. Gene microarray
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systems differ in terms of material used- short oligonucleotides, long oligonucleotides 
or cDNA. Oligonucleotide arrays typically are used for genome-wide (tens of thousands 
of genes) screening and cDNA arrays for the investigation of smaller sets of genes.
The use of microarrays for gene expression profiling was first published in 1995 in 
Science (Schena et al. 1995) and the first complete eukaryotic gene on an array was 
published in 1997. The applications of array technology in modem biology are large 
and growing and they have provided a powerful tool in areas of gene discovery, disease 
diagnosis, pharmacogenomics and toxicogenomics. Six of the most popular 
commercially available platforms include Codelink, Affymetrix, Agilent, NimbleGen, 
Febit and Applied Biosystems. For the purposes of this PhD project, an Affymetrix 
expression array has been used to determine the rodent hepatic expression profile after 
in vivo stimulation with T3.
A typical gene expression array experiment involves (Figure 38):
1. RNA isolation from the samples to be compared
2. Converting the RNA samples to labelled cDNA via reverse transcription
3. Hybridising the labelled cDNA to a glass side array
4. Remove the unhybridised cDNA
5. Detecting and quantitating the hybridised cDNA
6 . Comparing the quantitative data from the various samples.
Affymetrix's GeneChips are glass slide arrays manufactured using special 
photolithographic methods and combinatorial chemistry, which allow the 
oligonucleotide spots to be synthesised directly onto the array substrate. The analysis 
procedure specifies that the RNA samples are converted to biotin-labelled cDNA, and 
each sample is hybridized to a separate GeneChip. The hybridized cDNA is then stained 
with a streptavidin-phycoerythrin conjugate and visualized with an array scanner.
A single array experiment can generate thousands of data points and so the challenge 
lies now in accurate interpretation of this data and to this end there are many 
commercially available software packages to aid the investigator in making sense of 
their data.
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Figure 38 Schematic outline o f  sample preparation for an array experiment. Here the 
example compares gene expression differences between cancer cells and normal cells. 
cDNA from  the cancer cells is labelled red and that from  normal cells is labelled green 
prior to chip hybridisation.
Any discussion about microarrays must touch on the limitations and complexities 
inherently present. Both dual channel (these are hybridised with 2 different samples) 
and single channel arrays exist. The former generates relative expression values while 
the latter generates absolute expression values because only one sample has been 
hybridised.
Once a scanned image has been obtained there can be an initial visual inspection o f the 
data prior to normalisation. An example o f what is seen on the hybridised chip and the 
subsequent steps in analysis is shown in
Figure 39. Normalisation accounts for labelling efficiencies and detection levels for the 
fluorescent dyes as well as differences in the quantity/quality of RNA samples. In this
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way it acts as the first level o f filtering applied to the data. A num ber o f institutions 
provide free software to enable this analysis to be performed.
Figure 39 An actual gene array chip (top) and the basic steps o f  raw data analysis 
(bottom). Two differently labelled probes, green and red, have been applied to this chip. 
Red spots indicate greater binding o f  the red labelled probe and green o f  the green 
labelled probe. Yellow spots indicate equal binding and black spots reflect no signal 
because o f  no hybridisation (Verducci et al. 2006).
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Microarrays are imaged using an optical scanner and then these must be subjected to 
background correction to adjust for non specific binding and fluorescence from any 
other chemicals on the slide. The array contains multiple probes for each gene and these 
are scattered over the surface of the array and so variations in intensity from probe to 
probe for the same sample need to be resolved. Observed intensities are modified based 
on comparison with nearby background probes whose level of expression is known. On 
the Affymetrix array, each gene probe has a single nucleotide mismatch probe mate and 
the MAS 5.0 (Microarray Suite) of Affymetrix uses paired probes for adjustment and 
there is also the RMA or robust multichip average which uses quantile adjustment. The 
GC RMA method pools probes with comparable numbers of G-C bonds to achieve a 
stable mismatch adjustment.
After normalisation has taken place both within an array and between arrays, statistical 
techniques are used to evaluate and decipher the array data. The aims of these are to 
identify clusters of genes that are up or down regulated following the experimental 
stimulus. Thus normalisation forms part of the low level analysis and the high level 
analysis involves gene filtering then gene clustering before final gene annotation 
analysis.
5.1.1.1 Differential Expression
Fold change is used to compare differences in the level o f expression between the two 
experimental samples. The disadvantage is it does not take into consideration the 
variability in the data. So, genes with low expression values yet large fold changes may 
be identified as differentially expressed but genes that display small but reproducible 
changes in expression may be missed. Since tens of thousands o f genes are compared, 
many genes can be false positives. The False Discovery Rate or FDR has been proposed 
to handle the multiple comparison issues in the context of microarray data and the FDR 
is the expected proportion of false positives among all the rejected hypotheses. The 
FDR instead of trying to avoid any false positives controls the proportion of positive 
calls that are false positives. Put another way, the FDR is the ratio o f the typical number 
(over all permutations) of transcripts ‘discovered’ at random (false discoveries) versus 
the number detected in the experiment.
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5.1.1.2 Clustering Genes
Clustering is a data m ining technique used to group genes which have similar 
expression patterns. A heat map represents a com m on approach to present expression 
data. Genes index the rows and chips the columns. The variation in colour across the 
row reflects the expression pattern o f the gene. An exam ple from the 1 hour array in this 
thesis is shown in Figure 40.
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Figure 40 An example o f  higher level data analysis. Part o f  the dChip cluster 
hierarchical map fo r  the 1 hour array in this thesis. The three chips on the left are 
labelled S fo r  submitogenic and the three on the right are labelled M fo r  mitogenic. Red 
indicates greater expression in the submitogenic group fo r  each gene o f  interest shown 
here. EST = expressed sequence tags.
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5.1.1.3 A nnotation and functional characterisation
The final stage of higher level analysis is gene annotation. The current most relevant 
source of information for relating newly acquired gene expression level data to known 
functional and partial pathway information is the Gene Ontology GO database 
www.geneontology.org. It is a collaborative effort to address the need for a consistent 
description of gene products in different databases. Its three organising principles are 
molecular function, biological process and cellular component. Various tools such as 
GoMiner, Onto-Express and Go Term Finder allow the investigator to upload a full 
gene set and then view which GO categories have been enriched for the genes of 
interest.
5.1.2 T3and Microarrays
Previous reports of changes in liver gene expression in vivo after T3 administration are 
available and investigated the change from hypothyroid to hyperthyroid status and/or 
looked at later time points (> 6  hours) after stimulation.
Feng (Feng et al. 2000) compared hepatic expression profiles from T3 treated 
hypothyroid mice and hypothyroid mice using a quantitative fluorescent cDNA 
microarray. The array in this study composed of only 2,225 different mouse genes 
which represent approximately 10% of expressed hepatic genes. The comparison 
between the two groups was at 6  hours after mitogenic stimulation. 55 genes were found 
to be T3 responsive, of these 14 were positively regulated and 41 negatively. Bcl-3 (fold 
change + 2.5) was upregulated and further investigated in Chapter Four of this thesis 
using a murine knock-out model. The mRNA of another protein involved in cell 
proliferation, kinesin-like protein, was notably up-regulated with a fold change of + 2 .0 . 
In another study Flores-Morales (Flores-Morales et al. 2002) compared hepatic 
expression profiles of around 4,000 genes from wild type hypothyroid and wild type T3 
treated hypothyroid mice. A further comparison was between T3 treated hypothyroid 
TRp deficient mice and hypothyroid TRp deficient mice. The time points examined 
were at 2  hours after mitogenic stimulation and at 5 days. T 3 was found to regulate more 
than 200 genes and of these 60% were dependent on the TRp gene for T 3 regulation. 
The study showed a clear functional distinction between rapid ( 2  hours) and late T3 
effects in the mouse liver.
Weitzel (Weitzel et a l  2003) looked at hepatic expression in hypothyroid and T3 treated 
hypothyroid rats using a DNA microarray. The time points of 6 , 24 and 48 hours after 
T3 administration were examined. 62 of 4,608 genes displayed a reproducible T3
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response. Representative examples of differentially regulated genes from each of six 
different gene profile clusters were further characterised by either Northern blot analysis 
or quantitative real time PCR. The study identified several genes already known to be 
T3 responsive and involved in metabolic pathways: ANT2, myelin basic protein and 
ATP synthase p subunit. However the majority of differentially regulated genes were 
not primarily involved in metabolic functions, instead they encompassed translation, 
protein turnover, apoptosis and cell structure pathways.
Yen (Yen et a l  2003) studied the effects of ligand and thyroid receptor isoforms on 
hepatic gene expression profiles o f thyroid receptor knockout mice. 48 complimentary 
DNA microarrays were used to examine hepatic gene expression profiles in wild type 
and TRa and TRp knockout mice under different conditions: no treatment, treatment 
with T3, propylthiouracil (PTU) induced hypothyroidism and treatment with a 
combination with PTU and T 3. Hierarchical clustering analyses showed that the 57 
positively regulated genes fit into three main expression patterns: i) a pattern of basal 
repression during thyroid hormone deprivation and transcriptional activation after acute 
treatment with T3 (includes Bcl-3 in cluster 2) ii) little or no basal repression during 
thyroid hormone deprivation but strong transcriptional activation after T3 treatment, iii) 
basal repression in the absence of thyroid hormone with little activation after acute T3 
administration.
Stahlberg (Stahlberg et a l  2005) compared hepatic gene expression in hypothyroid 
mice and T3 treated hypothyroid mice 2 hours after a 5pg dose of T3. Malic enzyme I 
was up-regulated with a fold change of + 7.86 and cytochrome P450 4A3 was up- 
regulated with a fold change of +9.77.
Finally Moeller (Moeller et a l  2005) examined the effect o f T3 on the expression of 
more than 15, 0 0 0  genes in cultured human fibroblasts from normal individuals and 
individuals with resistance to thyroid hormone (RTH) to confirm the specificity of the 
hormonal effect. Incubation of cells for microarray analysis was for 24 hours. 148 genes 
were induced with a fold change of 1.4 or more. These represented 91 up-regulated and 
five down regulated genes. A number of genes not previously known to be induced by 
thyroid hormone were indentified in this study and include member RAS oncogene 
family brain antigen RAB3B and platelet phosphofructokinase.
As yet therefore the response after T3 in euthyroid rat liver at early time points has not 
been described in the worldwide literature and this strategy is usefully pursued in this 
Chapter.
146
5.2 Aims
To determine the in vivo rat hepatic expression profile after stimulation with
i) mitogenic dose T3 versus vehicle only at 3 hours post dose.
ii) mitogenic dose T3 versus sub-mitogenic dose T3 at 1 hour post dose.
The first array experiment compared the response between T 3 and vehicle only at an 
early time point of 3 hours post stimulation. The results demonstrated a number of cell 
cycle genes and prominently a number of transcription factors (Kruppel Factors) which 
were up-regulated. A further targeted analysis was performed of their expression time 
course profile (outlined in Chapter Six) which indicated that 60 minutes post T3 was of 
interest and therefore a second array experiment was performed at 60 minutes but now 
comparing a mitogenic with a sub-mitogenic doses of T3. The sub-mitogenic dose does 
not bring about cell proliferation but does reflect the more general T 3 effects on 
metabolism. Any differences therefore between these two stimuli would highlight 
changes in genes specific to the T3 mitogenic effect. The calculation of the sub­
mitogenic dose is described in the Methods section of this chapter.
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5.3 Materials and Methods
5.3.1 Animal Protocols
Please refer to General Methods Chapter 2.
Protocol one: Adult male SD rats, were administered a subcutaneous dose of 5pg T3, or 
vehicle only (n = 3), and sacrificed at 3 hours post dose for hepatic microarray analysis.
Protocol two: Adult male SD rats, were administered a subcutaneous dose of 5pg T3, or 
a sub-mitogenic dose o f 0.1 pg per animal (n=3), and sacrificed at 1 hour post dose for 
hepatic microarray analysis.
Liver was harvested and sectioned and pieces were snap frozen in liquid nitrogen and 
stored at -80°C for later analysis and RNA isolation.
The threshold at which the mitogenic effects of T 3 are apparent was established (2pg 
per animal) in Chapter Three. The proliferative effect o f T3 was only manifest at doses 
greater than 2pg per animal, with the peak at 5pg T 3 per whole rat. A comparison was 
therefore made between the 5pg mitogenic dose and a sub-mitogenic, although supra- 
physiological dose of 0 . 1  pg per animal, to allow changes in gene expression specific to 
the mitogenic effect to be observed. A t this lower T 3 dose, it is anticipated that the more 
general effects on metabolism will still occur, therefore if changes in expression are 
found these may be specifically due to the mitogenic effects of T3 on the liver.
5.3.2 RNA preparation
Please refer to General Methods Chapter 2.
Materials:
Promega RNAgents® Total RNA Isolation System (# Z 5 110)
RNAgents® Denaturing solution (Promega #Z5651)
2M Sodium acetate pH 4.0
Phenol:chloroform:isoamyl alcohol 125:24:1 (Sigma #P1944)
Ice cold 75% ethanol 
RNase free water 
1 .5ml centrifuge tubes
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Method:
500pl denaturing solution for 50mg liver tissue was chilled. The liver sample was 
disrupted using a pestel and mortar in liquid nitrogen and on ice. It was then added to a 
1.5ml centrifuge tube with the denaturing solution. 60 pi 2M sodium acetate was added 
and mixed. 600 pi phenol:chloroform:amyl alcohol was added and the tube was inverted 
3 to 5 times. It was chilled on ice for 15 minutes and then centrifuged at 10,000g at 4°C 
for 20 minutes. The top aqueous phase was transferred to a fresh DEPC treated tube.
An equal volume of the isopropanol was added and then incubated at -20°C for 5 
minutes. An RNA pellet was created by centrifugation at 10,000g for 10 minutes at 4°C. 
The pellet was then washed by adding at least 1ml of ice cold 75% ethanol. The pellet 
was broken up with a sterile pipette tip and then a further spin was undertaken at 
10,000g for 10 minutes at 4°C. The pellet was dried in a vacuum desiccator for 10 
minutes. The RNA was then dissolved in RNase free water and stored at -80°C.
5.3.2.1 RNA C leanup
Materials:
Qiagen RNeasy Mini kit (Qiagen, UK Cat. No. 74104)
Components of Buffer RLT, RW1 and RPE:
RLT- contains a guanidine thiocynate 
RWL-contains guanidium thiocynate and ethanol 
DNase I (Pharmacia)
10X DNase buffer
1M Tris pH 7.5 
1M M gCl2 
1M DTT
Recombinant RNasin Ribonuclease Inhibitor (Promega) 
p-Mercaptoethanol 14.3M (Sigma Aldrich)
Method:
RNA samples were subjected to DNase digestion to prevent any carry over of 
contaminating DNA. 72.5jil of sample containing l-2pg/p l of RNA, nuclease free 
water, IX DNase buffer, 2 units of DNase, 100 units of recombinant RNasin
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Ribonuclease Inhibitor, was mixed gently with a pipette, and incubated at 37°C for 30 
minutes. The samples were placed on ice, prior to loading onto spin columns supplied 
with the Qiagen RNeasy Mini kit as per General Methods Chapter 2.
The total RNA in solution was quantitated and analysed for purity by measuring its 
optical density at 260nm and 280nm. RNA was aliquotted and stored at -80°C .
5.3.2.2 RNA Integrity/Y ield
Assessed as described in General Methods Chapter 2. RNA gel electrophoresis for the 
samples obtained is shown in Figure 41 and Figure 42.
Figure 41 Denaturing RNA gel electrophoresis fo r  the 3 hour array RNA samples. The 
RNA is intact in all the samples as shown by the sharp 28S (top) and 18S (bottom) 
bands and the 2:1 ratio of28S:18S.
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Figure 42 Denaturing RNA gel electrophoresis fo r  the 1 hour array RNA samples. The 
RNA is intact in all the samples as shown by the sharp 28S (top) and 18S (bottom) 
bands and the 2:1 ratio of28S:18S.
An absorbance A26o/A28o ratio of above 1.8 was obtained for all the samples.
5.3.3 Microarray analysis
Array analysis was performed with Dr. M. Hubank at the Institute for Child Health 
Gene Microarray Centre, University College London. Double stranded cDNA was 
synthesised from 5pg total RNA, labelled with biotin by an in vitro transcription 
reaction (IVT), and hybridised to Affymetrix Rat Genome arrays, RAE230v2 
(Affymetrix, Santa Clara, CA) following standard procedures (www.affymetrix.com). 
The chip provides data on more than 30,200 transcripts including over 28,000 well 
substantiated rat genes. The chip is comprised of more than 31,000 probe sets and 
681,012 distinct oligonucleotide features. Quality of hybridisation was determined using 
Affymetrix.rpt files (background < 100). Probe level values (.CEL files) were obtained 
using Affymetrix GCOS. Two separate microarray experiments were conducted using a 
total of 1 2  genechips.
5.3.3.1 Data Analysis
Probe set summary values were generated from CEL files using dChip (C. Li 2001) 
software (www.dchip.org). Groups were compared by unpaired Welch t-test, p < 0.05.
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Empirical False Discovery Rate was estimated by permutation analysis. Data was 
filtered to remove genes with lower than 1.3 fold change. The final gene list fulfilling 
these statistical criteria can then be further interrogated using a number of freely 
available data mining tools. The ones used in this thesis are described next.
The genes with significant fold changes were functionally categorised using NetAffx™ 
(Affymetrix) www.affvmetrix.com, KEGG and GenMapp www.genmapp.org. The 
NetAffx™ free online analysis centre enables correlation of results with annotation 
information which is constantly updated providing the very latest information for probe 
set IDs and much Gene Ontology information.
KEGG (www.genome.ip/kegg) is the Kyoto Encyclopaedia of Genes and Genomes. It is 
a bioinformatics resource from the Kanehisa Laboratories in the Bioinformatics Centre 
of Kyoto University and the Human Genome Centre of the University of Tokyo. The 
KEGG gene catalogue contains 2 million genes from 32 eukaryotes and 420 bacteria so 
far.
The Gene Annotator and Pathway finder (GenMAPP) has been developed at the 
Gladstone Institutes, University o f California at San Francisco. The user chooses any 
map that may be of interest to them, for example cell cycle control. The expression 
dataset in the correct file format is then imported into the program and the data is 
displayed on the map with nominated colour changes reflecting up or down regulated 
genes. There are additional hyperlinks to more online information for each gene that 
may be of interest to the investigator.
In compliance with M IAME standards, Affymetrix data files (CHP and CEL) have been 
deposited in the ArrayExpress database at the European Bioinformatics Institute (EBI) 
http://www.ebi. ac. uk/arravexpre ss/. M IAME (Minimum Information About a 
Microarray Experiment) describes the minimum information that is needed to enable the 
interpretation of the results of the experiment unambiguously and potentially to 
reproduce the experiment.
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5.4 Results
5.4.1 T3 treated rat liver versus vehicle only rat liver at 3 hours
2,259 transcripts exhibited a change in expression of Fold Change (FC) greater than 
+1.3 or less than -1.3 (< > ± 1.3) with p value <0.05. 1,554 regulated transcripts 
corresponded to identified genes, of which 1,111 were negatively regulated and 443 
positively regulated. Regulated genes related to growth and transcription and general 
metabolic and signal transduction pathways are shown in Table 7. Genes with more 
marked changes (>  2  fold ) with p values < 0 . 1 0  are also included.
5.4.2 Mitogenic T3 treated rat liver versus Sub-mitogenic T3 rat liver at 
1 hour
As expected there were significantly fewer differences between the array data between 
the two groups.
230 transcripts exhibited a change in expression of FC < > ± 1.3 with p value < 0.05. 
160 regulated transcripts corresponded to identified genes, of which 65 were negatively 
regulated and 95 positively regulated. They are grouped as before and displayed in 
functionally related categories in Table 8 .
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Table 7 Functionally related hepatic genes up- and down regulated on the Affymetrix 
RAE230v2 expression array, 3 hours after T3 stimulation (negatively regulated genes in 
italics).
Probe ID D escription Fold
Change
P  value
M ETA B O LIC  EFFE C T S/SIG N A L  
TRANSDUCTION
Thyroid
1387852_at Thyroid hormone responsive protein 1.52 0.028
1367726_at Thyroid hormone receptor alpha -1.59 0.015
1387983_at Thyroid receptor beta -1.61 0.0134
1369744_at Thyroglobulin -2.37 0.06
1371010_at Thyroid transcription factor -2.44 0.06
Gluconeogenesis
1372264_at Phosphoenolpyruvate carboxykinase 1 1.74 0.013
Glycolysis/gluconeogenesis
1380045_at Pyruvate dehydrogenase phosphatase isoenzyme 
2
5.8 0.0003
1370725_a_at Glucose 6 phosphatase 2.14 0.007
1369510_at Glyceraldehyde 3 phosphate dehydrogenase 
(glycolysis)
-1.94 0.009
1369006_at Hexokinase 2 -2.28 0.029
Glycogen m etabolism
1369357_at Phosphorylase kinase alpha 1 -1.4 0.0068
1381756_at Alcohol dehydrogenase 6A class V -13.36 0.014
K rebs cycle
1381671_at Succinate coenzyme A ligase 3.82 0.02
136791 l_at Isocitrate dehydrogenase 3 1.75 0.004
1372790_at Malate dehydrogenase 1.49 0.041
1375290_at Citrate synthase -7.74 0.038
F atty  acid /  lipid m etabolism
1388373_at Adiponectin receptor 1 1.36 0.002
1375033_at Carnitine palmitoyltransferase l c -1.69 0.047
1387065_at Phospholipase c delta 4 -25.17 0.018
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F a tty  acid  d eg rada tion
1369666_at Glycerol 3 phosphate dehydrogenase 2 2.44 0.034
1394763_at Hydroxyacyl-coenzyme A dehydrogenase -1.7 0.038
F atty  acid  synthesis
1369328_at Acetyl-coenzyme A carboxylase beta -1.63 0.01
Insulin  action  & signalling
1370114_a_at Phosphoinositide 3-kinase polypeptide 1 
(p85alpha)
2.54 0.037
1387847_at Phosphatidylinositol 3-kinase catalytic subunit 
beta isoform
1.79 0.037
1369655_at Phosphatidylinositol 3-kinase class 3 1.35 0.045
1368019_at mTOR (FK506 binding protein 12) 1.34 0.026
1369050_at Phosphatidylinositol 3-kinase C2 1.31 0.04
1386888_at 4EBP1 -1.35 0.048
1368056_at TSC2 -1.37 0.044
1369357_at Phospkorylase kinase alpha 1 -1.4 0.007
1370605_a_at Leptin receptor -2.06 0.047
Signal tran sd u c tio n
1368958_at Protein kinase C and casein kinase substrate in 
neurons 1
10.09 0.053
1387708_at Adrenergic receptor alpha 2a 4.99 0.031
1370114_a_at Phosphatidylinositol 3-kinase regulatory subunit 2.54 0.037
1379207_at JNK/SAPK inhibitory kinase 2.37 0.04
1388066_a_at G protein receptor kinase 6 2.36 0.025
1368700_at Phospholipase C-likel 1.82 0.017
1388066_a_at Mitogen activated protein kinase 6 1.67 0.036
1387907_at Inositol 145-triphosphate receptor 1.43 0.01
1376039_at Serine/threonine kinase 6 -1.3 0.044
1370585_at Protein kinase C beta 1 -1.33 0.012
1371158_at Eph receptor A8 -1.64 0.037
1369741 _at Potassium inwardly rectifying channel subfam. j -1.72 0.012
1378997_at Eph receptor B6 predicted -2.27 0.036
1371219_a_at Phosphodiesterase 1C -5.37 0.02
1387065_at Phospholipase C delta 4 -25.17 0.012
P ro te in  dephosphory la tion
1380045_at Pyruvate dehydrogenase phosphatase isoenzyme 
2
5.8 0.00031
137919 l_x_at Protein tyrosine phosphatase receptor type R 1.93 0.045
G  p ro te in  coupled  recep to r
1368638_at 147 -1.63 0.041
1368796_at 54 -1.67 0.045
1368299_at S3 -2.28 0.03
1387182_at 37 -2.41 0.012
Bile acid  b iosynthesis
1368458_at Cytochrome p450 family 7 subfamily a 3.81 0.005
C ellu lar im m unity
1369529_at CSF3 -2.82 0.043
1371227_at CSF2 -8.32 0.018
C ytoskeleton
1378197_at Kinesin fam ily member C2 -1.36 0.037
1384885_at Tektin 2 -1.49 0.022
1377799_at Microtubule associated protein 6 -1.5 0.016
C ation  T ra n sp o rt
1368746_a_at ATPase H+/K+ transporting non-gastric alpha 
polypeptide
3.48 0.029
1369222„at Potassium channel subunit -4.08 0.024
H S P /pro tein  fo ld ing
1370018_at Heat shock 27kDa 2 2.32 0.023
1397502_at Peptidylprolyl isomerase B 1.97 0.049
Cell adhesion
1383783_at Protocadherin 9 (predicted) 5.88 0.04
1368320_at Neural cell adhesion molecule 1 4.17 0.02
1373487_at Spondin 1 -1.51 0.03
136838 l_at Cartilage acidic protein 1 -4.19 0.006
G R O W T H /T R A N S C R IP T IO N
K ru p p el F ac to rs
1368877_at Zinc finger 354A 7.64 0.079
1381395_at KF 15 1.66 0.019
1384432_at Zinc finger protein 96 1.57 0.016
1370209_at KF 9 / BTEB 1 1.36 0.047
1368067_at Zinc finger 148 1.35 0.0328
1368228_at Zinc finger 265 1.3 0.044
1380363_at Kruppel like factor 7 -1.46 0.016
1379880_at Kruppel like factor 3 -1.86 0.037
1375013_at Zinc finger protein 335 -2.29 0.041
T ran scrip tio n  factors
1372639_at Ring finger protein 30 2.95 0.009
1393278_at cAMP responsive element binding protein 3 2.13 0.024
1369853_at Transcriptional regulator relax -5.44 0.026
1382637_at E74 like factor 2 -6.59 0.043
A poptosis
1372016_at GADD 45 beta predicted 2.74 0.029
1369995_at Fas associated factor I -1.5 0.02
1370625_at FAS apoptotic inhibitory molecule 2 -1.64 0.044
1369198_at Apoptotic protease activating factor 1 -1.79 0.005
1370787„at Bcl-2 like 11 apoptosis facilitator -1.84 0.024
Cell cycle/proliferation
1397I26_at Minichromosome maintenance deficient domain 2.7 0.046
1367725_at PIM-3 2.34 0.045
1371150_at Cyclin D1 2.14 0.1
1386299_at Cullin 5 1.80 0.014
1399100_at Cyclin T2 1.63 0.016
1390343_at Cyclin C 1.48 0.013
1382664_at Cell division cycle 27 homolog 1.33 0.021
1367780_at Pituitary tumour transforming protein 1 -1.32 0.044
1375996_at Septin 1 -1.43 0.045
1370233_at Fibroblast growth factor 12 -1.53 0.028
1370788_at Fibroblast growth factor 4 -1.55 0.035
1370116_at Septin 3 -1.6 0.04
1382370_at Cyclin F -1.69 0.003
1377702_at Retinoblastoma 1 -1.7 0.017
1370294-a_at Cell division cycle 20 homolog -1.85 0.01
1369884_at Fibroblast growth factor 7 -1.86 0.043
1369608_at Fibroblast growth factor 16 -1.9 0.02
1387647_at Trefoil factor 1 (neg. reg. o fp ro lif) -2.2 0.023
1370042_at Stathmin-like 2 -3.73 0.048
1368388_at v-m af muscuhaponeurotic fibrosarcoma avian -4.14 0.042
RAS oncogene
1383089_at RAB21 1.56 0.04
1397839_at RAB15 -1.49 0.04
1368847„at RAB10 -1.52 0.02
N uclear receptors
1386935_at Nuclear receptor subfamily 4 group A member 1 -1.65 0.03
1369007_at Orphan nuclear receptor -1.65 0.03
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Table 8  Functionally related hepatic genes up- and down- regulated on the Affymetrix 
RAE230v2 expression array, 1 hour after mitogenic vs. sub-mitogenic T3 stimulation 
(negatively regulated genes in italics).
Probe ID Description Fold
Change
P value
M E T A B O L IC  E FFE C T S/SIG N A L  
T R A N SD U C TIO N
Insulin  signalling
137601 l_at MAPK 13 2.44 0.09
M A PK  signalling
1369255_at Interleukin 1 receptor type 1 1.77 0.03
1368592„at Interleukin 1 alpha 1.47 0.015
L ipid  m etabolism
1370387_at Cytochrome p450 subfamily 3 -2.12 0.01
1377407_at Aa2-174 -6.04 0.003
Proteolysis
1390018_at Dipeptidylpeptidase 10 2.11 0.048
1387819_at Pancreatic elastase 1 -2.61 0.00078
Ion tra n sp o rt
1375877_at Synaptotagmin 4 5.33 0.07
1388263_at Potassium voltage gated channel shaker related 
subfamily
-1.77 0.02
Cytoskeleton
1395485_s_at Myosin lb 1.35 0.039
1376124_at Wiskott-aldrich syndrome like (human) -1.39 0.031
Im m une response
1371015_at Myxovirus resistance 2 -17.31 0.1
G R O W T H /T R A N SC R IPT IO N
K ru p p e l F acto rs
1369363__at Sp4 4.15 0.04
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T ran sc rip tio n
1393571_at SRY-box containing gene 4 6.05 0.0093
1389909_at Nuclear receptor co activator 3.35 0.03
1369544_a„at Homeobox A 1 1.4 0.025
1385837_at H o m e o b o x  D 3 - 3 . 8 5 0 . 0 2 7
A poptosis
1389506_x_at FAS associated factor 1 1.62 0.035
1387521_at Programmed cell death 4 1.35 0.015
Cell cycle
1372685_at Cyclin dependent kinase inhibitor 3 2.22 0.023
1373722_at Kinesin family member 20A 1.96 0.04
1379582_a_at Cyclin A2 1.93 0.017
1393848_at Ribonucleotide reductase M2 (DNA replication) 1.83 0.04
1368260_at Aurora kinase b 1.82 0.026
1370294_a_at Cell division cycle 20 homolog 1.68 0.03
1383747_at ect 2 oncogene 1.63 0.021
1398482_at Bcl-3 (predicted) 1.48 0.007
1386857_at Stathmin 1 1.37 0.019
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5.5 Discussion
The transcriptome data presented here illustrate two facets of T3’s actions in rat liver in 
vivo -  the effects of sudden elevation of circulating T 3 above normal, and the more 
limited changes specific to administration of T3 above the dosage at which liver 
mitogenesis is initiated. The initial data set at three hours after administration of T 3 
adds to the observations on rodent liver made by Yen et al (Yen 2001; Feng et a l  2000) 
and Stahlberg et al (Stahlberg et a l  2005) , specifically by investigating rats rather than 
mice and in looking at an earlier time point, reflecting interest in the early events that 
rapidly lead to the initiation of DNA synthesis. Yen et al defined specific clusters of 
up-regulated and down regulated genes (their clusters 2 & 5) the expression of which 
was specifically associated with the response of the euthyroid rather than the 
hypothyroid liver to T3 administration; they and others (Flores-Morales et a l  2002; 
Wikenheiser-Brokamp 2006) also addressed the changes seen on thyroid replacement 
in hypothyroid mice.
There is no overlap between either the positively responding cluster (27 genes) or the 
negative (21 genes) identified by Yen at 6  hours in mice and in rats at 3 hours after 
single high dose T 3 in this thesis. Even the genes affected most prominently in their 6  
hours array - lipocalin2 (14-fold) and Bcl-3 (>3 fold) were unchanged according to the 
array data presented here at 3 hours.
At the three hour time point there are firstly physiologically plausible alterations in 
directly T3-related proteins, with up-regulation of thyroid-responsive protein, and down- 
regulation of thyroid receptor alpha and beta, thyroid transcription factor, and the 
transport protein thyroglobulin, the latter changes appropriate to the initiation of a 
negative feedback following over-stimulation of the T 3 pathway.
As anticipated there were multiple changes in the expression of enzymes of 
intermediary metabolism. A major function of thyroid hormone is regulation of 
thermogenesis, hyperthyroid states being associated with an elevation of basal 
metabolic rate reflecting stimulation of futile cycles of intermediary metabolism, with 
both increased synthesis and degradation of proteins, lipids and carbohydrates, and 
enhanced cation shuttling across cell membranes (Brent 1994). The known up- 
regulation of the rate-limiting enzyme of gluconeogenesis, phosphoenolpyruvate 
carboxykinase 1 (Barthel and Schmoll 2003), is shown here to be initiated by gene 
expression within 3 hours of stimulation, as is glucose-6 -phosphatase. Changes in Krebs 
cycle enzyme expression are divergent, with a marked down-regulation of citrate 
synthase but up-regulation of other components. A dominant decrease in citrate
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synthase activity would imply decreased capacity to divert acetyl coenzyme A to fatty 
acid synthesis, and there is a decrease in expression of some enzymes mediating fatty 
acid synthesis. The changes however are highly complex, and their proper 
interpretation would require serial observations linked with metabolic studies initiated 
to elucidate changes potentially relevant to cell proliferation.
5.5.1 Proliferative response
A set of cell-cycle related genes were up-regulated by 3 hours, including cyclin D1 (FC 
+2.14), the early expression of which has been associated with both T 3 induced liver 
proliferation and that induced by other primary mitogens. The fold change however did 
not reach statistical significance with a p value of < 0.1. As set out in Chapter Four the 
rise at the expression level of cyclin D1 after T 3 in rat liver studied in this thesis was 
observed at a later time point of 14 hours post dose and it may be that this is when the 
greatest and most significant fold change would be observed to occur.
The greatest fold change was in the serine-threonine kinase PIM-3 (FC + 2.34) -  a gene 
initially identified as a depolarisation induced gene in a rat phaeochromocytoma cell 
line (Amaravadi and Thompson 2005), and more recently shown to be aberrantly 
expressed in human hepatocellular carcinoma tissues and cell lines derived there from 
(Fujii et a l  2005), with a role both in cell cycle progression and in negative regulation 
of apoptosis. PEM-3 is selectively expressed in malignant lesions but not normal tissues 
of endoderm-derived organs such as liver (Li et a l  2006). Studies suggest that PIM-3 
promotes carcinogenesis as a negative regulator of apoptosis, most recently in human 
colon cancer cells (Popivanova et a l  2007).
There was also significant down-regulation of some of the genes governing expression 
of pro-apoptotic processes such as Fas-associated 1, apoptotic protease activating factor, 
and ‘Bcl- 2  like 1 1 * apoptosis facilitator but reflecting the complexity of the system 
other anti-apoptotic genes are also down regulated e.g. Fas apoptotic inhibitory 
molecule 2 .
Interestingly, Bcl-3 is up-regulated on the 1 hour array with a modest fold change of 
+1.48 and yet in Chapter Four it was shown that the T 3 proliferative response was not 
diminished in knockout mice for this gene. The up regulation is small and of course a 
rise in expression does not necessarily lead to an increase in protein expression and 
thereafter a rise in functional activity of the protein.
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Other notable genes linked to cell cycle control and importantly cycle progression are 
also up-regulated at 1 hour. The Aurora kinases play a critical role in mitosis and have 
been suggested as promising targets for cancer therapy due to their frequent over 
expression in a variety of tumours (Andrews 2005). Aurora kinase B is a regulator of 
kinetochore-microtubule attachment and has a number of substrates during mitosis. 
Proper functioning is required for faultless mitosis and hence cell proliferation.
Stathmin 1 (FC + 1.37) has some known functions but it is still to be fully described in 
the literature. Levels are noted to be elevated in various tumour cells and it is known to 
be a microtubule-destabilising phosphoprotein (Rowlands et al. 1995; Mistry and 
Atweh 2001). When stathmin 1 is phosphorylated by cyclin dependent kinase 2, its 
microtubule-depolymerizing activity is lost and the mitotic spindle is formed. Thus, 
regulation of Stathmin 1 expression is important for cell cycle progression.
Mammalian ECT-2 (FC +1.63 on the lh  array) is a proto-oncogene that forms an 
actomyosin contractile ring that separates the plasma membrane of two forming 
daughter cells during cell division (Saito et al. 2003). Amino-terminally truncated ECT- 
2  shows transforming activity in some cultured cells.
A further analysis of the 3 hour array data relevant to proliferative events is summarised 
in Table 9 and additional hypotheses can be generated.
Cell m em brane signal 
transduction  and  signal 
am plification
P ro te in
C h ap ero n in g
RAS
P ro to ­
oncogene
T ransla tion  machinery
Purine/pyrim idine
synthesis
Phosphatidylinositol 3- 
kinase, gamma polypeptide 
(+1.57)
HSPC210 (+1.8) v-ras (+1.99) Mouse methionyl-tRNA
fonmyltransferase
(+1-5)
MAP associated 
Protein 1 (+1.74)
HSPC021 (+1.79) RAB6 (+1.75) Lysyl-tRNA synthetase 
(+1.57)
PIM 3 (+2.1) HSP 105 (+1.61) RAB 2 (+1.59) Phosphoribosylpyrophosp 
hate symthetase (+1.58)
Phospholipase C, beta 4 
(+1.52)
HSPC182
(+1.5)
RAB4A
(+1.57)
5-aimnoimidazole-4- 
carboxamide 
ribonucleotide 
formyltransferase (+1.56)
Table 9 Additional up-regulated genes involved in the proliferative response. Fold 
change is indicated in brackets. (HSP = H eat Shock Protein)
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The T3 mitogenic signal upstream of membrane phospholipids may be mediated by 
PI3K (a proto-oncogene) and the M AP (Mitogen Activated Protein) kinase cascade is 
then activated via phospholipase C and PI3K leading to nuclear phosphorylation events 
and gene transcription. RAS family proto-oncogene products also contribute to the 
proliferative response. HSPs (Heat Shock Proteins) assist in protein chaperoning in 
readiness for cell division and translational proteins are expressed, necessary for the up 
regulated response (Didelot et a l  2006). Enzymes involved in purine/pyrimidine 
synthesis are produced permitting DNA synthesis.
5.5.2 GADD45beta
The key up-regulated genes after T 3 can be compared with those up-regulated by the 
primary mitogen 1, 4-bis-[2-(3, 5,-dichloropyridyloxy) benzene (TCPOBOP) in mice, 
which initiates proliferation via the constitutive androstenedione receptor (Columbano 
et a l  2001). Interestingly it is a much stronger mitogen in mice than rats, and it is also a 
more powerful mitogen than T3. The highest change in expression at 3 hours in 
TCBOPOP treated mice was in the Gadd45beta/MyD118 gene, up-regulated >3 fold at 
3 hours. There was a similar up-regulation over a similar time course after partial 
hepatectomy, and Columbano et al subsequently demonstrated that two distinct 
pathways can up-regulate Gadd45beta/MyD118 -  one activated during partial 
hepatectomy dependent on NFkB, and another enlisted by TCPOBOP via the CAR 
receptor (Columbano et a l  2005). In the 3 hour array it was found that T 3 also appears 
to recruit this gene with +2.74 fold up-regulation. The full role of Gadd45beta remains 
to be defined, but it has an anti-apoptotic role (De Smaele et a l  2001), and Columbano 
has suggested its expression at the onset of the cell cycle in different models of 
hepatocyte proliferation may indicate a role in the protection of hepatocytes from 
apoptosis.
5.5.3 Kruppel Factor Response
The Kruppel Factor transcription factors were notably up-regulated on the 3 hour array 
and therefore these are further investigated as plausible mediators of the T 3 mitogenic 
signal in Chapter Six.
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Chapter 6 Kruppel Factors
6.1 Background
In an effort to demonstrate a mitogenic effect of T3, early markers of its action have 
been pursued in this research thesis. In Chapter Four it was found that the rise in cyclin 
D1 occurred too late for it to be useful in measuring early T 3 effects in the organ 
perfusion system described in Chapter Three. Furthermore another plausible candidate, 
Bcl-3, was found not to be a critical mediator of the mitogenic T3 signal in a murine 
knockout model.
The previous chapter therefore outlined novel work using microarray technology to 
identify which genes are up or down regulated after T 3 administration in euthyroid rat 
liver. The hepatic expression profile after T 3 over time of plausible candidates is further 
pursued in this chapter.
The greatest change in expression on the 3 hour array was the up-regulation of a 
Kruppel factor, Zinc finger protein 354A (FC + 7.64). Indeed there was a cluster of 
changes amongst the Kruppel transcription factors, and this chapter therefore 
investigates these more closely. Using Real Time-PCR analysis, the expression of a 
panel of these evolutionarily conserved transcription factors is described, reflecting their 
known involvement in proliferation and differentiation and thus their biologically 
plausible candidature as mediators of the T3 mitogenic effect.
To elucidate further changes in gene expression associated with the proliferative effect 
of T3 the second expression microarray, comparing mitogenic and sub-mitogenic T3 
doses was performed at 1 hour post dose time point and as anticipated the largest cluster 
of function-associated genes demonstrating significant change after mitogenic T3 was 
amongst cell cycle genes. The only Kruppel factor for which differential expression 
was detected at 1 hour after T 3 was Sp4.
6.1.1 Kruppel Factors
Zinc Finger proteins exhibit very diverse functions, including RNA packaging,
transcriptional activation, apoptosis regulation, protein folding, lipid binding and DNA
recognition (Laity et a l  2001). Classically the zinc finger comprises of 2 cysteine and 2
histidine residues organised around a zinc atom. It was first recognised 15 years ago and
since then many more such proteins have been defined. The name Kruppel is derived
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from the fact that they exhibit homology to the Drosophila melanogaster segmentation 
gene product, Kruppel (Ghaleb et al. 2005). Many of the Kruppel factors exhibit tissue- 
selective expression and a range of regulatory functions. They typically regulate 
expression of genes which have GC rich promoters. A t least 21 members of the Kruppel 
family of proteins are encoded in the human genome which encompasses over 700 
genes that contain C2H2- type zinc fingers, equating to approximately 1 % of the human 
genome.
The Kruppel family’s 21 members show -65%  homology between members, of which 
at least 11 homologs have been identified in the rat (Kaczynski et a l  2003). Their 
defining feature is a highly conserved DNA-binding domain (with more than 65% 
sequence identity among family members) at the carboxyl terminus. The amino acid 
sequences in the zinc finger domains of the Kruppel Factors are closely related to one 
another but the regions outside the zinc fingers are usually unique (Figure 43).
The Kruppel Factors investigated here are ZFP354A, KF 15, KF 9, KF 4 and Sp4.
The greatest change in expression at 3 hours (FC + 7.64) on the first microarray was the 
up-regulation of the Zinc finger protein 354A. ZFP354A (also known as Kid-1, 
transcription factor 17) gene product plays a role in the establishment of a differentiated 
phenotype and proliferative control in rat proximal kidney tubule, and can be induced 
by membrane depolarization (Witzgall et al. 1998). It was the first KRAB-zinc finger 
protein for which a transcriptional repressor activity was demonstrated and contains 13 
C2H2 zinc fingers in groups of 4 and 9 separated by a 32 amino acid spacer. Its mRNA 
accumulates with age and is detected predominantly in the kidney. ZFP354A mRNA 
levels decline after renal injury secondary to ischaemia, an insult which results in 
epithelial cell dedifferentiation, followed by regenerative hyperplasia and 
differentiation. In the Witzgall study it was noted to be predominantly expressed in 
kidney with very little rodent hepatic expression on Northern blot analysis.
KF15 (Fold change + 1.66 on 3h array) was first identified as a protein that binds to the 
promoter of the gene for CLC-K1, a kidney specific chloride channel (Uchida et al. 
2000). Later it was shown to regulate the genes for the glucose transporter GLUT4 in 
adipocytes (Gray et a l  2002) and for acetyl-CoA synthase in muscle cells (Yamamoto 
et a l  2004). Among the organs KF15 is expressed at the highest level in the liver where 
in mice it has been shown that KF15 expression is up-regulated in the fasted state and 
down-regulated by feeding (Teshigawara et al. 2005). The same study showed that 
forced expression of KF15 in cultured hepatocytes increased the expression of 
phosphoenolpyruvate carboxykinase (PEPCK).
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KF9 (Fold change + 1.36 on 3 h array) is otherwise known as Basic Transcription 
Element-binding protein (BTEB). It is noted to be a T 3 regulated gene in developing rat 
brain (Denver et a l  1999) where T3 rapidly up-regulates BTEB mRNA in neuro-2a cells 
engineered to express TR pl but not in cells expressing T R al. In neuronal cells at least 
over expression of KF9 increases the number and length of neurites but has no effect on 
the rate of cell proliferation.
The only Kruppel factor for which differential expression was detected 1 hour after T 3 
(Fold change + 4.15) was Sp4 (trans-acting transcription factor 4 or Specificity Protein 
4), a member of the Sp-1 family, highly expressed in developing brain in the mouse, in 
which its absence is associated with early post-natal mortality (Lemer et a l  2005; 
Kolell and Crawford 2002). The range of its functions remains to be defined, but in 
general it appears to be an activator, and it presents one potential candidate for 
mediating T3’s mitogenic effects (Supp et a l  1996). Sp-4 shows a complex expression 
pattern but it is most abundant in neuronal tissue. In mice with targeted disruption of the 
Sp4 gene there are severe consequences for post natal development. Sp4nu11 mice 
develop until birth without severe consequences but after birth two thirds die within 4 
weeks (Gollner et a l  2001). Male Sp4nu11 mice do not breed and have a reduced testis 
size.
KF4 is discussed in more detail in the conclusions to this chapter. There was no change 
in its expression level on either of the array experiments but given its known role in cell 
proliferation it was thought prudent to investigate its expression over time after T3.
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Figure 43 The zinc finger m otif common to the Kruppel Factors- 2 cysteine and 2 
histidine residues organised around a zinc atom, and an unrooted phylogram o f  the 
human Kruppel Factors. Branch changes are proportional to amino acid changes.
6.2 Aims
i) To measure the expression of novel candidates (Kruppel Factor transcription factors) 
as potential mediators of the mitogenic effects o f T 3 over time in mitogenic versus sub- 
mitogenic T3 treated rat liver using quantitative Real Time PCR.
ii) To determine whether or not observed changes in gene expression are due to the time 
of day of animal sacrifice.
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6.3 Materials and Methods
6.3.1 Animal Procedures
Male Sprague-Dawley rats (250g) were housed in a temperature- and light-controlled 
room (12-hour light/dark cycle) with free access to food and water. Animal care and all 
procedures were compatible with the Animal (Scientific Procedures) Act 1986, UK 
Home Office.
Animals were sacrificed at the appropriate time points by a schedule one procedure. 
Liver was harvested and sectioned for histology and pieces were snap frozen in liquid 
nitrogen and stored at -80°C for later analysis and RNA isolation.
Protocol 1: Male SD rats, were administered a subcutaneous dose of either mitogenic T 3 
(5pg per animal) or (n = 3) sub-mitogenic T 3 (0.1 pg per animal) and sacrificed at 0, 20, 
40, 60, 90, 120, 150, 180, and 480 minutes post dose to provide RNA for serial 
assessment of individual gene expression (n=3 per time point).
Protocol 2: Male SD rats, were administered a subcutaneous dose of vehicle only at 
0900 (n=4) and sacrificed immediately and a second group were administered a 
subcutaneous dose of vehicle only at 0900 (n=4) and sacrificed 60 minutes later to look 
for changes in hepatic gene expression that may be due to the time of day of animal 
sacrifice rather than solely the effects of T3 on the hepatic transcriptome.
6.3.2 RNA preparation
Please refer to General Methods Chapter 2.
Frozen liver samples (-80°C) were homogenised with a Rotastar homogeniser in buffer 
containing guanidine thiocyanate and p-M ercaptoethanol and the total RNA was 
isolated using RNA MidiKit reagents (Qiagen, UK) following manufacturer’s 
guidelines.
6.3.2.1 RNA Integrity and Quantitation
Please refer to General Methods Chapter 2.
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A 260:280 nm absorbance ratio above 1.8 was obtained for all samples. RNA quality 
was assessed by denaturing formaldehyde gel electrophoresis. The 28S:18S ratio was 
2 : 1  for all samples.
6.3.2.2 Preparing for Q uantitative R eal T im e PC R /P reparation  o f  
standards
Please refer to General Methods Chapter 2.
63.2.3 cDNA synthesis
Please refer to General Methods in Chapter 2.
cDNA was prepared from 0.5pg total RNA using a QuantiTect Reverse Transcription 
reaction mixture following m anufacturer’s guidelines (Qiagen, UK).
6.3.2.4 Prim er D esign
Please refer to General Methods Chapter 2.
Primers were designed for KF15, ZFP354A, KF9, KF4, Sp4 and 18S (sequences in 
Table 10). The primer design rules outlined in Chapter Two were adhered to.
6.3.2.5 C onventional P C R  to check prim ers
Please refer to General Methods Chapter 2.
6.3.2.6 DN A  gel E lectrophoresis
Please refer to General Methods Chapter 2.
Conventional PCR was undertaken to check the primers and then to produce sufficient 
target amplicon for use in making necessary standards for the subsequent real time PCR 
reactions. Representative gels are shown in Figure 44 and Figure 45.
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Table 10 Primer sequences used fo r  the Real Time PCR and the size o f  the am pliconfor 
each sequence
KF15 F 5’- CCAATGCCAAACCTAT -3’
R 5’- CTACATGTGGTTCTCGTCGGTGGAG -3’ 
Amplicon length 161 base pairs
ZFP354A F 5’- GAGCTCCTCACGTATAGCAC -3* 
R 5’- GGTTGGTAAGGGATGACCTA -3’ 
Amplicon length 103 base pairs
KF4 F 5’- TGATGGTGCTTGGTGAGT -3’
R 5’- TTGCACATCTGAAACCACAG -3’ 
Amplicon length 201 base pairs
KF9 F 5’- ATACAGGTGAACGGCCCTT -3’ 
R 5 - TCCGAGCGCGAGAACTTTT -3’ 
Amplicon length 63 base pairs
Sp4 F 5’- ATGAGCGATCAGAAGAAGGAGG -3’ 
R 5’- GAGTCCCTATTTTGCTGCAAGT -3’ 
Amplicon length 175 base pairs
18S F 5 - CTTAGAGGGACAAGTGGCG -3’
R 5 - GGACATCTAAGGGCATCACA -3’ 
Amplicon length 69 base pairs
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Figure 44 2% agarose gel electrophoresis o f  the PCR products, (a) Kruppel factor 15 
(201 base pair amplicon) and (b) ZFP354A (103 base pair amplicon) on agarose gels 
after conventional PCR. Lane 1 in each gel contains 7p i  o f  Hperladder IV  and Lane 2 
contains either Kruppel Factor 15 or ZFP354A DNA. The arrows indicate the position 
o f  the 200 base pair marker in Lane 1.
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Figure 45 2% agarose gel electrophoresis o f  the PCR products, (a) Kruppel fac tor 4 
(161 base pair amplicon) and (b) 18S (69 base pa ir amplicon) on agarose gels after 
conventional PCR. Lane 1 in each gel contains 7p i  o f  Hperladder IV  and Lane 2 
contains either Kruppel Factor 4 or 18S DNA. The arrows indicate the position o f  the 
100 base pair marker in Lane 1.
6.3.3 Preparation of standards
Please refer to General Methods Chapter 2.
M ethod
5pl of cDNA from a sample was used to make specific product so as standards could be 
made for the real time PCR analysis for both all Kruppel Factors and 18S.
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6.3.3.1 Amplicon Excision from DNA Agarose Gel
Please refer to General Methods Chapter 2.
6.3.3.2 A m plicon extraction from  agarose gel
Please refer to General Methods Chapter 2.
6.3.3.3 DNA estim ation
Please refer to General Methods Chapter 2 .
6.3.4 Amount of specific product estimation using Avogadro’s number
Please refer to General Methods Chapter 2.
The number of amplicon molecules was calculated using Avogadro’s number (6.022 
xlO23), the molecular weight of the amplicon and the estimated concentration o f 
amplicon.
6.3.5 Real Time PCR
Please refer to General Methods Chapter 2.
Real Time PCR was performed on a Rotor-Gene 3000 Real Time PCR machine in 
O.lmL strip tubes. A QuantiTect SYBR Green M aster Mix (Qiagen) was used (See 
Chapter 2).
The PCR reaction utilised an initial activation step for 15m at 95°C, then 45 cycles of 
95°C for 30s, 60°C for 30s, 72°C for 30s, finally 72°C for 10 minutes.
Relative quantitation was used to determine amount of target with external standards 
(Bustin 2005) after initial generation of suitable standard curves for each Kruppel 
Factor. The copy number was normalised to 18S RNA. Accuracy of the assay is 
demonstrated by showing reproducibility across more than one real time run; and this is 
what was done ( two separate real time runs were performed) (See General Methods 
Chapter Two).
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6.4 Results
For ZFP354A, KF 15, and KF 9 there were marked transient rises in gene expression, 
peaking 60 minutes after T3 administration, but no differences between animals 
receiving mitogenic or sub-mitogenic doses. These Kruppel Factors are therefore clearly 
T 3 responsive (Figure 46-48).
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Figure 46 The hepatic ZFP354A response to T3 over time comparing (a) mitogenic with 
(b) sub-mitogenic doses o f  Tj. The expression analysis used real time PCR with copy 
number per reaction normalised to 18S copy number. Each time point represents n—3 
mean and range.
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Figure 47 The hepatic KF15 response to T3 over time comparing (a) mitogenic with (b) 
sub-mitogenic doses o f  T3. The expression analysis used real time PCR with copy 
number per reaction normalised to 18S copy number. Each time point represents n - 3  
mean and range.
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Figure 48 The hepatic KF9 response to over time comparing (a) mitogenic with (b) 
sub-mitogenic doses o f  T3. The expression analysis used real time PCR with copy 
number per reaction normalised to 18S copy number. Each time poin t represents n=3 
mean and range.
Interestingly, there was a divergence of expression of KF4 between mitogenic and sub- 
mitogenic dose of T3 with a fall in expression at 2 0  minutes after a mitogenic dose, not 
observed in the sub-mitogenic liver (Figure 49).
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Figure 49 The hepatic KF4 response to T3 over time comparing (a) mitogenic with (b) 
sub-mitogenic doses o f  Tj. The expression analysis used real time PCR with copy 
number per reaction normalised to 18S copy number. Each time point represents n=3 
mean and range.
For Sp4 (Figure 50) expression there was no evident trend that emerged over time, 
although there was greater expression at 60 minutes after mitogenic T3 and this 
confirms the up-regulation noted on the 1 hour array where a fold change o f + 4.15 was 
found.
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Figure 50 The hepatic Sp4 response to Tj over time comparing mitogenic with sub- 
mitogenic doses o fT 3. The expression analysis used real time PCR with copy number 
per reaction normalised to 18S copy number. Each time point represents n=3 mean and 
range.
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6.4.1 Changes in gene expression are not due to time of day of animal 
sacrifice
Figure 51 shows that between the time points of 0900 and 1000 there was no change in 
the hepatic expression of the Kruppel Factors KF 15 and ZFP354A. For the Kruppel 
Factors 4 and 9 the same result was obtained. The increase in expression of the Kruppel 
factors at 60 minutes post dose seen previously is not therefore due to a change in the 
hepatic transcriptome according to the time of day of animal sacrifice.
Hepatic KF15 Expression in SD Rats at Time 0 and 60 mins after Vehicle only
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Figure 51 Real Time PCR analysis o f the Kruppel Factor response (copy number per 
reaction normalised to 18S copy number) fo r  KF 15 and ZFP354A after vehicle only at 
0900 (time o f  animal sacrifice) and sixty minutes later at 1000 (time o f  animal 
sacrifice).
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6.5 Discussion
The analysis performed here is based on gene expression profiles at the mRNA level of 
the Kruppel Factors ZFP354A, KF 15 and KF 9. These were shown to be T3 responsive 
but no differences were found between mitogenic and sub-mitogenic treated liver and 
consequently they do not appear to critically mediate the mitogenic T 3 response. 
However this study did not examine effects T3 may have at the protein level on pre­
formed transcription factors. Another possible pathway of T 3 action might be through 
rapid ‘non-genomic’ activation of pools of transcription factors which can then go about 
activating downstream pro-proliferative signalling pathways leading to DNA synthesis 
and cell division. A proteomics based approach in the future may identify those 
involved and is a future aim of this project.
Proteomics encompasses diverse techniques that allow different aspects of protein 
structure and function to be analysed. Among the proteomic techniques mass 
spectrometry has emerged as the main method for analysing the production and function 
of proteins in biological systems (Cravatt et al. 2007). Recent published work has 
described the use of a proteomics based approach in the analysis of the hepatic 
regenerative response in the rat (Sun et al. 2007). Twenty four proteins were noted to be 
differentially expressed one hour after partial hepatectomy and these were functionally 
grouped to together. These evolving and powerful protemic techniques should be used 
to examine the hepatic response to mitogens including T3.
6.5.1 KF 4
While the majority of the Kruppel factors showed no difference in response to 
mitogenic and sub-mitogenic doses of T3, there was however a transient fall in Kruppel 
Factor 4 expression seen at 20 minutes only after a mitogenic dose o f T3. KF4 also 
known as Gut enriched Kruppel Factor, plays a role as a tum our suppressor gene, 
exerting an inhibitory effect on cyclins and their cyclin dependent kinase partners, and 
blocks G l/S  phase progression (Shields et al. 1996; Rowland et a l  2005). In gut 
epithelium, its down-regulation is associated with cell hyper-proliferation (Ghaleb et al. 
2005). Among the KF4 regulated cell cycle genes many up-regulated genes are 
inhibitors of proliferation whereas genes that promote proliferation are repressed. KF4 
levels rise following DNA damage, cell-cycle arrest in response to serum withdrawal 
and contact inhibition (Chen et al. 2001). These observations established KF4 as a stress 
and differentiation associated inhibitor of proliferation and confirm its tumour
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suppressor function. Indeed its expression is lost in various human cancers and recently 
it has been shown to undergo promoter methylation and loss of heterozygosity in 
gastrointestinal cancer (Wei et a l  2005). KF4 mRNA and protein is over expressed in 
70% of mammary carcinomas.
In a human colonic adenocarcinoma cell line (HT-29), KF4 over-expression 
significantly inhibited cyclin D1 mRNA levels as well as cyclin D1 promoter activity. 
As discussed previously the activation of cyclin D1 early in the hepatic mitogenic 
response to T3 has been described. In transient transfection experiments KF4 was found 
to decrease cyclin D1 promoter activity by 55% (Shie et a l  2000). Sequential deletion 
and site-directed mutation analysis of the cyclin D1 promoter have identified the 
sequence in a region containing an Spl response element, to be essential for KF4 
function. The inhibitory effect of KF4 on cyclin D1 promoter activity was completely 
abolished by an excessive amount of Spl DNA and KF4 significantly reduced the 
stimulatory function of Spl suggesting that KF4 and Spl may compete for the same 
binding site on the cyclin D1 promoter. These results indicate that KF4 is a 
transcriptional repressor of the cyclin D1 gene and that the inhibitory effect of KF4 is, in 
part, mediated by an interaction with the Spl binding domain on its promoter.
Thus it is plausible to hypothesise that T3 might exert its effect on inducing 
proliferation, at least in part by suppression of KF4 transcription. A number of 
companies produce commercially available antibodies to KF4 and it would therefore be 
interesting to investigate T3 stimulated liver samples to look for changes in KF4 
expression at the protein level using either an enzyme linked immunosorbant assay 
(ELISA) or Western blot approach.
6.5.2 Sp-4
Sp-4 showed differential expression 60 minutes after a mitogenic compared to a sub- 
mitogenic dose of T3. Recent work using RNA interference has revealed that Sp-4 is 
expressed in pancreatic cancer cells and plays an important role in regulating expression 
of VEGF (vascular endothelial derived growth factor) in these cells (Abdelrahim et a l
2004). The allied molecule Sp-3 was shown to be a key regulator of G1 to S phase cell 
cycle progression in these cells and there clearly remain as yet unidentified roles for Sp- 
4 and its involvement in control of proliferation. The commercial availability of 
antibodies to Sp-4 means it may be further analysed in the setting of T3 induced 
hepatocyte proliferation.
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In conclusion, this chapter describes the response to T3 amongst important transcription 
factors- the Kruppel Factors, however no one transcription factor has conclusively 
emerged as a likely critical early mediator of the mitogenic T3 response. In the next 
chapter therefore analysis turns to investigating early events by examining the signalling 
pathway upstream of cyclin D1 activation, in an effort to find a new critical early 
mediator of the hepatic mitogenic T3 response.
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Chapter 7 mTOR Mediates the Mitogenic 
T3 Response
7.1 Background
7.1.1 Signalling upstream of cyclin D1
In an effort to understand what may precede cyclin D1 activation after T3 stimulation, it 
is important to explore the web of signalling interactions that are involved (Davis et a l  
2000). This approach could lead to identifying earlier mediators of the hepatic 
proliferative response to T3.
An important pathway that merits interrorgation in this context involves 'm TO R ' or the 
mammalian target of rapamycin. In this chapter the hypothesis ‘mTOR mediates the 
hepatic mitogenic T3 response’ is investigated on the basis that the target of rapamycin 
(TOR) plays a pivotal role in integrating signals from mitogens and nutrients that 
regulate cell growth (Nelsen et a l  2003a). The importance o f mTOR in mediating 
proliferation signals is supported by a number of published studies, one o f which noted 
that in the liver mTOR mediates the hepatocyte proliferative response to amino acid 
infusion (Ijichi et a l  2003; Nelsen et a l  2003b). In another it was shown that mTOR 
can also provide an alternative pathway of liver regeneration following partial 
hepatectomy as revealed in animals in which the ability to respond to tyrosine growth 
factor receptors is deficient e.g. STAT3 deficient mice (Haga et a l  2005).
Rapamycin is already known to inhibit liver regeneration in vivo in rats in a dose 
dependent manner up to 1 . 0  mg/kg where one sees elimination of the normal 
regenerative response (Francavilla et a l  1991) and it can also inhibit hepatocyte 
proliferation under cell culture conditions (Francavilla et a l  1992).
Furthermore, several studies conducted in mammalian cells have shown that rapamycin 
inhibits the expression of cyclin D l, important in cell cycle progression and 
proliferation as described in Chapter 4 (Hidalgo and Rowinsky 2000). In cultured rat 
hepatocytes rapamycin prevents the up-regulation o f cyclin D l and it inhibits 
regeneration in the mouse after partial hepatectomy but this can be overcome by 
transfection with cyclin D l (Nelsen et a l  2003a). To assess whether there was an in 
vivo as opposed to just an in vitro effect, rapamycin-treated mice were transfected with
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cyclin D l using an adenoviral system and the result was an increase o f DNA synthesis 
measured by BrdU incorporation o f 14% compared to 0% in control-transfected mice.
7.1.2 mTOR pathways
Rapamycin is a macrolide produced by the bacterium Streptomyces hygroscopicus and 
derives its name from the island of Rapa Nui from where it was discovered in a soil 
sample in 1970. Its initial use was as an anti-fungal agent but its potent 
immunosuppressant properties were quickly realised and as a result it went relatively 
unexploited for a number of years until the early 1990s when its target was identified. 
The mTOR gene was described in 1994 and it was as late as 1997 that the drug was 
approved by the Federal Drug Administration as an anti-rejection agent in renal 
transplantation. Now there has been an explosion of interest in rapamycin and its newer 
analogues and many are now in clinical trials for uses as varied as combating cancer and 
treating coronary artery disease.
The mammalian target o f rapamycin is a well conserved 289 kDa serine-threonine 
kinase (Figure 52) that regulates cell-cycle progression and is specifically inhibited by 
rapamycin (Wullschleger et a l  2006). Every eukaryote genome examined contains a 
TOR gene. mTOR regulates cell growth by integrating four major inputs: growth 
factors, nutrients (especially amino acids), and energy and stress, (for example hypoxia) 
(Rohde et a l  2001; Martin and Hall 2005). Commercial antibodies are able to detect 
total mTOR and also the active form of the kinase, phosphorylated mTOR. 
Phosphorylation at serine residue 2448 leads to mTOR activation (Kenessey and 
Ojamaa 2006).
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Figure 52 (a) The structure o f  the ternary complex o f  FKB12- rapamycin binding 
domain (FRB) (red), rapamycin (green) and FKBP12 (blue) (Choi et al. 1996). (b) 
Chemical structure o f  rapamycin and its binding sites fo r  FKBP12 (blue region) and 
mTOR (red region).
Rapamycin includes two separate moieties, the TO R -binding and the FKBP 12-binding 
regions. To be active biologically, rapam ycin m ust form  a ternary com plex w ith m TOR 
and FKBP 12, which is a cytosolic binding protein collectively called im m unophilin. 
Therefore, rapam ycin acts to induce the dim erization o f m TOR and FKBP12. The 
formation o f  a rapam ycin-FK B P12 com plex results in a gain-of-function because the 
complex binds directly to m TO R and inhibits the function o f mTOR and the m TO R- 
mediated signalling netw ork (Tsang et al. 2007).
7.1.2.1 mTOR Activation- Upstream Events
Among the signal inputs, growth factor- and horm one (e.g. insulin)-induced mTOR 
activation is the best characterized, and is m ediated by the activation of 
phosphatidylinositol-3-kinase, PI3K. A ctive PI3K  localizes to the cell m em brane and 
catalyzes the conversion o f phosphatidylinositol (4,5)-biphosphate [PtdIns(4,5)P2] into 
phosphatidylinositol (3,4,5)-triphosphate [PtdIns(3 ,4 ,5 )P 3]. Subsequently 
PtdIns(3 ,4 ,5 )P 3 recruits and activates AKT, w hich, in turn, phosphorylates and 
inactivates the tuberous sclerosis protein com plex (TSC), which is a heterodim er 
com posed o f TSC 1 and TSC2. TSC2 acts as a G TPase-activating protein (GAP) for the 
small GTPase Rheb, and the action o f TSC  is thought to be m ediated by Rheb, possibly
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by the binding of Rheb to the kinase domain of mTOR, which activates mTOR in a 
GTP-dependent manner (Inoki et a l  2002; Nobukini and Thomas 2004).
Several studies also show that GTP-loading of Rheb induces a conformational change in 
mTOR that results in activation of mTOR and phosphorylation of downstream effector 
proteins. Other studies have shown that AKT phosphorylates mTOR directly at 
Ser2448, but the functional significance of phosphorylation of this remains to be 
established.
7.1.2.2 mTOR Activation- Downstream Events
Growth and development require mTOR, and disruption of mTOR results in embryonic 
lethality and severe developmental defects (Gangloff et al. 2004). At the cellular level, 
mTOR is central to the regulation of both catabolic and anabolic processes. In response 
to optimal growth stimuli, mTOR promotes the synthetic capabilities of the cell by up- 
regulating key processes such as ribosome biogenesis and protein translation, which 
lead to an increase in cell mass and size, and, thus, accelerated proliferation. The best 
characterized downstream effectors o f mTOR are the ribosomal protein S6  kinases 
(S6 K) and 4E-BP1 (also called PH AS-I). S6K1 is phosphorylated directly by mTOR 
during stimulation with either nutrients or growth factors, which results in a selective 
increase in the translation of mRNA transcripts that contain a 5' tract of oligopyrimidine 
(5'-TOP) motif. The 5 '-TOP mRNAs encode components of the translation apparatus 
such as elongation factors and ribosomal proteins. Thus, mTOR-dependent activation of 
S6K1 promotes an overall increase in protein synthesis. However, S6  phosphorylation 
and translation of 5 '-TOP mRNAs are still responsive to mitogens in a rapamycin- 
dependent manner in a S6K1/S6K2 double-knockout mutant, which indicates that an 
alternative effector is also present. 4E-BP1 is an inhibitor of eukaryotic translation 
initiation factor 4E (eIF4E). After hyperphosphorylation by mTOR, 4E-BP1 dissociates 
from eIF4E, which allows eIF4E to associate with the 5 '-CAP of mRNAs and initiate 
translation.
7.1.3 Elaboration of Hypothesis
The hypothesis underlying this chapter is that T3 recruits the mTOR pathway and the 
potential means by which this may work is through a non-genomic effect. In addition 
there is evidence for mTOR involvement fom the gene array experiment of Chapter
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Five where mTOR is up-regulated (FC + 1.34) at the mRNA level after administration 
of T3.
The extra-nuclear or ‘non-genomic’ T3 actions were discussed in detail in Chapter 1 but 
to re-capitulate, T3 is well known to classically ligand with its nuclear receptor P 
isoform in the liver to effect gene transcription (Aranda and Pascual 2001; Yen 2001). 
However a number of T3 actions occur too rapidly to be explained by this ‘genomic’ 
pathway and hence a set of ‘non- genomic’ actions have been increasingly described 
(Bassett et al. 2003; Davis et a l  2007). The site of these non-genomic actions may be 
the plasma membrane, cytosol or cellular organelles. They include the regulation of ion 
channels for example and involve the generation o f intracellular secondary messengers 
and induction of signalling cascades such as cyclic AMP or the protein kinase cascades 
(Davis and Davis 2002).
There is some recent evidence that T3 in human cells can activate the mTOR pathway 
(Cao et al. 2005). This group showed that in human fibroblasts T3 activates mTOR by 
way of phosphatidylinositol 3-kinase which is activated first by the liganded TRpl 
receptor in a non-genomic mechanism of activation. The kinase then activates 
Akt/protein kinase B which phosphorylates the mTOR at S2448 bringing about its rapid 
activation and subsequent phosphorylation o f p70s6k which is involved in translation 
initiation.
A diagram summarising the proposed T3 - mTOR signalling pathway is shown in Figure 
53.
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Figure 53 The signalling mTOR network and its relationship to 7 ? and cell cycle 
progression. Tj receptors are located either at the cell membrane or in the cell nucleus 
(classical genomic mechanism). By acting at the cell membrane (non classical mode o f  
thyroid hormone action) a signal transduction cascade is activated that brings about 
AK T activation by PI3K and this then allows mTOR activation by inhibition o f the TSC  
complex and subsequent Rheb activation. mTOR activation leads to translation o f  genes 
necessary fo r  cell cycle progression. M ost important amongst these is cyclin D l which 
acts with CDK4 to phosphorylate Rb and allow release o f  E2F transcription factors 
which transactivate further genes necessary fo r  S phase to progress.
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7.2 Aims
a) To assess the in vivo hepatocyte proliferative response to T 3 in rapamycin treated 
rodents.
b) To examine the change in phosphorylated mTOR in mitogenic T3 treated rat liver and 
sub-mitogenic T3 treated rat liver over time using an immunohistochemical technique 
and Western blot analysis.
c) To examine T 3 treated rodent liver for phosphorylated AKT (upstream of mTOR) and 
the downstream effector phosphorylated p70S6kinase using an immunohistochemical 
technique.
d) To stimulate primary human hepatocytes with T 3 and monitor the phosphorylated 
mTOR response using Western blot analysis and to stain human liver sections for 
phosphorylated mTOR and study the pattern of staining.
e) To administer the PI3K inhibitor wortmannin to rats in vivo and assess the hepatocyte 
proliferative response to T3 to determine whether the hepatic mTOR pathway is 
activated by T3 through PI3K.
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7.3 Materials and Methods
7.3.1 Animal Procedures and Protocols
Adult male Sprague Dawley rats (200-250g) were housed in a temperature- and light- 
controlled room (12-hour light/dark cycle) with free access to food and water. Animal 
care and all procedures were compatible with the Animal (Scientific Procedures) Act 
1986, UK Home Office.
T3 was obtained from Sigma (Poole, England) and dissolved in 1M NaOH at a 
concentration of lmg/ml. It was administered to rats by subcutaneous injection at a dose 
of 5pg per whole animal in 1ml total volume diluent (960pl NaCl and 40pl 1M NaOH).
Protocol 1
Rats (n=4) were administered an i/p dose o f rapamycin (proetinkinase.de GmbH) 
1.5mg/kg solubilised in Dimethylsulfoxide (DMSO) and delivered in a volume of 500pl 
normal saline two hours before 5pg of T3 was administered subcutaneously. Thirteen 
hours later a second dose of rapamycin 0.75mg/kg i/p was administered.
A second group of control rats (n=4) were administered an i/p dose of vehicle only at 
the same time points followed by 5pg T3.
One hour prior to sacrifice all animals received an intra-peritoneal injection of BrdU 
(Sigma, Poole England) 50 mg/kg solubilised in normal saline at a concentration of 
12.5mg/ml.
Animals were sacrificed 24 hours after the dose of T3 was administered by a schedule 
one procedure and livers were immediately removed, sectioned and placed in formalin 
before processing ready for immunohistochemical analysis of the BrdU hepatocyte 
proliferative response.
Protocol 2
Rats were administered a subcutaneous dose of either mitogenic T3 (5 jig per animal) or 
sub-mitogenic T3 (0.1 pg per animal) and sacrificed at (n=3 per time point) 0, 20, 40, 60, 
90, 120, 150 ,180 and 480 minutes post dose for immunohistochemical assessment of 
the hepatocyte phosphorylated mTOR response, phosphorylated AKT and 
phosphorylated p70S6kinase response. Liver samples were snap frozen in liquid 
nitrogen then stored at -80°C for later protein isolation for Western blot analysis. The 
sub-mitogenic dose still brings about the metabolic consequences of T3 administration
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but crucially does not lead to proliferation of the hepatocytes (see Results Chapter 
Three).
Protocol 3
Adult male SD rats (n=7) were injected i/p with lOOpg/kg wortmannin in 0.5mls normal 
saline (Cell Signalling Tech. # 9951 from stock 5 mg/ml in methanol) and 30 minutes 
later injected with 5pg T3 subcutaneously. Twenty three hours later BrdU was 
administered to flash label hepatocytes undergoing DNA synthesis and 1 hour later 
animals were sacrificed in the usual manner.
A second group of rats (n=5) were administered vehicle only i/p and then a 5pg 
mitogenic dose of T 3 prior to BrdU flash labelling twenty three hours later and one hour 
later sacrifice by a schedule one method.
Livers were removed, sectioned and placed into formalin for 24 hours, prior to routine 
histological processing.
The dose and timing of administration of wortmannin was based on that other workers 
have used to bring about successful PI3K inhibition in vivo in the rat (Pustylnyak et a l
2005). The approximate half life of the drug is 2 hours.
7.3.2 Immunohistochemistry
Please refer to General Methods Chapter 2.
Formalin fixed tissues were embedded in paraffin and 4pm  thick sections were cut. 
Incorporation of BrdU into hepatocyte nuclei was detected using a mouse monoclonal 
antibody (Dako Ltd., Cambridge, UK) followed by a biotinylated rabbit anti-mouse IgG 
secondary antibody (Dako Ltd., Cambridge , UK).
Phosphorylated mTOR was localised using a rabbit monoclonal anti phospho-mTOR 
serine-2448 antibody (Cell Signalling Tech., MA) followed by a biotinylated goat anti­
rabbit IgG secondary antibody (Dako, Cambridge UK). Visualisation was by the 
indirect peroxidase technique using 3,3’—diaminobenzidine (Sigma, Poole England) as a 
substrate.
Phosphorylated p70S6kinase and phosphorylated AKT were detected in rat liver using 
the appropriate antibodies (see Chapter 2).
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7.3.3 Statistical Analyses
Hepatocytes positive for phosphorylated mTOR were counted over a low power xlOO 
original magnification which equates to a tissue section area of 3.14mm2. The mean of 4 
such fields was taken and plotted as the mean ± range.
The statistical difference between the means was determined using a Student’s t test; p 
< 0.05 was considered significant.
7.3.4 Primary Human Hepatocyte Culture
The harvested human hepatocytes (work done by other colleagues) were plated into 6  
well plates at a density of 2  million cells per well (see General Methods Chapter 2). 
Each experimental sample was designated ‘B S’ and then given a sequential number.
For each time point 2 6 -well plates were prepared; one for vehicle only stimulated cells 
and one for T3 stimulated cells. Cells were incubated in medium made with T 3 deplete 
FCS (See General Methods Chapter Two).
On the morning of day 1 cells were either treated with T 3 (final concentration 100 nM 
derived by adding 1.34[xl T 3 stock at 1 |mg/pil to 20mls of medium) or vehicle only (from 
1.34 pi 1M NaOH to 20mls medium) and harvested at time points 0, 15, 25, 40, 60, and 
90 minutes post stimulation.
A volume of 2mls medium was used per well of a 6  well plate.
At the end of each time point plates were placed in a -80°C freezer to terminate the 
experiment and shortly thereafter protein lysates were made using 500pl RDPA lysis 
buffer per 6  well plate. Cells were lysed with the help of a cell scraper (see Chapter 2). 
The human livers examined were BS43, BS44, BS45 and BS47.
7.3.5 Western Blot analysis
Rat and human protein lysate samples were quantitated using the BCA method and 
stored aliquoted out in smaller volumes at -80°C (see Chapter Two General Methods). 
Lysates were run on SDS-PAGE gels prior to protein membrane transfer and 
subsequent probing with primary antibodies to phosphorylated mTOR and total mTOR. 
50pg of protein was loaded per lane. The mean protein concentration of the rat liver 
lysates was 1 0  mg/ml and for the human hepatocyte lysates it was 1 1  mg/ml.
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Following incubation with primary antibody to phosphorylated mTOR (p-mTOR) and 
then the appropriate secondary antibody, the membrane was stripped using Pierce 
Stripping Buffer to enable re-probing of the membrane with an antibody to total mTOR. 
Total mTOR acted as a loading control against which p-mTOR could be normalised.
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7.4 Results
7.4.1 Rapamycin inhibits the peak proliferative response to T3
Rapamycin significantly inhibits the proliferative hepatocyte response brought about by 
T3 (p < 0.04) (Figure 54). A striking reduction by alm ost 50%  is seen in the num ber of 
positive BrdU hepatocytes at 24 hours in the anim als w hich received T 3 and rapam ycin.
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Figure 54 Photomicrographs comparing the maximum hepatocyte proliferative BrdU  
response at 24 hours after 5p g Tj in adult male SD rats by immunohistochemistry after 
(a) rapamycin and (b) vehicle only, xlO  objective, (c) BrdU proliferative response 
comparing rapamycin and Tj treated animals with Tj and vehicle only treated animals 
(p < 0.04). 2,000 hepatocyte nuclei were scored.
194
7.4.2 Positive control for phosphorylated mTOR
Sections o f  hum an colon cancer (donated by the Royal Free histopathology department) 
were used as positive controls for phosphorylated m TOR (Figure 55). The antibody 
used reacts with hum an and rat phosphorylated m TOR.
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Figure 55 Sections o f  human colon carcinoma stained for phosphorylated mTOR to act 
as positive controls for the subsequent immunohistochemistry experiments. The top 
section is incubated with no prim ary antibody and stains negative fo r  phosphorylated 
mTOR (negative control). The bottom section is a positive control and positive brown 
staining (see arrows) can be seen in some cells at the base o f  a colonic crypt, x40 
objective.
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7A 2.1 Mitogenic but not sub-mitogenic T3 induces a surge in mTOR 
phosphorylation
There is a clear surge in the number of hepatocytes staining positive for phosphorylated 
mTOR at 90 minutes after mitogenic T3 but no such response is seen after the sub- 
mitogenic dose. There is a return to baseline by 3 hours post T3 (Figure 56). The sub- 
mitogenic dose is still more than 2,500 times supra-physiological but does not result in 
the proliferation of hepatocytes (see Results Chapter 3).
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Figure 56 (a-b) Photomicrographs showing the peak phosphorylated mTOR hepatocyte 
response at 90 minutes after mitogenic Tj, x40 objective. Cells surrounding vessels 
stain strongly positive but this is also seen in unstimulated liver.
(c) the response is compared with sub-mitogenic Tj at 90 minutes where very few  
hepatocytes stain positive fo r  phospho- mTOR , xlO  objective
(d) the time course o f  phospho-mTOR expression in mitogenic versus sub-mitogenic T 3 
treated rat liver. There is a surge in the number o f  positive hepatocytes fo r  phospho- 
mTOR at 90 minutes after mitogenic T 3 but not in the sub-mitogenic treated group. (*p
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< 0.05 vs vehicle only treated liver at 90 minutes). Numbers o f  positive cells were 
scored over the area o f  tissue visualised using the xlO objective, which equates to 
3 .14mm2'
The pattern o f staining for p-mTOR was striking in that cells surrounding major vessels 
stained positive. This can be seen in Figure 56b and Figure 57 where the cytoplasm of 
cells surrounding this major vessel is clearly positive. This was seen both in quiescent 
and T3 treated rat liver and these cells were not scored when assessing the response to
T3.
Figure 57 Tissue section o f  unstimulated quiescent rat liver x40 objective stained fo r  
phosphorylated mTOR. Note positive staining in cells surrounding a major vessel.
1A.2.2 The induced phosphorylation is localised to the midzone
It has been previously demonstrated that the T 3 mitogenic effect is localised to the 
midzone although the reason for this is not known (Malik et al. 2003). Interestingly the 
phosphorylated mTOR hepatocyte response is localised to the same area in the hepatic 
lobule and this would be consistent with these cells later undergoing DNA synthesis and 
eventual replication in response to the initial mitogenic T3 signal.
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7.4.3 Investigating AKT and p70S6kinase
7.4.3.1 Rat phosphorylated AKT
AKT activation may precede that of mTOR in a T3 sensitive pathway. The signalling 
network was further probed using an antibody directed against phosphorylated AKT 
(pAKT). Tissue sections from the entire mitogenic T3 time course in the rat were 
examined for pAKT. Evident was subtle membranous (Figure 58) and occasional 
cytoplasmic staining that did not alter in distribution or intensity over time following T3 
stimulation. Given the nature and distribution of the staining, any increase in staining 
after T3 may be difficult to see. On blinded visual inspection of the sections no overall 
change in staining was observed. This is in contrast to the well established method of 
counting discretely stained nuclei positive for BrdU described elsewhere in this thesis.
Figure 58 Tissue section o f  unstimulated rat liver x40 objective stained fo r  
phosphorylated AKT. The staining is subtle and restricted to the cell membranes across 
most tissue sections. There was no change in this pattern o f  staining over time following  
T3 stimulation.
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7.4.3.2 Rat p70S6kinase liver immunohistochemistry
One known downstream effector of p-mTOR is p70S6kinase. To investigate whether 
this became activated following T3 stimulation, rat liver tissue sections from the 
mitogenic T3 time course experiment were examined for phosphorylated p70S6kinase 
(Figure 59). The pattern of staining was very similar to that seen for pAKT and no 
increase in staining was observed over time after T3.
Figure 59 Tissue section o f  unstimulated rat liver x40 objective stained fo r  
phosphorylated p70S6kinase. The staining is subtle and predominantly restricted to the 
hepatocyte cell membranes. Some hepatocyte cytoplasmic staining can also be seen. 
There was no increase in distribution and/or intensity o f  staining following mitogenic 77 
stimulation.
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7.4.4 Phosphorylated niTOR in T3 treated rat liver over time- Western 
Blot Analysis
There was no significant change in the amount of phosphorylated mTOR over time in
T3 stimulated rat liver as measured by Western lot analysis (Figure 60). Indeed the peak
seen in the immunohistochemical analysis at 90 minutes post mitogenic T3 dose is not
replicated in the Western blot analysis. This may well reflect the fact that in
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unstimulated rat liver there is a basal level of phosphorylated mTOR seen particularly 
around the hepatic vasculature and therefore subtle increases or decreases in the amount 
of this active enzyme may not be detected using the Western blot technique which may 
not be sensitive enough to detect small changes in p-mTOR.
20 min 40 min 60min 90 min 120 min 150 min 180 min 8 hrs 
Time post Mitogenic T3
Figure 60 Western blot analysis o f  the hepatic phosphorylated mTOR response over 
time after Tj in vivo in the adult male SD rat. The graph represents optical density o f  
the p-mTOR protein bands relative to total mTOR protein bands when each blot was 
probed with the relevant antibodies. (Mean and range n=3).
7.4.5 The phosphorylated mTOR response in Primary Human 
Hepatocytes
Collagen coated wells were examined using phase microscopy on Day 1 to assess 
quality and extent of cell attachment before and after washing and prior to undertaMng 
the T3 time course experiments (Figure 61). In all cases there was good cell attachment. 
The hepatocyte yield per perfusion was between 138 million to 400 million cells with a 
mean viability of 70% as measured by trypan blue exclusion (See General Methods 
Chapter Two).
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Figure 61 BS 43 phase x  20 objective Day 1. There is good cell attachment to the well 
after washing and a reasonable monolayer o f  hepatocytes can be seen.
Representative film s after a W estern blot was probed for phosphorylated m TO R and 
then total m TOR (after the m em brane was stripped and re-probed) are show n in Figure 
62. Positive and negative controls using 293 cell lysates are also shown.
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Figure 62 (A) Western blot o f  293 cell positive and negative control lysates fo r  
phosphorylated mTOR (upper half) and re-probed fo r  total mTOR (lower half) (B) BS43 
Western blot fo r  phosphorylated mTOR at time 0 and 15 minutes after Tj and vehicle 
only using primary human hepatocyte cell lysate. The membrane was re-probed fo r  
total mTOR after stripping. An equal amount o f  protein lysate was loaded in each lane 
(50pg). Lanes with no primary antibody were negative and the mTOR bands are o f  the 
correct molecular weight when measured against a rainbow m arker confirming 
specificity fo r  mTOR detection.
7.4.5.1 BS 43
In this hum an hepatocyte experim ent the am ount o f phosphorylated m TO R  is greater in 
the T3 treated hepatocytes at all time points, except at 40  m inutes post stim ulation where 
the am ount is greater in the vehicle only treated  cells (F igure 63).
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Figure 63 Western blot analysis o f  the BS43 phosphorylated mTOR response over time 
after stimulation o f  primary human hepatocytes with T3 (T) or vehicle only (V). The 
optical density (OD) o f  the phospho-mTOR protein band is relative to the optical 
density fo r  the total mTOR protein band.
7.4.S.2 BS44
In BS44 an increase in mTOR hepatocyte phosphorylation is seen at each time point 
after T3 stimulation apart from at 40 minutes where less p-mTOR than is seen when 
compared to the vehicle only treated cells (Figure 64).
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Figure 64 Western blot analysis o f  the BS44 phosphorylated mTOR response over time 
after stimulation o f  primary human hepatocytes with T3 (T) or vehicle only (V). The 
optical density (OD) o f  the phospho-mTOR protein band is relative to the optical 
density fo r  the total mTOR protein band.
7.4.5.3 BS45
The trend seen in BS 43 and BS 44 is replicated in BS45 (Figure 65).
Time m inutes post stim ulus
Figure 65 Western blot analysis o f  the BS45 phosphorylated mTOR response over time 
after stimulation o f  primary human hepatocytes with (T) or vehicle only (V). The 
optical density (OD) o f  the phospho-mTOR protein band is relative to the optical 
density fo r  the total mTOR protein band.
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7.4.S.4 BS47
BS 47 was examined. The T3 stimulated hepatocytes contained greater amounts of 
phosphorylated mTOR at the time points examined (Figure 6 6 ) including 40 minutes 
post stimulation.
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Figure 6 6  Western blot analysis o f  the BS47 phosphorylated mTOR response over time 
after stimulation o f  primary human hepatocytes with T3 (T) or vehicle only (V The 
optical density (OD) o f  the phospho-mTOR protein band is relative to the optical 
density fo r  the total mTOR protein band.
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7.4.6 Mean of Western blots for BS Livers
The mean result o f the Western blot analysis of the response to T 3 in primary human 
hepatocyte culture is shown in Figure 67. There is a greater amount of p-mTOR at every 
time point when compared to vehicle only apart from at 40 minutes post stimulation 
when there is a greater amount in the vehicle only treated cells. The results however do 
not reach statistical significance.
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Figure 67 The primary human hepatocyte response to T3 over time as measured by 
Western blot protein band densitometry analysis fo r  p-mTOR normalised to total 
mTOR. Mean o f  all fo u r  BS livers is plotted +/- SD. There is an increase in the amount 
o f p-mTOR every time point apart from  at 40 minutes when there is more in the vehicle 
only treated cells. The differences do not reach statistical significance.
1A.1 Human Liver phosphorylated mTOR immunohistochemistry
Initial immunohistochemical analysis was performed on human liver to assess the 
pattern of mTOR staining with a view to using this as a future marker o f the T3 response 
in the perfused human liver samples described in Chapter Three.
An interesting pattern o f staining for phosphorylated mTOR was noted in a random 
number of BS livers that were examined. These histological sections are from pieces of 
liver which were placed into formalin soon after resection and are not those from liver 
pieces which underwent organ perfusion as described in the experiments o f Chapter 3.
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In some, very little staining is noted (Figure 70) while in others the staining is quite 
dram atic in its intensity and distribution. In these sam ples such as BS39, there is avid 
staining around vessels (Figure 68) but then there are large areas w here one sees the 
hepatic parenchym a also staining positive. This is in contrast to that w hich one sees in 
the rat where there is still notable staining around the vessels but not in large areas o f 
the parenchym a as seen in BS39.
Clearly this liver tissue was fixed once it had arrived back at the laboratory and 
therefore had been ex-vivo for at least tw o hours. The organ m anipulation alone during 
the surgery is another factor w hich m ay explain w hy the staining for p-m TO R  is so 
variable and any one o f  these instances w hich affected the liver (for exam ple an episode 
o f hypoxia) could give rise to m TO R phosphorylation. A next logical step would be to 
exam ine sections o f hum an liver obtained at the tim e o f  a liver biopsy w hen the 
specim en is fresh and is fixed in form alin alm ost im m ediately. T his may better reflect 
the true in vivo scenario.
Figure 68 Tissue section o fB S39  x  20 objective stained fo r  phosphorylated mTOR. Note 
the positive cytoplasmic staining o f  hepatocytes to the left o f the tissue section and the 
biliary cells staining strongly positive to the right o f  the tissue section.
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Figure 69 Tissue section o f  BS39 x40 objective. A similar area o f  liver is now shown 
under higher magnification and non parenchymal cells (biliary in origin) stain strongly 
positive to the left o f  the tissue section.
Figure 70 Tissue section of'BS29 stained fo r  phosphorylated mTOR x20 objective. Most 
hepatocytes stain weakly positive in this tissue section but strong staining is only seen in 
structures in the portal tract.
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7.4.8 The in vivo response to T3 in wortmannin treated SD rats
To assess whether the mTOR phosphorylation comes about as a result of the 
involvement of the upstream signalling enzyme PI3kinase, the PI3K inhibitor 
wortmannin was administered to rats in vivo to see if it reduced the T3 hepatocyte 
proliferative response (Figure 71).
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Figure 71 The male SD rat hepatocyte T3 proliferative response measured by BrdU  
incorporation after pre-treatment with wortmannin or vehicle only in vivo prior to 
administration o f  a mitogenic dose o fT 3. (WORT = wortmannin).
A reduction in the percentage of BrdU positive hepatocyte nuclei in those animals pre­
treated with wortmannin at a dose of lOOpg/kg can be seen. The difference however 
does not reach statistical significance.
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7.5 Discussion
In summary, in this study inhibition by rapamycin of the T 3 proliferative hepatocyte 
response was demonstrated in vivo in rats. Immunohistochemistry demonstrated a surge 
in mTOR phosphorylation in midzone hepatocytes 90 minutes after a mitogenic dose of 
T3 and it is already known that T3 brings about eventual proliferation of the midzone 
hepatocytes. Western blot analysis did not confirm a change in phosphorylated mTOR 
at the same time points after T 3 in rat liver. Immunohistochemical examination of the 
other likely involved enzymes p70S6kinase and AKT was undertaken but there was no 
change in the intensity of staining for these phosphorylated enzymes after T3.
The mTOR response in T 3 treated human hepatocytes was then investigated using the 
technique of Western blot analysis and human liver sections were stained for 
phosphorylated mTOR to determine the pattern and extent of staining in unstimulated 
human liver samples. The Western blot experiments did not confirm the involvement of 
mTOR at early time points in T3 treated primary human hepatocytes. Finally, the 
involvement of PI3K upstream of mTOR was investigated by the in vivo rodent 
wortmannin experiment. The difference in the BrdU proliferative index between 
animals pre-treated with wortmannin and vehicle only did not reach statistical 
significance although there was an interesting trend suggesting a real biological effect. 
For this to be confirmed a further experiment needs to be undertaken which uses a 
greater number of animals in each experimental group.
Turning to the technique of Western blot analysis, a clear protein band for p-mTOR in 
unstimulated liver is seen and the immunohistochemistry confirms the presence of p- 
mTOR in cells surrounding the major vessels in quiescent rat liver. There was no 
change in the intensity of the protein bands for p-mTOR as measured by densitometry 
after T3 over time in rat liver, but this likely reflects a lack of sensitivity using Western 
blot analysis where an increase over the basal amount is not detectable using 
densitometry measurements of the protein bands. It must be remembered that the 
increase in mTOR phosphorylation is restricted to a small number of midzonal 
hepatocytes after T3 at 90 minutes post dose and this increase in the amount of p-mTOR 
may not be detectable using a Western blot approach. To overcome this problem the 
future use of an ELISA technique may better detect these subtle changes more 
satisfactorily.
The BS human liver sections examined stained strongly positive for p-mTOR in many 
areas and therefore using immunohistochemical or Western blot techniques to detect 
changes in response to T3 may not be sensitive enough as is the case in the rat liver
211
scenario. Indeed a strong protein band is seen for p-mTOR in unstimulated human 
hepatocytes at time 0. There is little published in the worldwide literature on p-mTOR 
expression in human liver. One group has examined human hepatocellular carcinoma 
liver samples using an immunohistochemical technique with the same manufacturer’s 
antibodies as used in this thesis (Sahin et at. 2004). Analysis was on formalin fixed 
paraffin embedded samples collected over a period of sixteen years. Increased 
expression of p-mTOR was found in 15% of hepatocellular carcinoma but p-mTOR was 
negative in non neoplastic liver tissue but no actual immunohistochemistry 
photomicrographs are shown to demonstrate this finding. This is in contrast to the 
marked staining shown in this thesis for p-mTOR in human liver. These BS samples 
were however only formalin fixed after they were transported by road stored on ice in 
USW solution to the laboratory and clearly the handling of the tissue may have brought 
about activation of mTOR phosphorylation.
A recent study examined PTEN expression in human and rodent liver samples and 
found that unsaturated fatty acids inhibited PTEN expression in HepG2 cells via 
activation of a signalling complex formed by mTOR and NF-Kp (Vinciguerra et a t  
2008). As part of the analysis p-mTOR expression was studied using Western blot 
analysis in ZDF, male Wistar and Lou/C rats. A strong basal protein band on Western 
blot analysis can be seen in all three species for p-mTOR, but it was particularly strong 
in the Lou/C rat and comparable to the band seen in unstimulated male SD rat liver 
found in this thesis.
The primary human hepatocyte work presented here is therefore suggestive but not 
conclusive of T3 increasing the levels of human phosphorylated mTOR. If there is a 
subtle effect it needs to be confirmed with a greater number of experimental replicates 
and it is necessary to measure the change in p-mTOR using a more sensitive method 
than Western blot analysis, such as ELISA. It is also not clear if the time course chosen 
is the correct one as the T3 may be exerting its effect on hepatocytes within seconds or 
minutes and this change may not be seen when examining the time points chosen in this 
thesis.
Another possible explanation for why a significant effect was not observed is that in 
monolayer hepatocyte cell culture the co-operation of other cells which may be 
necessary to bring about the observed in vivo mitogenic response is lacking. In addition 
the hepatocytes have been through a host of mechanical and biochemical handling 
procedures before they are plated out and it is not known if this handling alone is
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enough to stimulate mTOR phosphorylation and this is perhaps why a strong protein 
band at time 0 is seen for p-mTOR.
It is also important to note that the T3 concentration used in vitro (lOOnM) may be 
inadequate as if  5|ag is distributed in all of the 15mls of the rat’s circulating blood 
volume this equates to a concentration of about 500 nM in vivo. The choice of lOOnM 
was based on the fact that published data used this concentration of T 3 to bring about 
successful activation of PI3K and mTOR in fibroblasts and cardiomyocytes (Kenessey 
and Ojamaa 2006)
In future it would be highly desirable to isolate the hepatocytes that undergo 
proliferation in response to T3 and this could be achieved by utilising the technique of 
laser capture microdissection to specifically study the midzone hepatocytes; indeed it is 
in these cells that the surge in mTOR phosphorylation is seen 90 minutes post mitogenic 
T3 and it is in the midzone that the T3 exerts its proliferative effect. Laser 
microdissection can be performed on cryostat liver to isolate 3,000 to 5,000 hepatocytes 
and then mRNA and/or protein expression analysis can be performed on these cells 
(Melle et a l  2004; Melle et al. 2007). Although technically demanding a number of 
studies now report the use of laser microdissection to study just single cells.
7.5.1 The Non-Genomic Effect
The results in this Chapter indicate that mTOR phosphorylation is an important early 
event in mediating the mitogenic effects o f T3 on rat liver. Due to the rapidity of this 
response, it is hypothesised that this T3 effect is acting through a so-called ‘non- 
genomic’ mechanism via phosphatidylinositol 3-kinase activation followed by AKT 
phosphorylation acting through the intermediates Rheb and TSC complex with 
subsequent activation of the mTOR downstream effectors p70S6 kinase and 4E-BP1, 
the mammalian translational regulators (Figure 72). These would effect important 
downstream cell cycle regulators such as cyclin D 1 enabling cell cycle progression and 
published work has clearly demonstrated that rapamycin inhibits expression of cyclin 
D1 (Hidalgo and Rowinsky 2000).
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Figure 72 The T3 activation o f  proliferative pathways acting through mTOR via a ‘non­
genomic’ mechanism. T< activates PI3K which brings about downstream activation o f  
AKT then mTOR leading to nuclear transcription events (M oeller et al. 2006).
There is gathering evidence from the literature for T 3 acting through the hypothesised 
pathway. Cao (Cao et al. 2005) shows that T 3 increased ZAKI 4 alpha expression in 
human skin fibroblasts and this was through Serine 2448 mTOR phosphorylation 
leading to p70S6 kinase phosphorylation. The pathway acted through AKT 
phosphorylation and PI3K, as PI3K inhibitors blocked the T 3 effect. They showed an 
association between thyroid hormone receptor p i and the PI3K-regulatory sub-unit 
p85a (Moeller et al. 2006).
Kenessey (Kenessey and Ojamaa 2006) shows T 3 acts through the PI3K pathway in rat 
cardiomyocytes where it increases 3H-leucine incorporation at 24 hours in cultured 
cells. The study demonstrated a direct interaction between cytosolic T R al and the p85a
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subunit of PI3K and also further downstream activation of AKT then mTOR leading to 
p70S6K activation. The T3 effects were blocked by PI3K inhibitors and rapamycin. 
Coutant et al (Coutant et a l  2002) examined the role of this pathway in primary rat 
hepatocyte culture. They showed a dose dependent inhibition of DNA replication by 
the PI3K inhibitor LY294002, in EGF stimulated hepatocytes. A dose dependent 
inhibition was also shown with rapamycin up to complete abolition of the DNA 
replicative response with EGF. In addition a link to cyclin D1 protein expression and its 
inhibition by LY294002 and rapamycin was demonstrated.
Recently further evidence has emerged showing that the mTOR pathway is thyroid 
hormone responsive. Thyroid hormone activates AKT to bring about cardiac 
hypertrophy in mice and there is activation of the pathway seen in cardiomyocyte cell 
culture. The induced cardiac hypertrophy was completely inhibited by rapamycin 
(Kuzman et a l  2007). Furthermore it is now known that the thyroid hormone receptor 
TRp, mediates AKT activation by T 3 in pancreatic beta cells (Verga et a l  2007).
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Chapter 8 General Discussion
8.1 What was achieved
The long term goal pursued in this research diesis is therapeutic, enabling the use of T3 
in the setting of human liver disease to augment and improve a patient’s functioning 
hepatic mass and the overall original aim of this thesis was to demonstrate a mitogenic 
effect of T3 on human liver which no-one else has yet been able to achieve. Furthermore 
workers have not been able to demonstrate a mitogenic effect on rodent liver cells in 
vitro, but the in vivo model has been well characterised up to now.
The work presented here has significantly contributed to our understanding of the 
mitogenic mechanism of action of T3 on hepatocytes however a direct mitogenic effect 
was not conclusively demonstrated in primary human hepatocytes or in rodent or human 
liver pieces which underwent organ perfusion. Nonetheless results from this research 
project offer some novel insights into the mechanism of action of T 3 when acting as a 
direct hepatic mitogen.
The experiments sought to identify an early marker (within 6  hours) of the T3 mitogenic 
effect which could be utilised firstly in the organ perfusion experiments of Chapter 3 
and later in the primary human hepatocyte work undertaken in Chapter 7. In pursuit of 
such an early marker, cyclin D l, important in cell cycle progression, was first 
investigated in Chapter 4. Its levels were found to rise after T 3 stimulation (at 14 hours) 
at both the mRNA and protein levels, however this rise is not as early as others have 
described (within 2 to 4 hours). Its use therefore as a marker of early T3 effects in the 
organ perfusion experiments was not pursued further. A second likely mediator of the 
mitogenic response, the oncogene Bcl-3, was next probed by examining the hepatocyte 
proliferative response to T 3 in Bcl-3 knockout mice. The proliferative response was no 
less in the knockout animals and so Bcl-3 was not investigated any further.
Work moved forward to try and identify novel mediators o f the T3 response using the 
powerful technique of expression based gene array technology in Chapter 5. A host of 
genes potentially associated with proliferation and cell cycle control were identified and 
most notable amongst these were the Kruppel like transcription factors which were 
shown to be T3 responsive using Real Time PCR technology in Chapter 6 . Their rise at 
the expression level was common to both mitogenic and sub-mitogenic T 3 treated liver, 
confirming their T 3 responsiveness, except in the case of the tumour suppressor Kruppel
216
Factor 4 where a fall in expression was noted after the mitogenic T3 dose at 20 minutes. 
This Kruppel factor remains a candidate as a mediator of the proliferative hepatocyte 
response.
In Chapter 7, the mTOR pathway was explored as an early mediator of the T3 
proliferative response and a clear rise in active phosphorylated mTOR after 90 minutes 
at the immunohistochemical level following a dose of mitogenic but not sub-mitogenic 
T3 was shown. In the remainder of that chapter experiments were undertaken which 
attempted to demonstrate a T 3 effect on mTOR activation in primary human 
hepatocytes. There is a trend seen using Western blot analysis with a greater amount of 
p-mTOR in the T3 treated hepatocytes over early time points but the increase across 4 
different human liver primary hepatocyte preparations did not reach statistical 
significance when compared to vehicle only treated cells. The involvement of PI3K 
upstream of mTOR in mediating the T3 signal is suggested by the reduction in the 
hepatocyte proliferative response in rodents pre-treated in vivo with the PI3K inhibitor 
wortmannin. The change however did not reach statistical significance, nonetheless may 
be biologically significant and an experiment with more replicates needs to be 
conducted.
8.2 Signalling, receptors and PI3K
Based on this collection of experimental observations it is clear that the mitogenic
mechanism of action of T3 in the liver is complex, probably utilising more than one
signalling pathway with effects attributable to ‘genomic’ and ‘non-genomic’ pathways
to bring about the proliferation of midzone hepatocytes. The work underscores the
emerging importance of the ‘non-genomic’ signalling pathways involved as it is about
1 0  years ago that reports began to tentatively describe membrane or cytosol forms of
nuclear receptors that could mediate rapid responses following ligand binding which
could not be explained by slower nuclear transcriptional events. Now in 2008 it is well
established that many nuclear receptor family members are coupled to the rapid
activation of cytoplasmic signal transduction pathways that generally emanate from
membrane-associated or membrane-integral receptors and ion channels. Novel new
receptors have been identified that bind ligand and these receptors are distinct from their
nuclear counterparts (Revankar et a l  2005). Nuclear and non-nuclear receptors
represent two integrated arms of the same signalling pathway. As outlined in Chapter
7’s introduction it is likely that the mTOR mediated response is via T3 binding to the
TRP receptor isoform which is most prevalent in the liver. The receptor may be cytosol
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or membrane associated or both but clearly other as yet to be identified receptors may 
be involved in mediating the T3 effect.
PI3K may be involved in the upstream regulation of the T3 response and dysregulation 
of PI3K signalling is increasingly shown to contribute to the development of abnormal 
cell growth and a variety o f neoplasms (Engelman et a l  2006). There is further recent 
evidence to suggest that the AKT-mTOR-p70S6kinase pathway is thyroid hormone 
responsive and involved in the control of cell proliferation via PI3K activation. 
Kaneshige (Kaneshige et al. 2000) developed a TRp mutant knockin mouse harbouring 
a frame-shift mutation in carboxyl-terminal 16 amino acids, termed TRpPV. This type 
of mutation was identified in a patient with the syndrome of thyroid hormone resistance 
termed RTH. The TRpPV mouse reproduces the RTH phenotype one sees in humans 
with elevated levels of thyroid hormone and non-suppressible TSH levels. PV interferes 
with the transcriptional activity of TRs leading to repression of the positively regulated 
T3 genes. However as these TRpPVPV mice age they develop follicular thyroid 
carcinoma. Mutant PV increases the phosphorylation of AKT in the thyroid lesions 
(Furuya et a l  2007) and this comes about through activation of PI3K in TRpPVPV mice. 
The p85a subunit of PI3K binds to PV three times more strongly than to TRp.
8.3 Species differences
The in vivo hepatic response to T3 is well characterised in the rodent but as a direct 
mitogenic response has not been shown in human hepatocytes consideration has to be 
given to the likely differences in response between species and how these differences 
can quickly be recognised so the ultimate goal of using mitogenic T3 in humans can be 
realised.
Most of the detailed work conducted in the field of liver regeneration has been 
performed in the rodent model and this is indeed the case when examining the 
mitogenic action of T3 on the liver. It is highly likely there will be inter-species 
variation in the hepatic proliferative response to T3 just as there is in the response to 
partial hepatectomy between rats and mice where the duration of the cell cycle in the 
latter species is longer hence resulting in a more latent peak in hepatocyte proliferation. 
It is difficult to allow for these differences in the interpretation of the experiments 
undertaken in this thesis but there are obvious differences between species and their 
response to primary mitogens. For example when taking into consideration the response 
to PPAR ligands, these cause peroxisome proliferation in rodents but not in human liver
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where they are crucially not hepatocarcinogenic whereas they can cause liver tumours in 
rodents.
There is limited data on the physiological and molecular processes underlying human 
liver regeneration as most of the work has been carried out in rodents, dogs, pigs, frogs 
and zebra fish (Hata et a l  2007). The regeneration of human liver has been studied in 
patients with hepatocellular injury such as in fulminant hepatic failure but also in 
patients who have undergone partial hepatectomy. An intermediate step therefore is the 
use of a primate model and this needs to be considered but there is little published data 
on studies of hepatic regeneration in a primate model. In human patients with right lobe 
allografts there is an increase in the amount of Ki-67 staining of hepatocytes compared 
with cadaveric allografts and by 3 weeks there is restoration of liver volume in the right 
lobe allograft group of patients due to this proliferation of the hepatocytes (Huang et a l 
2004). By contrast Gaglio et al (Gaglio et a l  2002) describe some pilot work in the 
Macaca mulatta monkey. The proliferative response was studied in 3 animals that 
underwent partial hepatectomy, by examining serial liver biopsies in the days following 
surgery. The peak in expression of the cell cycle antigen Ki-67 occurred after 3 weeks 
and this is dramatically different to the peak seen in rats following PH which is seen to 
occur within a matter of hours.
Studying the effects of mitogens in a primate model, although extremely useful and 
informative would nonetheless present numerous difficulties, notably the great costs 
involved in such experiments and the sensitive ethical issues surrounding the use of 
primates. A more plausible route to pursue with regards to this thesis is further intensive 
work on perfecting the organ perfusion technique in Chapter 3 and to begin tissue slice 
experiments which may better reflect the in vivo scenario in humans. These techniques 
will reduce the ethical and economic costs of animal experiments and once perfected in 
a robust system could prove very valuable in modelling the T3 mitogenic hepatic 
response across many different species.
8.4 The Dose in Humans
A potential criticism in trying to extrapolate the use of T 3 from the rodent model to man,
is that the dose required in man may be potentially toxic and therefore clinically
inappropriate. This needs to be addressed as it is central to the future use of this
hormone in man. The main instance in which T3 is currently administered to humans
acutely is in the setting of myxoedema coma due to hypothyroidism. Due to the earlier
recognition of the hypothyroid state this is a rare clinical entity however patients do still
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present to hospital and in England in 2004 there were 11 such cases. Endocrinologists 
would treat this condition with a dose of intravenous T3 of 75pg in the first 24 hours 
(Kearney and Dang 2007). This equates to about lpg/kg in the human and the dose used 
in the animal model in this thesis is 20pg/kg. The similarity between these doses means 
it is very likely T3 will be used safely in the future in humans to act as a primary liver 
mitogen. Furthermore the cardiovascular effects of T3 in healthy male volunteers has 
been studied (Schmidt et al. 2002) when lOOpg is injected intravenously into a forearm 
vein over 1 minute. Simultaneous infusion of a P adrenergic blocking drug was 
administered to limit the cardiovascular side effects but the T3 exhibited excellent 
tolerability and there were no adverse events.
In conclusion therefore, this thesis has described interesting new hepatic signalling 
pathways that are T3 responsive as well as the importance of mTOR in mediating the 
proliferative T3 effect. To enable an effect to be demonstrated in human hepatocytes 
further work still needs to be done and this will be best achieved using the techniques of 
liver slice technology prior to the necessary clinical trials being undertaken of mitogenic 
T3 in humans with liver diease.
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Background: Tri-iodothyronine, T3, a primary hepatic mitogen offers exciting 
therapeutic opportunities in liver surgery and in acute liver disease to increase liver 
mass and function. It has been impossible to directly demonstrate an effect of T3 in 
humans. Its effects are modelled in rodents in vivo. An understanding of the mitogenic 
mechanism of action of T3 is crucial prior to its human use.
Kruppel Factors (evolutionarily conserved zinc finger containing transcription factors) 
are implicated in virtually all facets of cellular function, including proliferation, 
apoptosis, differentiation and neoplastic transformation. During a structured analysis of 
liver gene expression induced by T3 we investigated KF expression; in particular 
pursuing the hypothesis that alteration in expression of one of these may define a 
critical pathway involved in the T3 proliferative response.
Aim: To analyse the hepatic expression of T3 regulated genes using a whole-rat 
genome microarray, then to investigate the hepatic expression over time of some KFs 
using quantitative real time PCR.
Methods: An Affymetrix expression array compared RNA prepared from mitogenic T3 
treated and submitogenic T3 treated rat liver at lh. Real time PCR was used to measure 
the expression of Kruppel factors over time in mitogenic and submitogenic T3 treated 
rat liver.
Results: ZFP354A, KF15 and KF9 are not critical in mediating mitogenic T3 effects as 
their expression rises in both mitogenic and submitogenic T3 treated rat liver. Sp4 
however exhibits a FC of +4.15 on the microarray and its expression is increased at lh  
after mitogenic T3 using quantitative real time PCR, confirming the microarray result.
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Conclusion: Sp Kruppel Factors contribute to a metastatic tumour phenotype and are 
known to be involved in cell cycle control but their exact roles are yet to be fully 
described and identified. Sp4’s up-regulation as an early event in T3 induced liver 
proliferation (but not when T3 is at submitogenic doses) suggests it plays a critical role 
in the mitogenic action of T3 on the liver.
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STIMULATION OF HEPATOCYTE PROLIFERATION AND LIVER 
GROWTH BY TRI-IODOTHYRONINE AND ITS RELATIONSHIP TO BCL-3 
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Background: We and others have demonstrated the effects of thyroid hormone as a 
mitogen that induces hepatocyte proliferation and enhances liver mass. These 
experiments provide a potential strategy to use primary mitogens in the field of liver 
surgery, enhancing liver mass thus pre-conditioning the liver prior to resection or living- 
related transplants. We use Feng et al’s data from a cDNA microarray of livers of 
hypothyroid mice subjected to T3 stimulation at mitogenic doses. There were 55/2225 
mouse genes regulated by T3 and we used these to identify possible candidates for the 
proliferative pathway initiated by T3. The genes affecting cell proliferation included 
Kiplp, CHD-1 and Bcl-3. Bcl-3 appeared as a plausible candidate for the mitogenic 
effects of T3 -  Bcl-3 is an IKB- related protein that enhances NF-KB activity resulting 
in the expression of a variety of cellular genes, including those regulating cell 
proliferation, and Bcl-3 mutations in human lymphocytes induce cellular proliferation. 
The first two proteins are mitotic spindle components.
Methods: We confirmed by microarray, in euthyroid rats subject to a mitogenic dose of 
T3, that Bcl-3 mRNA was also unregulated in rats within 3h of T3 administration. We 
then used real time PCR to quantify levels of Bcl-3 mRNA in the liver and SDS-PAGE 
electrophoresis/western blotting to demonstrate protein expression serially.
Results: Hepatocyte proliferation in rats peaked at 24 hours (7±1.1% cf. <1%) after T3. 
There was a progressive increase in expression of Bcl-3 in the livers of rats receiving 
T3, with the peak increase in mRNA expression (Bcl-3:18S ratio 0.63 ± 0.11 cf. 0.40 ± 
0.03 in controls -  P < 0.01) and protein expression (P < 0.01) also occurring 24 hours 
after T3 was given. However, comparing Bcl-3 knockout mice and the wild-type 
parental strain, there was no difference in the proportion of hepatocytes in DNA 
synthesis 28h after T3 administration.
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Discussion: The potential use of primary mitogens in liver surgery in humans is 
dependant on identifying the underlying mechanism in rodents. Although there is an up- 
regulation of Bcl-3 in the livers of rodents stimulated with T3 this IKB-related protein 
does not appear to be critical to the process of T3 induced liver cell hyperplasia.
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